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How to improve ambulatory care of opioid-addicted patients? 
A pharmacoepidemiological approach  
assessing the value of urine drug screening tests. 
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ABSTRACT 
 
Since the recognition of addiction as a mental disease, specific treatments have been 
developed. For opioid-addicted patients, opioid maintenance drugs (methadone, 
buprenorphine and buprenorphine/naloxone) have been showed to decrease opioid use, 
related diseases (HIV, hepatitis C), to improve social outcomes and to decrease mortality. 
In France, because buprenorphine is easily accessible, most of opioid-addicted patients are 
mainly managed by general practitioners (GPs). Nevertheless, the assessment of 
psychoactive substance use by the physician, thanks to self-report and clinical 
examination, is known to underestimate the use of psychoactive substances. The 
implementation of urine drug screening tests should improve this assessment. These tests 
enable a qualitative detection of psychoactive substances in the urine.  
The objective of this thesis is to assess the value of urine drug screening in opioid 
addicted patients managed in ambulatory care. This assessment has been conducted in 
three parts. The first one aimed to summarize the knowledge concerning drug tests in the 
literature and of French GPs. The second one aimed to assess the effectiveness of drug 
tests in managing opioid-addicted patients using observational cohorts conducted from 
French health insurance system databases. Finally, the last part aimed to confirm the value 
of urine drug screening tests in real life and thus, to assess their efficacy planning a 
pragmatic cluster randomized controlled trial in general practice. 
In the first part, we first investigated French GPs’ knowledge and practices 
concerning drug tests. We conducted a descriptive cross-sectional study by postal 
questionnaires sent to a random sample of GPs in the Midi-Pyrénées area of France. Many 
French GPs treating opioid-addicted patients regularly did not perform drug tests and 
lacked knowledge of them. Secondly, we summarize the evidence pertaining to the 
efficacy of urine drug screening for medical management. A systematic review of clinical 
trials, quasi-randomized and observational studies was performed. The value of urine drug 
screening in managing patients was not clearly indicated in these studies.  
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The first work of the second part aimed to assess the effectiveness of drug tests for 
treatment retention in outpatients starting opioid substitution therapy. A retrospective 
cohort of patients starting opioid substitution treatment was created from the data of the 
French health insurance system database for the Midi-Pyrenees region. Use of a drug test 
in follow-up of opioid substitution treatment, although rarely prescribed, significantly 
improved treatment retention. The second work assessed the effectiveness of drug tests on 
mortality using a national database: the “Echantillon Généraliste des Bénéficiaires” 
(permanent beneficiaries sample). This work confirmed the association between drug tests 
and retention in treatment but did not find an association with mortality. 
All these results were used to plan the third part: a pragmatic cluster randomized 
controlled trial (the ESUB-MG study). We present the protocol of this study aiming to 
assess the impact of on-site urine drug screening tests in general practice compared to 
routine medical care on opioid maintenance treatment retention at six months in patients 
initiating buprenorphine.  
To conclude, this thesis has shown that urine drug screening tests were rarely done 
in France for managing opioid-addicted patients and that few studies had assessed their 
value. Nevertheless, drug tests seem to have a positive effect on opioid maintenance 
treatment retention. The on-going pragmatic randomized trial we proposed should bring 
sufficient level of evidence to assess effectiveness of on-site urine drug screening in 
general practice for patients treated by buprenorphine.  
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INTRODUCTION: OPIOID-ADDICTION MANAGEMENT IN PRIMARY CARE 
 
 
Introduction : prise en charge des patients ayant une addiction aux opiacés en soins primaires 
L’addiction aux opiacés est une pathologie chronique classée dans les pathologies mentales. Les traitements 
de maintenance aux opiacés associés  à des interventions psychosociales sont les traitements les plus 
efficaces pour ces patients. Les médicaments que sont la méthadone et la buprénorphine ont montré leur 
efficacité sur plusieurs critères de jugement cliniques dont la mortalité. Leur efficacité est néanmoins limitée 
par des ruptures de traitements qui sont fréquentes et précoces.  
La prise en charge de ces patients en Europe est partagée entre les centres spécialisés, les médecins 
généralistes et les structures de bas seuil. La prise en charge en médecine générale serait, selon certaines 
études, aussi efficace voir plus efficace, que la prise en charge en centre spécialisé. Néanmoins, entre les 
différents pays européens, les réglementations permettant aux médecins généralistes de prescrire ces 
traitements diffèrent. La méthadone est le médicament le plus souvent prescrit (75 à 80% des patients à 
l’échelle européenne).  
En France, la situation est assez différente puisque les conditions de prescription et de délivrance de la 
buprénorphine sont plus souples que celles de la méthadone. Les patients français sont donc majoritairement 
traités par buprénorphine et ce, en médecine générale. La médecine générale, de par ces caractéristiques, 
est adaptée à la prise en charge de ces patients.  
Pour autant, l’offre de soins reste hétérogène pour ces patients et les médecins généralistes impliqués dans 
leur prise en charge font face à certaines difficultés parmi lesquelles la sous évaluation fréquente, par 
l’interrogatoire et l’examen clinique, des substances consommées par les patients. Pour pallier à cette 
difficulté, l’utilisation de tests de dépistage des substances psycho actives a été proposée. Ils auraient 
d’autant de valeur que leur résultat se lit en quelques minutes (ce qui semble adapté au contexte de la 
médecine générale : prise de décision généralement rapide, dans le temps de la consultation) ; et que 
plusieurs études ont montré la validité de leur utilisation au lit du malade, et notamment au cabinet du 
médecin généraliste.  
Ces tests donnent des résultats qualitatifs par une technique immunochimique qui peuvent être confirmés par 
un dosage en laboratoire à l’aide de la méthode de référence : la chromatographie couplée à la 
spectrométrie de masse. Leurs limites doivent être connues par les cliniciens pour bien interpréter leurs 
résultats. 
Ces tests sont recommandés en France : un premier avant la mise sous médicament (avec un caractère 
obligatoire avant l’initiation de méthadone), et d’autres pendant le suivi selon le jugement du médecin. Les 
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tests pourraient permettre d’évaluer les consommations du patient tout au long de la prise en charge et donc 
permettre indirectement une évaluation du craving.  
Les valeurs diagnostiques de ces tests sont bien établies mais leurs conséquences sur la prise en charge des 
patients sont mal connues. Pour autant, les programmes de surveillance ont montré leur efficacité sur des 
critères de jugement cliniques. 
L’objectif de cette thèse est d’évaluer l’intérêt des tests urinaires de dépistage pour les patients dépendants 
aux opiacés pris en charge en médecine ambulatoire. Cette évaluation a été conduite en 3 parties : 1) une 
synthèse des connaissances des tests dans la littérature, et par les médecins généralistes français ; 2) une 
évaluation de l’efficacité des tests pour la prise en charge des patients dépendants aux opiacés par des 
études observationnelles de cohorte sur les bases de données de l’Assurance Maladie ; 3) la confirmation de 
leur intérêt en médecine générale en planifiant la mise en place d’un essai pragmatique contrôlé randomisé 
en médecine générale. 
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OPIOID-ADDICTION AND ITS TREATMENT 
 
Opioid addiction is currently defined as a “chronic, relapsing disorder” (Dole & 
Nyswander, 1967; Nyswander & Dole, 1967). As all addiction, this disease is classified as 
a mental disease in the Diagnostic and Statistical Manual of Mental Disorders DSM (with 
different terminologies from DSM III to DSM V). Mortality of untreated heroin 
dependence is consistently estimated at 1–3% per year, at least half of which because of 
heroin overdose (Darke & Hall, 2003). Beyond mortality and morbidity, heroin 
dependence inflicts enormous social and economic costs due to crime, unemployment, 
relationship breakdown, and the costs of law enforcement.  
Opioid maintenance treatment (OMT), combined with psychosocial interventions, 
was found to be the most effective treatment option for opioid users. In comparison with 
detoxification or no treatment at all, methadone or buprenorphine treatments show 
significantly better outcomes regarding drug use, criminal activity, risk behaviours and 
HIV-transmission, overdoses and overall mortality, as well as better rates of retention in 
treatment (WHO, 2009). Data from systematic reviews show that methadone maintenance 
is the most effective treatment in retaining patients in treatment and suppressing heroin use 
(Amato et al., 2005; Mattick, Kimber, Breen, & Davoli, 2008). The systematic review by 
Mattick et al. demonstrated the efficacy of buprenorphine maintenance treatment, with a 
lower retention rate than methadone but giving a similar decrease in opiate consumption 
(Mattick et al., 2008).  The combination of buprenorphine and naloxone (marketed as 
Suboxone®) was created to prevent the injection of buprenorphine. Nevertheless, its 
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effectiveness in preventing intravenous use of buprenorphine is not yet clear (Bruce, 
Govindasamy, Sylla, Kamarulzaman, & Altice, 2009; Simojoki, Vorma, & Alho, 2008).  
Effectiveness of opiate maintenance treatment is mainly limited by drop-outs. Early 
drop-outs are frequent (Stein, Cioe, & Friedmann, 2005) and are often under estimated in 
studies (Encrenaz, Rondeau, Messiah, & Auriacombe, 2005). Rate of drop-outs would be 
close to 50% in the first 6 months in Germany (Soyka, Zingg, Koller, & Kuefner, 2008). In 
France, early drop-outs are frequent and occur often in the first year of treatment (Batel et 
al., 2004; Duburcq, Charpak, Blin, & Madec, 2000). Treatment interruptions exist also and 
must concern more than 50% of patients in France (Pradel et al., 2004). This is an 
important issue as the end of OMT was associated with a higher somatic morbidity in the 
first year after leaving OMT (Skeie et al., 2013) and with a three-fold higher mortality 
(particularly the fifteen days immediately after stopping the treatment) in 5577 patients 
from the United Kingdom General Practice Research Database (Cornish, Macleod, Strang, 
Vickerman, & Hickman, 2010). 
No consensus exists in OMT withdrawal. In an Australian study, 62% of the patients 
were worried about the end of OMT (Winstock, Lintzeris, & Lea, 2011).  
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OPIOID-ADDICTED PATIENTS’ MANAGEMENT  IN EUROPE 
 
 
 
In the European Union during 2012, 1.3 million people received treatment for illicit drug 
use. In Germany, Spain, France, Italy and the United Kingdom, 80 % of drug users were in 
contact with treatment (EMCDDA, 2014). 
The average annual prevalence of problematic opioid use among adults (from 15 to 
64 years old) is estimated at around 0.4 %, representing 1.3 million opioid users in Europe 
in 2012 (EMCDDA, 2014). Patients using mainly heroin, as their primary drug, 
represented 46 % of all drug users who entered specialized treatment in 2012 in Europe 
(180 000 patients). They represented also around 26 % of those entering treatment for the 
first time, of whom more than 10% misused opioids other than heroin (EMCDDA, 2014).  
Patients entering outpatient treatment for primary opioid use have a mean age of 36 
years, with a more than three quarters of men (EMCDDA, 2014). Almost all countries 
report an increase in the mean age of their opioid patients since 2003 (EMCDDA, 2010). 
An average time lag of about 10 years is reported between first use of opioids and first 
contact with drug treatment (EMCDDA, 2010). Opioid users entering treatment have 
higher rates of unemployment, lower levels of educational attainment and higher levels of 
psychiatric disorders than patients reporting other primary drugs (EMCDDA, 2010).  
The two main modalities of outpatient treatment in Europe are psychosocial 
interventions and opioid maintenance treatment (OMT). For opioid users, they are often 
provided in combination. 
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OMT is the predominant treatment option for opioid users in Europe and is mostly 
conducted in outpatient settings, which can include specialist centres, general practitioners’ 
surgeries and low-threshold facilities. OMT, generally integrated with psychosocial care, is 
provided at specialized outpatient centres but can be also provided by general practitioners 
(GPs), usually under shared care arrangements with specialized treatment centres. A 12-
month naturalistic study of 2 694 patients in OMT in Germany showed that GPs can 
achieve better results than specialized centres in terms of retention in treatment, abstinence 
rates and co-consumption of other drugs (Wittchen et al., 2008). Other studies have shown 
that the implementation of OMT in general practice is cost-effective (Gossop, Stewart, 
Browne, & Marsden, 2003; Hutchinson et al., 2000). 
A comparison of the number of patients treated by OMT in the European Union 
with the estimated number of problematic opioid users suggests a treatment coverage rate 
of about 50%, with considerable variation between countries (from 10 to 60%), represented 
in Figure 1. In Belgium, Czech Republic, Denmark, France, Italy, Cyprus, Netherlands, 
Portugal, United Kingdom, Croatia, all GPs are allowed to prescribe OMT. In Germany, 
Ireland, Luxembourg, Austria, Slovenia, Norway, only those who have been specifically 
trained or accredited are allowed to prescribe it. In Bulgaria, Estonia, Greece, Spain, 
Lithuania, Hungary, Poland, Romania, Slovakia, Finland, Sweden, only specialists in 
treatment centres can provide OMT.  More than the authorization to prescribe, the legal 
regulation framework can be a barrier for OMT supplying if administrative tasks are 
numerous as, for example, in Germany (Schulte et al., 2013). 
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Figure 1 : Estimated proportion of problematic opioid users undergoing maintenance treatment in 
some European countries (EMCDDA, 2010) 
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Most patients treated by OMT in Europe receive methadone (75 - 80 %), and 
buprenorphine is used in 20–25 % of all OMT provided in Europe and in more than 50 % 
in some countries (of which France, see Figure 2). The buprenorphine–naloxone 
combination, approved by the European Medicines Agency in 2006, has been introduced in 
most of the European countries. Other options, which represent a small percentage of all 
OMT, include slow-release morphine, codeine and diacetylmorphine (heroin).  
 
 
Figure 2 : Predominant OMT at national level (EMCDDA, 2014): buprenorphine in red, methadone in 
yellow, and both equally in orange. 
 
Buprenorphine is, thus, more widespread in France than in other countries; but, the 
efficacy and the safety of this drug are well known (Lee, Grossman, DiRocco, & 
Gourevitch, 2009; Simoens, Matheson, Bond, Inkster, & Ludbrook, 2005). Its use tends to 
be more common; for example, British GPs are favourable to its widespread (Strang et al., 
2007).  
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OPIOID-ADDICTED PATIENTS’ MANAGEMENT  IN FRANCE 
 
More recent data estimates that near 150 000 patients are treated, in France, by an opioid 
maintenance treatment (OMT) (Commission Nationales des stupéfiants et des 
psychotropes, 2010). Methadone, buprenorphine and buprenorphine-naloxone received 
marketing authorization in 1995, 1996 and 2006 respectively, for maintenance treatment 
for major opiate dependence as part of overall medical, social and psychological 
therapeutic management. These drugs are prescribed and delivered according to two 
different, very strict guidelines. Methadone, a pure µ agonist, is a listed narcotic and can be 
prescribed for a maximum of 14 days and delivered for a maximum of 7 days. Primary 
prescription of methadone is restricted to physicians in specialized units and to hospital 
physicians. When the patient is stabilized, treatment may be continued in an outpatient 
setting and followed up by any physician, whether specialist or generalist practitioner 
(GP). Buprenorphine, a partial µ agonist, is a class I psychotropic drug (Schedule III of the 
1988 Convention) and can be prescribed for maximum periods of 28 days and delivered for 
periods of 7 days. It can be prescribed by any physician, whether specialist or GP, and can 
be delivered in any local pharmacy. In summary, in France, methadone must be started in a 
specialized unit or a hospital and can be continued, after the patient is stabilized, in an 
outpatient setting, whereas buprenorphine is easily accessible as it can be started in a 
specialized unit, a hospital or an outpatient setting. The physician can prescribe methadone 
for a maximum of 14 days and buprenorphine for 28 days, but the pharmacist must deliver 
the medication only for 7-day periods unless otherwise indicated by the prescriber.  
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In ambulatory practice, GPs are involved in initiating treatment by buprenorphine 
and follow-up of treatment by buprenorphine and methadone. Because buprenorphine is 
easily obtainable (Fatseas & Auriacombe, 2007), more than three-quarters of patients 
treated for opioid addiction receive buprenorphine
 
(Auriacombe, Fatséas, Dubernet, 
Daulouède, & Tignol, 2004; Fatseas & Auriacombe, 2007; Thirion et al., 2001) and most 
of them are treated in general practice using this drug (Fatseas & Auriacombe, 2007; 
Thirion et al., 2002). The number of people receiving opiate maintenance treatment (OMT) 
was estimated at around 100,000 for buprenorphine and around 35,000 for methadone in 
2009 (Commission Nationales des stupéfiants et des psychotropes, 2010). 
Maintenance on OS is requisite for successful treatment. Buprenorphine retention is 
associated with a decrease of drug consumptions (heroin, cocaine, benzodiazepines) (De 
Ducla, Gagnon, Mucchielli, Robinet, & Vellay, 2000; Thirion et al., 2001), of morbidity 
and mortality, with an improvement of social insertion (Lavignasse et al., 2002), and also, 
with a decrease of infectious risks related to injection (Human Immunodeficiency Virus 
HIV, hepatitis C and B) and with a best compliance with antiretroviral drugs (Moatti et al., 
2000).  Retention on OS (methadone in the cited study) was beneficial for patients, were 
they discharged involuntary or not and against medical advice or not (Wang et al., 2012). 
Opiate substitutive drug benefits are applicable whatever the motivations of the patient to 
take the treatment.  
French guidelines stipulate that stopping OMT can be suggested after a period of 
patient’s stabilization if the patient wants it (HAS, 2004). This little-known modality may have 
concerned 6.7% patients treated with buprenorphine in Haute-Garonne (south-western France 
area) in 2010 (Porcher, Poutrain, Lapeyre-Mestre, & Persil, 2012). 
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AN APPRAISAL TO MAXIMIZE: HETEROGENEITY OF CARE ACCESS, BARRIERS FOR GENERAL 
PRACTITIONERS  
 
The management of opiate-dependent patients in France is shared among specialized centres 
and general practitioners (GPs). As previously cited, management in general practice may offer 
advantages (Gossop, Stewart, Browne, & Marsden, 2003; Hutchinson et al., 2000; Wittchen et 
al., 2008). Despite that, heterogeneity of care access was highlighted in the 2004 clarification 
on therapeutic strategy for managing opioid-addicted patients (HAS, 2004), such as inequality 
in this care access according to geographic area. These heterogeneity and inequality exist in 
terms of choice of opioid maintenance treatment and of number of prescribers and pharmacists 
dispending OS (HAS, 2004). 
Today, even if GPs are concerned like health caregivers, often primary care providers, 
a minor part of them is engaged in the management of opioid-addicted patients. Twenty 
percent of GPs used to manage these patients in 2001/2002 (Feroni et al., 2004), which is a 
stable number compared to 1999, with most of them having one or two maintained patients 
(Thirion et al., 2002). 
Several GPs are afraid of drug trafficking which keeps growing (Michel, 2009), 
particularly with the reported frequent resale of buprenorphine (Frauger et al., 2012) and 
its misuse for recreational purpose, even though this misuse is limited in the US (Cicero, 
Surratt, & Inciardi, 2007) and in France (buprenorphine misuse concerns around 10% of 
patients treated with buprenorphine) (Nordmann et al., 2012). Opiate maintenance 
treatments are, always in 2008, within the two first drugs the most illegally obtained in 
France (by 'street market', 'gift', 'theft', 'forged prescription', and 'internet') (Frauger et al., 
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2012). Buprenorphine was one of the drugs for which prescriptions were the most forged 
between 2001 and 2004 (Boeuf & Lapeyre-Mestre, 2007).  
Buprenorphine trafficking is also supported by the « doctor-shopping » 
phenomenon (i.e. patients consulting several physicians in the order to have prescriptions 
for the same drug) (Pradel et al., 2004). Doctor-shopping is considered by several authors 
as one of the most common way to illegally obtain drugs (Inciardi, Surratt, Cicero, & 
Beard, 2009; Winther & Bramness, 2009). And, actually, since the beginning of OMT in 
France, non-rational behaviours have been shown (Lapeyre-Mestre et al., 2003). It would 
concern 25% to 40% of these patients (Pradel et al., 2004). No lower retention rate was 
shown for these patients (Lapeyre-Mestre et al., 2003). The aim of polyprescription 
remains unclear (to sustain black market, to increase dose, to misuse buprenorphine, etc.) 
as studies assessing for the best this issue are performed in reimbursement databases.  
To struggle against street market of buprenorphine, the Summary of Product 
Characteristic and the Haute Autorité de Santé (HAS) guidelines (HAS, 2004) recommend 
that the physician and the pharmacist act systematically in concert. This collaboration is 
actually not always performed (54% of the physicians concerned in Bouches-du-Rhône in 
2002). Predictive factors are physician’s training in addictology care, being in touch with a 
network, having a favourable opinion of buprenorphine prescription in ambulatory care, 
and early moving into the patient management. This collaboration is associated with 
positive outcomes for the patient’s management (Feroni et al., 2005).  
Whatever it be, these behaviors of certain patients cause damage to opioid-addicted 
patients who are suffering from stigmatization from the general public as well as health 
professionals, of whom the GPs. In a study performed by the Observatoire Français des 
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Drogues et des Toxicomanies OFDT, two over three GPs reported their refusal to manage 
some opioid-addicted patients consulting them (OFDT, 2002). A medical thesis about 
difficulties experienced by the GPs in prescribing OMT highlighted relational difficulties 
reported by GPs in front of these patients (Laleu, 2013). More generally, high levels of 
stigmatization toward psychiatric patients have been shown by studies conducted in health 
professionals or medical students (Ay, Save, & Fidanoglu, 2006; Li, Li, Thornicroft, & 
Huang, 2014; Mukherjee, Fialho, Wijetunge, Checinski, & Surgenor, 2002). Stigmatization 
restricts care access, treatment quality and life quality of patients suffering from 
psychiatric disorders (Livingston & Boyd, 2010; Thornicroft, 2008). The representation of 
addiction as a disease is not the rule, and for GPs less than for psychiatrists (Lawrence, 
Rasinski, Yoon, & Curlin, 2013). Representations and stigmatization can be decreased by 
medical education and training (Balhara, Yadav, Arya, & Kataria, 2012; Mas & Hatim, 
2002). Moving attitudes by this way seems essential but takes time.   
Finally, one of the difficulties for physicians involved in treating opioid-addicted 
patients is to evaluate the concordance between the patient's word and his drug use (OMT 
and other illicit drugs) (Lavie et al., 2008) while associated drug use is frequent (at least 
one or two thirds of patients under OMT would also consume alcohol and benzodiazepines 
(Lapeyre-Mestre et al., 2003)).  
In the field of addiction, assessment of substances consumption is crucial for 
diagnosis and, even more, for medical management. Nevertheless, this assessment is often 
difficult as self-reports use to under estimate psychoactive substances’ consumption 
(Galletly, Field, & Prior, 1993; Kilpatrick, Howlett, Sedgwick, & Ghodse, 2000; Lundy et 
al., 1997; Olshaker, Browne, Jerrard, Prendergast, & Stair, 1997; Perrone, De Roos, 
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Jayaraman, & Hollander, 2001). One Scandinavian study in 2009 (Mordal, Holm, 
Mørland, & Bramness, 2010) compared the assessment by the psychiatrist of drug 
consumption in an emergency setting to that obtained by a urine drug screening test 
(UDT); the reference method being chromatography-tandem mass spectrometry. The 
physician had correctly assessed the consumption of alcohol but the assessment for illicit 
substances was not so good for others psychoactive substances. The value of urine drug 
screening was assessed comparing urine screening tests’ results and chromatography. At 
the same time, urine drug screening presented a better sensitivity for benzodiazepines, 
opiates and for cannabis. This study clearly showed that physicians’ assessment of 
psychoactive drug use lead to underestimate the true consumptions, and UDT would be 
useful in making decisions about treatment. 
By contrary, in certain context, patients can overestimate their use of psychoactive 
substances notably when entering a detoxification program (Zullino, Krenz, Eap, 
Benguettat, & Khan, 2008).  
Despite advances during these thirty last years in managing and treating patients with 
abuse or addiction, addiction management consists always in a difficult practice 
(Governmental Plan 2008-2011 (MILDT, 2008)) exposing the GP by contrast to the 
multidisciplinary team of a specialized centre (called Centre de Soins d’Accompagnement et de 
Prévention en Addictologie CSAPA in France) or to an hospital addiction care unit team.  
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The characteristics of general practice according to the World Organization of National 
Colleges, Academies and academic associations of general practice/family physicians 
(WONCA) are that it: 
a) is normally the point of first medical contact within the health care system, providing 
open and unlimited access to its users, dealing with all health problems regardless of the age, 
sex, or any other characteristic of the person concerned. 
b) makes efficient use of health care resources through coordinating care, working with 
other professionals in the primary care setting, and by managing the interface with other 
specialties taking an advocacy role for the patient when needed. 
c) develops a person-centered approach, orientated to the individual, his/her family, 
and their community. 
d) promotes patient empowerment. 
e) has a unique consultation process, which establishes a relationship over time, 
through effective communication between doctor and patient. 
f) is responsible for the provision of longitudinal continuity of care as determined by 
the needs of the patient.  
g) has a specific decision making process determined by the prevalence and incidence 
of illness in the community.  
h) manages simultaneously both acute and chronic health problems of individual 
patients.  
i) manages illness which presents in an undifferentiated way at an early stage in its 
development, which may require urgent intervention.  
j) promotes health and well-being both by appropriate and effective intervention.  
k) has a specific responsibility for the health of the community.  
Assessing the value of urine drug screening tests                                                                              Introduction
26 
 
l) deals with health problems in their physical, psychological, social, cultural and 
existential dimensions (WONCA, 2011).  
Thus, the practice of general practice is completely adapted to the management of 
addicted patients. Furthermore, the practice of general practice is characterized by managing 
complex situations.  
Nevertheless, decision making may be in a short term (mean time of consultation is 18 
minutes for psychiatric disorders (DREES, 2006)) and without the support of a 
multidisciplinary team. These characteristics have to be taken into account before to offer a 
help to GPs.  
In other medical domains, tools adapted for ambulatory care demonstrated their value 
in making decision about treatment like the rapid diagnostic test of sore throat (Portier et al., 
2001).  One study directed by the Direction de la Recherche, des Etudes, de l’Evaluation et des 
Statistiques DRESS about general practice highlighted that the good practice guidelines are the 
first help tool for prescription and patients’ management (DREES, 2007). 
In this context, UDT would be useful in making decisions about treatment in opiate 
addicted patients and would help GPs engaged in the management of opioid-addicted patients. 
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CHARACTERISTICS OF URINE DRUG SCREENING TESTS  
 
Drug tests can be carried out by immunochemical methods, either by automated analyzers 
in the biology laboratory or by drug screening kits in the surgery of the physician. 
Screening can be done during the patient’s visit, in either a specialized addiction centre or 
the physician’s office with an immediate lecture of results. These tests (whether on a 
laboratory automat or using a commercial kit) are qualitative and have defined thresholds. 
Results can be confirmed by the reference method, liquid or gas phase chromatography 
with mass spectrometry, which gives quantitative measurements (Bagøien, Morken, 
Zahlsen, Aamo, & Spigset, 2009). Laboratory tests, regardless of the method or the 
biological medium, are reimbursed by the French health insurance system with no limit on 
their number or time period. On-site urine drug screening (OS-UDT) by commercial kits is 
not reimbursed by the French health insurance system but some specialized addiction 
networks in France provide them to their members. 
It is possible to observe differences in sensitivity and specificity between available 
commercial tests for which detection thresholds can vary; fields covered by each test are, 
themselves, also variable. These tests have limits which need to be recognized to ensure 
pertinent treatment. In addition, it is essential to ensure that they propose a qualitative 
determination to be able to interpret the significance.  
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Positivity threshold are generally in accordance with the recommendation of the 
National Institute on Drug Abuse (NIDA) (NIDA, 1986) and the Substance Abuse and 
Mental Health Administration (SAMSHA) (SAMSHA, 2008) (See Table 1). These 
recommendations are from the working world in which urine drug screening tests are only 
performed for controlling. The SAMSHA increased the threshold for screening opiates in 
2008 (2000ng/mL instead of 300ng/mL) to avoid false positive to ingestion of poppy-
seeds. Nevertheless, many laboratories maintained the threshold of 300 ng/mL to preserve 
the opiates screening sensibility (Moeller, Lee, & Kissack, 2008). Thus, most commercial 
kits always use the threshold of 300 ng/mL.  
Table 1 : Cutoff values used in workplace (Moeller et al., 2008) 
 
 
Substance 
 
Initial drug test level 
(immunoassay) 
(ng/mL) 
 
Confirmatory drug test level 
(gas chromatography-mass 
spectrometry) 
(ng/mL) 
 
 
Marijuana metabolites 
 
50 
 
15 
Cocaine metabolites 300 150 
Opiate metabolites 2000 2000 
Amphetamines 
 
1000 500 
 
Positivity thresholds currently used are (NIDA, 2008):  
- buprenorphine: 10 ng/mL 
- methadone: 300 ng/mL (or the metabolite 2-ethylene-1,5-dimethyl-3,3-
diphenylpyrrolidine EDDP: 100 ng/mL)  
- opiates: 300ng/mL  
- cocaine: 300 ng/mL  
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Urine drug screening tests deter opiates, in particular morphine and codeine, but not 
fentanyl nor oxycodone (specific immunoassays can be used for these substances). Urine 
drug screening tests for alcohol are not validated and those for benzodiazepines are not 
testing all benzodiazepines (Z-drugs are not detected: zopiclone and zolpidem). 
The physician must take into account detection time windows for interpreting the 
given results. Table 2 describes these time windows. 
Table 2: Time windows for the detection of drugs of abuse in urine (Moeller et al., 2008) 
 
Drug 
 
 
Time 
 
Alcohol 
 
7 - 12 h 
Amphetamine/Metamphetamine 48 h 
Benzodiazepine  
Short-acting 3 d 
Long-acting 30 d 
Cocaine metabolites 2 - 4 d 
Marijuana  
Single use 3 d 
Moderate use (4times/wk) 5 -7 d 
Daily use  10 -15 d 
Long term heavy smoker >30 d 
Opioids  
Codeine  48 h 
Heroin  48 h 
Hydromophone  2 - 4 h 
Methadone  3 d 
Morphine 48 - 72 h 
Oxycodone 2 - 4 d 
Propoxyphene 
 
6 - 48 h 
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The physician must also be watchful about interactions. Numerous false negatives 
exist, notably for cocaine and benzodiazepines; the tests have better intrinsic qualities for 
the detection of opiates (1.9% false negatives) (Table 3) (Pesce et al., 2010). False positive 
exits also, mainly with psychotropic drugs (Table 4). 
Table 3: Percent of false negatives obtained by urine drug screening test (in the consulting rooms of 
physicians) in chronic pain patients (Pesce et al., 2010) 
 
Drug 
 
 
Total tested 
 
Percent false negative 
 
Amphetamine 
 
2792 
 
9.3% 
Benzodiazepines 3301 22% 
Cannabinoid 2921 10.6% 
Cocaine 2840 50% 
Methadone 2735 6.1% 
Opiates 
 
3414 1.9% 
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Table 4: Agents leading to false positive results (Brahm, Yeager, Fox, Farmer, & Palmer, 2010; 
Moeller et al., 2008) 
 
Substance tested 
 
 
Agents leading to false positive results 
 
Amphetamine or 
Methamphetamine 
 
Amphetamines derivates (benzphetamine, chlobenzorex, l-Deprenyl, 
dextroamphetamine, fenproporex, MDMA, methylphenidate, 
phentermine) 
Antihistamines/decongestants (brompheniramine, ephedrine, 
pseudoephedrine phenylpropanolamine, phenylephrine, 
phenylpropanolamine) 
Antidepressants (bupropion, trazodone, desipramine, trimipramine) 
Antipsychotics (chlorpromazine, promethazine, thioridazine) 
Other agents (amantadine, isomethepthene, isoxsuprine, labetalol, 
ranitidine, ritodrine, selegiline, trimethobenzamide) 
 
Methadone Antihistamines/decongestants (diphenhydramine, doxylamine) 
Antidepressants (clomipramine) 
Antipsychotics (chlorpromazine, quetiapine, thiorizadine) 
Other agents (verapamil) 
 
Opioids, opiates and heroin Opiate derivates (dextrometorphan, heroin, opiates – codeine, 
hydromorphone, hydrocodone, morphine -, poppy seeds) 
Antihistamines (diphenhydramine) 
Antibiotics (quinolones, rifampin) 
Other agents (quinine, verapamil and metabolites) 
 
Benzodiazepines Antidepressants (sertraline) 
NSAIDS (oxaprozin) 
 
Cannabinoids Cannabinoids derivates (dronabinol, hemp-containing food) 
NSAIDS (ibuprofen, naproxen, tolmetin) 
Proton pum inhibitors 
Other agents (efavirenz) 
 
Cocaine Coca leaf tea 
Topical anesthesics containing cocaine 
 
Tricyclic antidepressants Antiepileptics (carbamazepine) 
Antihistamines (cyproheptadine, diphenhydramine, hydroxyzine) 
Antipsychotics ( quetiapine) 
Other agents (cyclobenzaprine) 
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In the Scandinavian study previously cited (Mordal et al., 2010), the assessment by 
the psychiatrist of drug consumption in an emergency setting was less efficient than the 
assessment obtained by a urine drug screening test. The reference method was 
chromatography-tandem mass spectrometry.  The physician had correctly assessed the 
consumption of alcohol but the assessment for illicit substances was not so good: 76% 
sensitivity for amphetamines, 61% for benzodiazepines, 57% for opiates, 55% for cannabis 
and only 50% for cocaine. Specificity rates varied from 94 to 99% for the various classes 
of substances. At the same time, UDT presented a sensitivity of 76% for amphetamines, 
83% for benzodiazepines, 80% for opiates and 97% for cannabis. The specificity rates 
varied from 82 to 100% for the various classes of substances.  
Table 5: Physician's assessment of recent substance intake (n = 325) and on-site urine screening tests 
results (n = 92) compared with urine laboratory findings serving as the reference standard (Mordal et 
al., 2010) 
  
Physician assessment 
 
 
On-site screening test 
  
Sensitivity  
(95%CI), % 
 
 
Specificity  
(95%CI), % 
 
Sensitivity  
(95%CI), % 
 
Specificity  
(95%CI), % 
 
Benzodiazepines  
 
61 (53 – 68) 
 
94 (90 – 97) 
 
83 (71 – 94) 
 
84 (74 – 94) 
Opiates  57 (37 – 75) 96 (92 – 98) 80 (55 – 100) 99 (96 – 100) 
Amphetamine  76 (64 – 88) 96 (93 – 98) 76 (58 – 94) 99 (96 – 100) 
Cannabis  55 (42 – 68) 96 (93 – 98) 97 (91 – 100) 82 (72 – 92) 
Cocaine  50 (10 – 90) 99 (98 – 100) - 100 (100) 
Ecstasy  
 
- - - 100 (100) 
 
In another study, sensibility for buprenorphine with 3 different OS-UDT varied 
from 88 to 100% and specificity from 91 to 100 % (Leino & Loo, 2007).  
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A recent study in the Netherlands compared UDT results performed by physicians 
and nurses in an emergency setting and not specifically trained to their use versus UDT 
results analyzed by the same immunochemical technique but in a laboratory by trained 
technicians. The sensitivity of three different commercial kits (screening for opiates, 
methadone, cocaine, tricyclic antidepressants and barbiturates) was assessed (considering 
tests performing in the laboratory as the gold standard) and ranged from 80 to 100% and 
specificity from 93 to 100% with no difference between the tests performed in the 
emergency setting than in the laboratory (Attema-de Jonge, Peeters, & Franssen, 2011). 
As far as we know, no study reported positive and negative predictive values. 
Furthermore, studies cited above concerned mainly chronic pain patients treated by 
opioids. If sensitivity and specificity can be extrapolated to a population of opioid-addicted 
patients because of their intrinsic value, positive and negative predictive values depend on 
the prevalence of the studied phenomenon and, thus, should be assessed in this specific 
population to be discussed.  
In medical offices, immunoassays have been shown to be reliable (Manchikanti, 
Malla, Wargo, & Fellows, 2011a, 2011b). Performing UDT at the physician office seems, 
thus, to be an appropriated answer to the requirements and questions for optimizing the 
management quality. Whatever it be, prudence is recommended for managers of clinical 
laboratories and good quality information is therefore required for clinicians in the field 
(Melanson et al., 2010).  
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GUIDELINES ABOUT URINE DRUG SCREENING TESTS VERSUS PRACTICES IN FRANCE  
 
In France, summaries of product characteristics of methadone and buprenorphine (which 
govern the legal aspects of their prescription), such as circulars of the Direction Générale 
de la Santé DGS n°14 (7 March 1994) and n°4 (11 January) and n°29 (31 March 1995) 
reminded conditions of the marketing authorization (Autorisation de mise sur le marché 
AMM) and detail the recommendations about urine tests. Methadone prescription 
guidelines detail the recommended urine tests: a first, obligatory test before starting 
methadone treatment and later control tests. The first urine test confirms current drug 
consumption and the absence of methadone intake. Tests are subsequently done once or 
twice a week during the first 3 months of treatment, then twice monthly. When the patient 
has been transferred to an outpatient setting, tests can be done if the physician considers it 
necessary. Tests are not obligatory for buprenorphine. The circular of the Direction de 
l’Hospitalisation et de l’Offre de Soins DHOS of the 29th April 2002 took over the 
elements of 1994 and 1995 and detailed that urine tests have to be continued once a month 
without time limit. In 2004, updated French guidelines on optimal opiate addict care 
reinforced these recommendations and advised a standardized screening test schedule in 
the initiation of buprenorphine treatment
 
(HAS, 2004).  This biological analysis can also be 
proposed for the follow-up with the patient’s consent. The OMT group from the addiction 
commission of the French health ministry highlighted the value of urine monitoring to 
improve therapeutic management quality and specified that performing these analyses must 
not weigh care ask and it accessibility. Lead-time of laboratory results actually are a barrier 
to a good management of patients addicted to opioids. Moreover, all patients do not 
perform these analyses as agreed with the physician. These analyses are, besides, 
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expensive leading the DGS to interview their utility. A clarification was published in 
October 2011 by the French agency of medicinal products, called Agence Française de 
Sécurité Sanitaire des Produits de Santé AFSSAPS at this time (AFSSAPS, 2011). The 
need for urine testing was reminded before starting an OS with the patient’s consent; and 
the possibility of urine testing after that. 
Some physicians, using regularly UDT, specifically in specialized centres or in 
hospital report that they bring a help to the dialogue, in addition to enable drug use 
monitoring. On the other hand, others argue that the use of these tests will be in opposition 
with the confident patient-doctor relationship. Nevertheless, a freedom of the speech could 
be trigger after talking with the patient of the results of the urine drug screening test. The 
addicted patient is extremely self under evaluated; the declaration of a drug use to his 
physician (but also to himself) is often difficult and could be as difficult as the relationship 
with the physician is of quality. The opioid-addicted patient process is difficult and 
deterring sooner relapses enables to talk about consumptions and craving and to reinforce 
therapeutic management. 
Urine screening would so have two goals: 
- A “technically” first one when starting treatment to check the absence of an 
anterior treatment by methadone before prescribing it and to assess 
associated consumptions to start buprenorphine or methadone. 
- A second one in the follow-up to assess consumptions and to facilitate the 
dialogue about craving by the way of this assessment. The value would be 
then to repeat them more frequently than monthly: weekly with contingent 
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take-homes would be a condition with better outcomes in heroin use 
(Chutuape, Silverman, & Stitzer, 2001). This assessment could of course be 
associated with other assessment tools (craving calendar for example). 
Guidelines highlight the use of the first “technically” test when starting treatment 
and advised tests for the follow-up in an optional manner without explaining their potential 
value at this stage. However, when you consider addiction as a chronic relapsing disease, 
the potential value of the second test seems obvious. 
Practices may differ from guidelines and from the above defined framework. In 
specialized centres (CSAPA), practices are heterogeneous between health professionals of 
a same CSAPA as well as between different CSAPA (Saura, 2011).  
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IMPACT OF URINE DRUG SCREENING TESTS  
 
For opioid maintenance treatments, these tests are used to assess the achievement of 
abstinence and the intake of the drug used for opioid maintenance as well as for the 
assessment of others consumptions. Their place could be, before starting OMT, to 
complete the initial assessment and to decide to prescribe the OMT: or in the follow-up, to 
monitor the consumptions and the craving, to evidence with the patient the achievement of 
abstinence, to have a positive reinforcement when results are negative and to deter as soon 
as possible the use of the substance to talk about it with the patient and reinforce the 
therapeutic management if necessary. UDT should be of significant use for GPs treating 
opioid-addicted patients by promoting dialogue, further educating patients in treatment-
related issues and network-based work. 
The value of drug tests for the diagnosis of substance abuse has been demonstrated: 
many studies agree that drug tests are more sensitive than self-reports (Galletly et al., 1993; 
Kilpatrick et al., 2000; Lundy et al., 1997; Olshaker et al., 1997; Perrone et al., 2001) or 
physician clinical evaluation (Mordal et al., 2010). Nevertheless while diagnostic value of 
these tests is well demonstrated, the consequences of carrying out these tests on 
management of treatment have not been established.  
In school programs (Roche, Bywood, Pidd, Freeman, & Steenson, 2009) and in 
occupational drivers (Cashman, Ruotsalainen, Greiner, Beirne, & Verbeek, 2009), drug 
tests are known to be effective respectively on the illicit drug use and injuries. In 
emergency settings, a recent review found that drug tests may have no influence on 
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therapeutic management (Tenenbein, 2009). In chronic non-cancer pain patients, the 
effectiveness of urine testing to reduce opioid misuse is still debated (Starrels et al., 2010). 
In the field of algology, these tests are frequently used to reduce the risk of misuse 
of opioids prescribed over the long term for chronic non cancer pain. The American 
recommendations advocate, before initiating treatment, the collection of written consent 
from the patient, and urine drug screening tests to identify any risk of misuse (Chou et al., 
2009). These recommendations are also applied in the whole North-America (Gourlay, 
Heit, & Almahrezi, 2005). Procedures for urine drug testing are well described in this field 
(Christo et al., 2011; Owen, Burton, Schade, & Passik, 2012). Urine drug screening tests 
are also used for adolescents, generally at the request of the parents, but there is a great 
lack of training in correctly carrying out and analysing these tests correctly (Levy, Harris, 
Sherritt, Angulo, & Knight, 2006). 
Few studies explored the consequences of carrying out these tests on medical 
management whereas they should have a particular value in primary care while outpatients 
care is developing (Walley et al., 2008). Since few years, actually, the use of these tests has 
been increasing in general practice. American general practitioners question the possibility 
of using these tests in their daily practice (Standridge, Adams, & Zotos, 2010), at a time 
when, in some countries, the use of rapid blood tests as a therapeutic aid is becoming 
common practice (glycosylated haemoglobin, cholesterol, INR, etc.) (Blattner, Nixon, 
Dovey, Jaye, & Wigglesworth, 2010; Laurence et al., 2008).  
Some addiction network used performing these tests: the « Passage » network in 
Toulouse conducted a pilot study to assess drug use: 17.7% of the first prescriptions have 
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been questioned, many associated consumptions were shown, particularly of 
benzodiazepines (unpublished data).  
Besides, monitoring procedures have been shown useful and effective to control 
behaviours of patients treated with an OMT. A first study, in France, suggested that the 
behaviours of patients treated with OMT depended less on the nature of the maintenance drug 
than the nature of the delivery and monitoring practices (Barrau et al., 2001). Efficacy of 
prescription monitoring programs has been shown in the US to decrease opioid analgesics 
consumptions (Chakravarthy, Shah, & Lotfipour, 2012; Simoni-Wastila & Qian, 2012). In 
France, they are associated with a decrease of doctor-shopping indicators (Pradel et al., 2009). 
Consumptions’ monitoring by OS-UDT should decrease doctor-shopping behaviours and 
improve compliance of patients. 
Compliance of patients on OMT could be improved by a monitoring procedure such as 
on-site urine drug screening test (OS-UDT). Patients may be self-motivated by the negativity 
of OS-UDT. Testing will urge GPs to be more attentive to substances’ consumptions of their 
patients. This higher attention from GP will be beneficial for patients. 
All these data highlight the importance of monitoring in OMT programs. Monitoring in 
OMT programmes should be beneficial for GPs and patients modifying their behaviours. As 
reminded above, available treatments are effective. To help GPs assessing consumptions with a 
basic tool like OS-UDT should help them to be more at ease with addictive diagnoses and 
should promote their involvement in opioid-patients management. This can only have 
beneficial outcomes for patients in terms of care access but also in terms of a decrease of 
morbidity and mortality thanks to a longer OMT retention. 
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OBJECTIVE 
 
The objective of this thesis is to assess the value of urine drug screening in opioid-addicted 
patients managed in ambulatory care.  
This assessment has been conducted in three parts: 
- The first one aimed to summarize the knowledge concerning urine drug 
screening tests in the literature and of French GPs.  
- The second one aimed to assess the effectiveness of drug tests in managing 
opioid-addicted patients using observational cohorts conducted from French 
health insurance system databases.  
- Finally, the last part aimed to confirm the value of urine drug screening test 
in real life and thus, to assess their efficacy planning a pragmatic cluster 
randomized controlled trial in general practice. 
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PART 1: KNOWLEDGE CONCERNING URINE DRUG SCREENING TESTS  
 
This first part aimed to summarize the knowledge concerning drug tests in the literature 
and of French GPs. As few studies assessed the prevalence of performing drug tests and 
the knowledge of UDT outside the North America, we aimed to investigate these issues in 
France by a transversal descriptive study. Besides, while the diagnostic value of UDT was 
clearly established and studies demonstrating their value on the therapeutic management 
were sparse, we aimed to summarize the evidence on this issue with a systematic review. 
 
Partie 1 : Connaissance des tests urinaires de dépistage 
Synthèse des connaissances des tests dans la littérature et par les médecins généralistes français  
Première publication : 
Cette étude descriptive menée en Midi Pyrénées avait pour objectif d'évaluer les connaissances et 
l’utilisation des tests urinaires de dépistage des médecins généralistes prenant en charge des patients 
dépendants aux opiacés. Un questionnaire a été envoyé par courrier postal à 1340 médecins généralistes 
tirés au sort à partir des bases de données de l'Union Régionale des Médecins Libéraux. Le taux de réponse 
était de 37% (n=496), 482 questionnaires ont été inclus. Parmi ceux-ci, 24,1% des médecins prenaient en 
charge régulièrement des patients dépendants. Concernant les tests urinaires de dépistage, 3,4% des 
médecins en réalisaient au cabinet médical à l'initiation et au suivi d'un traitement substitutif. Ces médecins 
manquaient d'information sur l'existence de ces tests, leur fiabilité, les moyens de se les procurer.  
Deuxième publication : 
Une revue systématique de la littérature a été réalisée selon les recommandations internationales PRISMA 
avec pour objectif d’évaluer si la réalisation de test urinaire de dépistage modifiait la prise en charge 
médicale et ses conséquences pour les patients abuseurs ou dépendants (ou à risque de l’être). La recherche 
a été effectuée le 26 octobre 2011  sur plusieurs bases de données : PubMed, ISI Web of Science, PsycINFO, 
Cochrane database of systematic reviews, Cochrane central register of controlled trials, Cochrane Drugs 
and Alcohol group et National Institute of Drug Abuse (NIDA). Deux relecteurs ont sélectionné 
indépendamment les articles selon des critères d’inclusion précis ; leur accord a été évalué par le coefficient 
κ de concordance inter évaluateur.  Les données des articles inclus ont été extraites à l’aide d’une grille 
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standardisée. Leur qualité a été évaluée par des échelles validées (score de Starrels, GRADE, CONSORT et 
STROBE). Une synthèse qualitative a été menée. Sur 6046 articles identifiés, 8 ont été inclus : 1 essai 
clinique randomisé, 2 études quasi-expérimentales type avant/après, 1 étude de cohorte, et 4 études 
transversales descriptives. Ces études de qualité faible à moyenne ont montré que la réalisation de tests 
urinaires de dépistage entrainait peu ou pas de modification de prise en charge dans des populations de 
patients en centre anticancéreux, en centre antidouleur, en service de médecine, et aux urgences 
psychiatriques ou médicales. Les critères de jugement de ces études étaient hétérogènes et subjectifs. 
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STUDY 1: ON-SITE DRUGS OF ABUSE URINARY SCREENING TESTS FOR THE MANAGEMENT OF 
OPIATE-ADDICTED PATIENTS: A SURVEY AMONG FRENCH GENERAL PRACTITIONERS  
PRESENTATION OF THE STUDY 
Dupouy J, Bismuth S, Oustric S, Lapeyre-Mestre M 
On-Site Drugs of Abuse Urinary Screening Tests for the Management of Opiate-
Addicted Patients: A Survey among French General Practitioners 
European Addiction Research 2012; 18: 175‑83 (Dupouy, Bismuth, Oustric, & Lapeyre-
Mestre, 2012) 
OBJECTIVE  
The objective of this first study was to investigate French GPs’ knowledge and practices 
concerning drug tests with a focus on OS-UDTs. 
METHOD  
To perform an overview on this topic, we conducted a descriptive cross-sectional study in 
ambulatory practice. A random sample of 1340 GPs (i.e. one third of all GPs in the database) 
was selected from the Union Régionale des Médecins Libéraux’s (URML) computerized 
database of all GPs working in ambulatory practice in the Midi-Pyrénées area of France 
(region of south-western France, 3 million inhabitants). GPs with a nonexclusively 
ambulatory family practice were excluded. Postal questionnaires were sent in December 2009. 
RESULTS 
Of the 1340 send questionnaires, 496 were returned (37.0%) and 482 (36.0%) were included 
in the analysis. Of the 482 GPs in the sample, 116 (24.1%) regularly treated opiate-addicted 
patients. Only 31 of them (26.7%) used drug tests and 4 of them (3.4%) performed OS-UDT 
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in their consultation rooms. The main reason for not performing UDT was a lack of 
knowledge about screening test: most of the GPs did not perform OS-UDT because they were 
unaware of whether such tests were reliable or available. Among the few GPs using tests, the 
consequence they reported was mainly reinforcing dialogue with the patient. 
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 Introduction 
 Since 1996, two drugs have been approved in France 
for the treatment of opiate addiction: methadone, a long-
acting agonist at the   receptor, and buprenorphine, a 
long-acting partial agonist at the   receptor. The rules of 
prescription for these two drugs differ widely and they 
are both delivered in different ways. Methadone use is 
governed by the regulations on the application of narcot-
ics in France  [1] . Initial methadone prescription is re-
stricted to specialized addiction centers and usually re-
quires strict patient compliance with a supervised daily 
intake, as well as urinary tests. Psychosocial support and 
follow-up is also usual. When patients are stable, a higher 
amount of methadone can be given for take-home treat-
ment. Switching from treatment centre to general practi-
tioner (GP) prescription is also possible. Methadone must 
be prescribed on a special form for controlled substances 
and for no more than 14 days. It must be dispensed by the 
pharmacist named on the prescription. As of January 
2002, the initial prescription of methadone can be made 
by any hospital practitioner in order to make access to it 
easier. In contrast, buprenorphine, a psychotropic medi-
cine in Schedule III of the 1988 Convention  [1] , is not clas-
 Key Words 
 Opioid-related disorders   Substance abuse detection   
Family practice   Immunoassay   Opiate substitution 
treatment 
 Abstract 
 In France, opiate-addicted patients are mainly managed by 
general practitioners (GPs). Because on-site abuse drugs uri-
nary screening tests (ODUTs) are now on the market, we in-
vestigated French GPs’ knowledge and practices concerning 
drug tests with a focus on ODUTs. We conducted a descrip-
tive cross-sectional study in ambulatory practice. Postal 
questionnaires were sent to a random sample of GPs in the 
Midi-Pyrénées area of France in December 2009. Of the 482 
GPs in the sample, 116 (24.1%) regularly treated opiate-
addicted patients. Only 31 of them (26.7%) used drug tests 
and 4 of them (3.4%) performed ODUTs in their consultation 
rooms. Most of the GPs did not perform ODUTs because they 
were unaware of whether such tests were reliable or avail-
able. Many French GPs treating opiate-addicted patients 
regularly did not perform ODUTs and lacked knowledge of 
them.  Copyright © 2012 S. Karger AG, Basel 
 Received: September 5, 2011 
 Accepted: January 10, 2012
 Published online: March 23, 2012 
European
Addiction
cRe es ar h
 Julie Dupouy 
 University of Toulouse, Department of Family Practice
Faculté de Médecine Rangueil 
 133, route de Narbonne,  FR–31063 Toulouse (France) 
 Tel. +33 561 145 978, E-Mail julie.dupouy   @   dumg-toulouse.fr 
 © 2012 S. Karger AG, Basel
1022–6877/12/0184–0175$38.00/0 
 Accessible online at:
www.karger.com/ear 
D
ow
nl
oa
de
d 
by
: 
IN
SE
RM
 D
IS
C 
IS
T
19
3.
54
.1
10
.3
3 
- 1
0/
21
/2
01
4 
4:
01
:5
7 
PM
 Dupouy  /Bismuth  /Oustric  /
Lapeyre-Mestre 
 Eur Addict Res 2012;18:175–183 176
sified as a narcotic in France and can be prescribed by any 
physician and dispensed by any community pharmacist. 
Prescription must be on a special form for controlled sub-
stances and may be for a maximum of 28 days. Since Sep-
tember 1999, buprenorphine has had to be dispensed in 
multiples of 7 days. The Summary Product Characteris-
tics of buprenorphine mention that maintenance treat-
ment with buprenorphine has to be included in a global 
programme of medical, social and psychological care. 
The recommended daily dose ranges from 4 to 10 mg, 
with a maximum of 16 mg. Health authorities have also 
encouraged training programmes on addiction and the 
formation of informal networks of GPs, pharmacists and 
specialized centers. 
 In ambulatory practice, GPs can be involved in initiat-
ing treatment by buprenorphine and follow-up of treat-
ment by buprenorphine and methadone. Because bu-
prenorphine is easily obtainable  [2] , most opiate-addicted 
patients are treated in general practice using this drug  [3] . 
The number of people receiving opiate maintenance 
treatment (OMT) was estimated at around 100,000 for 
buprenorphine and around 35,000 for methadone in 
2009  [4] . The proportion of French GPs involved in these 
patients’ treatment is around 20%  [3] . 
 The Summary of Product Characteristics of metha-
done specifies that an initial urinary analysis has to be 
performed to assess opiate addiction and to confirm the 
absence of methadone before initiating methadone pre-
scription. Then, urinary analyses have to be performed 
once or twice a week during the first 3 months of treat-
ment, and twice a month after this period. Substances 
tested for will be methadone, opiate, alcohol, cocaine, 
amphetamines, cannabis and LSD. After the patient has 
been transferred from a specialized center to a GP, uri-
nary analyses can be used at the GP’s discretion. If a pa-
tient is treated with buprenorphine, there is no regula-
tory requirement for urine testing. In 2004, French guide-
lines  [5, 6] reasserted the compulsory need for urinary 
analyses to initiate methadone prescription and recom-
mend them before buprenorphine prescription and dur-
ing the follow-up of both treatments. These guidelines 
highlight the need to establish consistent regulations on 
urinary analyses. GPs who began prescribing OMT after 
2004 might be more informed on drug tests than GPs 
who prescribed OMT since a long time.
 Screening assays based on immunoassay procedures 
 [7] are used to assess the consumption of substances. 
Confirmatory procedures with the gold standard for 
drug testing (liquid or gas chromatography-mass spec-
trometry) can then be performed. Recently, on-site uri-
nary screening tests have become available in France, 
granting GPs the opportunity to use them in their con-
sulting rooms. For the following, we will use DTs for drug 
tests and ODUTs for on-site drug of abuse urinary screen-
ing tests. The term DT will refer to all techniques per-
formed in order to search for drugs of abuse in a biologi-
cal liquid (urine or blood). It will include screening assays 
by immunoassay procedures, performed in the consult-
ing room or in a laboratory, and confirmatory testing by 
chromatography-mass spectrometry. The term ODUT 
will be reserved for urine screening assays by immunoas-
say procedures performed on-site, that is to say in the 
consulting room.
 The aim of this work was to investigate GPs’ knowl-
edge and use of DTs with a focus on ODUTs according to 
their involvement in opiate-addicted patients’ treatment 
in an area of south-western France. 
 Materials and Methods 
 This study was conducted in the Midi-Pyrénées area, a region 
of south-western France with 3 million inhabitants. A random 
sample of 1340 GPs (i.e. one third of all GPs in the database) was 
selected from the Union Régionale des Médecins Libéraux’s 
(URML) computerized database of all GPs working in this area in 
ambulatory practice. A postal questionnaire was sent out in De-
cember 2009, with a prepaid envelope enclosed to return the ques-
tionnaire. GPs with a nonexclusively ambulatory family practice 
were excluded.
 The questionnaire included the following items: demographic 
and professional characteristics and GPs’ level of involvement in 
the domain of drug abuse (for online supplementary material, see 
www.karger.com/doi/10.1159/000336540). One question assessed 
addictology training, which is acquired in continuous self-train-
ing in France. Performing DTs or ODUTs was assessed at bu-
prenorphine treatment initiation and during follow-up for bu-
prenorphine or methadone treatment. We also considered the im-
pact of these tests on patient management and reasons for not 
using them. Finally, a number of questions sought to assess GPs’ 
interest in ODUTs. 
 The deadline for returning the questionnaire was 28 February 
2010. Data capture and analysis were performed with EPIDATA 
Entry  and Analysis  . Two groups of GPs were defined: GPs
who regularly treated opiate-addicted patients (more than once 
a month) and those who infrequently (less than once a month) or 
never did. A descriptive analysis was performed with a univariate 
analysis by   2 test to compare demographic and professional 
characteristics between the two groups. Use of DTs was assessed 
in the group of GPs regularly treating opiate-addicted patients. A 
  2 test was performed to compare if GPs who had been practicing 
for less than 5 years (implementation of national guidelines) used 
more DTs than other GPs (who had been practicing between 5 
and 15 years or more than 15 years). Use and knowledge of 
ODUTs was assessed in the group of GPs regularly treating opi-
ate-addicted patients. For that, two subgroup analyses were per-
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formed: the first subgroup included GPs who performed DTs (be 
they blood or urinary tests in laboratories or at the site of consul-
tation) in order to know how performing DTs affected patient 
management; the second analysis included GPs who did not per-
form ODUTs, and aimed to ascertain their reasons for not per-
forming them.
 Results 
 Six questionnaires were sent back because of errone-
ous addresses. Four hundred and ninety-six question-
naires were returned filled in, which constitutes a re-
sponse rate of 37%, although five arrived after the dead-
line and were not included ( fig.  1 ). Of the remaining 
questionnaires, eight were excluded because physicians 
did not engage exclusively in ambulatory family practice 
(five were angiologists, two were retired and one worked 
exclusively in a health-care facility). One GP was exclud-
ed because he did not answer the question investigating 
his involvement in the treatment of opiate-addicted pa-
tients. This left 482 questionnaires which were included 
in the analysis.  Table 1 shows the demographic and pro-
fessional characteristics of the GPs included.
 One hundred and sixteen physicians (24.1%) regularly 
treated opiate-addicted patients, 248 (51.4%) managed 
them rarely (less than once a month), and 118 (24.5%) 
never did so ( fig. 1 ). Forty-nine physicians (10.2%) had 
addictology training and 33 (6.8%) belonged to an addic-
tology care network. One hundred and forty-five physi-
cians (30.1%) had prescribed OMT at least once. 
 GPs regularly treating opiate-addicted patients were 
more frequently trained in addictology, participated 
more frequently in an addictology network, prescribed 
OMT more frequently (univariate p  ! 0.001) and were 
482 questionnaires included
= 482 GPs
GPs treating opiate-addicted
patients regularly: 116
GPs treating opiate-addicted
patients infrequently or never: 366
GPs not performing
ODUTs: 95
GPs performing
ODUTs: 9
GPs performing DTs
in laboratory: 22
1,340 questionnaires sent
496 questionnaires returned
Erroneous addresses: 6
No answer: 838
After the deadline: 5
Not exclusively ambulatory family 
practice: 8
No answer about frequency of
treating opiate-addicted patients: 1
GPs performing
ODUTs: 16
GPs not performing
ODUTs: 278
GPs performing DTs
in laboratory: 12
GPs performing DTs
in laboratory or
consulting rooms: 31
GPs performing DTs
in laboratory or
consulting rooms: 28
No response: 12No response: 72
 Fig. 1. Groups and subgroups of GPs in-
cluded. Main results. ODUTs = On-site 
drugs of abuse urinary screening tests; 
DTs = drug tests. 
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located nearer to a laboratory (p = 0.041). By contrast, 
they were not significantly different in gender (p = 0.143), 
duration of practice (p = 0.242) or type of practice (p = 
0.177) ( table 1 ).
 Of the 116 GPs regularly treating opiate-addicted pa-
tients, 31 physicians (26.7% of GPs regularly treating opi-
ate-addicted patients) reported using DTs ( fig. 1 ). Twen-
ty-seven (23.3%) reported using them for the initiation or 
follow-up of OMT: 7 only for initiation, 11 only for follow-
up and 9 for both situations ( table 2 ). GPs who had been 
practicing for less than 5 years did not use DTs more than 
other GPS (p = 0.347). Only four physicians (3.4%) re-
Table 1.  Demographic and professional characteristics of all GPs in the sample and broken down by treatment of opiate-addicted
patients
Characteristics of GPs All GPs 
(n = 482)
GPs treating 
opiate-addicted 
patients regularly
(n = 116)
GPs treating 
opiate-addicted 
patients infrequently 
or never (n = 366)
p 
value1
Sex
Man 328 (68.0%) 85 (73.3%) 243 (66.4%) 0.143
Woman 138 (28.6%) 27 (23.3%) 111 (30.3%)
No response 16 (3.3%) 4 (3.4%) 12 (3.3%)
Location
Town centers 180 (37.3%) 62 (53.5%) 118 (32.2%) <0.001
Suburbs 133 (27.6%) 23 (19.8%) 110 (30.1%)
Rural areas 169 (35.1%) 31 (26.7%) 138 (37.7%)
Duration of practice
Less than 5 years 40 (8.3%) 14 (12.1%) 26 (7.1%) 0.242
5 to 15 years 89 (18.5%) 21 (18.1%) 68 (18.6%)
More than 15 years 352 (73.0%) 81 (69.8%) 271 (74.0%)
No response 1 (0.2%) 0 (0.0%) 1 (0.3%)
Type of practice
Sole 192 (39.8%) 40 (34.5%) 152 (41.5%) 0.177
Group practice 290 (60.2%) 76 (65.5%) 214 (58.5%)
Distance from a laboratory
Nearby (less than 10 km) 384 (79.7%) 99 (85.5%) 285 (77.9%) 0.041
Further away but used to work with this facility 93 (19.3%) 15 (13.0%) 78 (21.3%)
No easy access to a laboratory 2 (0.4%) 0 (0.0%) 2 (0.5%)
No response 3 (0.6%) 2 (0.5%) 1 (0.3%)
Addictology training
Yes 49 (10.2%) 31 (26.7%) 18 (4.9%) <0.001
No 426 (88.4%) 84 (72.4%) 342 (93.5%)
No response 7 (1.4%) 1 (0.9%) 6 (1.6%)
Participation in addictology network
Yes 33 (6.8%) 30 (25.8%) 3 (0.8%) <0.001
No 441 (91.5%) 85 (73.3%) 356 (97.3%)
No response 8 (1.7%) 1 (0.9) 7 (1.9%)
Prescription of OMT
Yes 145 (30.1%) 86 (74.1%) 59 (16.1%) <0.001
No 327 (67.8%) 27 (23.3%) 300 (82.0%)
No response 10 (2.1%) 3 (2.6%) 7 (1.9%)
1Univariate analysis by 2 test between GPs regularly treating opiate-addicted patients and GPs rarely or never treating opiate-
addicted patients.
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ported performing ODUTs initially and during follow-
up. Six physicians reported using ODUTs in other con-
texts, namely uncovering illicit drug consumption in pa-
tients denying this practice for two GPs; requisitioning by 
the French police force for one GP; screening for illicit 
drugs such as cannabis in minors at parents’ request for 
one GP, and follow-up of cannabis addiction for one GP. 
The remaining GP did not specify his reason for carrying 
out these tests. 
 These 31 GPs reported that performing DTs led them 
to change their management of opiate-addicted patients 
( table 3 ): 9 (29.0%) did not prescribe any treatment follow-
ing the test; 22 (71.0%) reinforced therapeutic education; 
15 (48.4%) referred their patients to a specialist, and two 
Table 2.  Use of DTs (many answers possible) in the group of GPs regularly treating opiate-addicted patients
(n = 116)
Kind of screening tests Yes (n = 31) No (n = 85) No response
Blood tests at laboratory
For initiating OMT 2 (1.7%) 110 (94.8%) 4 (3.4%)
For follow-up OMT 6 (5.2%) 104 (89.7%) 6 (5.2%)
Urinary tests at laboratory
For initiating OMT 11 (9.5%) 103 (88.8%) 2 (1.7%)
For follow-up OMT 15 (12.9%) 94 (81.0%) 7 (6.0%)
Urinary tests at practice (ODUTs)
For initiating OMT 4 (3.4%) 111 (95.7%) 1 (0.9%)
For follow-up OMT 4 (3.4%) 110 (94.8%) 2 (1.7%)
For other reasons 6 (5.2%) 97 (83.6%) 13 (11.2%)
Table 3. Change in addicted patients’ management because tests were performed (many answers possible) in the 
subgroup of GPs regularly treating opiate-addicted patients and performing DTs (n = 31)
Patients’ management Yes No No response
Nonprescription of OMT 9 (29.0%) 16 (51.6%) 6 (19.4%)
Reinforcement of therapeutic education 22 (71.0%) 5 (16.1%) 4 (12.9%)
Referral to a specialised consultation 15 (48.4%) 12 (38.7%) 4 (12.9%)
Other 2 (6.5%) 10 (32.3%) 19 (61.3%)
Table 4.  Reasons for not performing ODUTs in the subgroup of GPs regularly treating opiate-addicted patients 
and not using ODUTs (n = 95)
Reasons for not performing ODUTs Yes No No response
Utility considered insufficient 13 (13.7%) 46 (48.6%) 36 (37.9%)
Cost judged too expensive 13 (13.7%) 34 (35.8%) 48 (50.5%)
Tests considered too long or difficult 9 (9.5%) 38 (40.0%) 48 (50.5%)
Tests’ reliability unknown 42 (44.2%) 20 (21.1%) 33 (34.7%)
Tests’ existence unknown 50 (52.6%) 26 (27.4%) 19 (20.0%)
How to procure tests unknown 59 (62.8%) 16 (17.0%) 19 (20.2%)
Other 7 (7.4%) 34 (35.8%) 54 (56.8%)
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confirmed that they had made other changes (many an-
swers possible).
 Of the 116 GPs regularly treating opiate-addicted pa-
tients, 95 (81.9%) reported that they did not perform 
ODUTs. The reasons reported included ( table 4 ) a lack of 
knowledge about ODUTs – 50 GPs (52.6%) were unaware 
of their existence – and the constraints of ODUTs – 59 
GPs (62.8%) were unaware of how to obtain them. Seven 
GPs reported other reasons: two said that they lacked 
training, and one thought that doing urinary screening 
tests would be considered as a lack of trust in patients and 
might reveal interpersonal problems. The remaining four 
cited reasons mentioned above. The rate of nonresponse 
ranged from 20% to 56.8% for this question.
 In the group of GPs regularly treating opiate-addicted 
patients, the use of ODUTs seemed useful for 65 phy-
sicians (56%) at the initiation of OMT and 73 (62.5%)
during follow-up ( table 5 ). Forty-four physicians (37.9%) 
thought that performing these tests would allow them to 
treat more opiate-addicted patients and to prescribe more 
OMT ( table  5 ). The rate of nonresponse ranged from 
16.4% to 24.1%.
 Discussion 
 This observational study investigated GPs’ knowledge 
and use of ODUTs. Some limitations must be acknowl-
edged. First of all, we performed an anonymous postal 
survey among a sample of GPs randomly selected from 
the whole population of GPs working in the Midi-Pyré-
nées area. One third of GPs were selected and we obtained 
a global response rate of 37%, excluding erroneous ad-
dresses and questionnaires which went astray in the post. 
This response rate is low but similar to response rates ob-
tained from recent French surveys using electronic or 
postal questionnaires to investigate GPs’ practices (from 
23 to 35%)  [8–11] . We did not issue a reminder. Thus, we 
cannot exclude a selection bias in respondents. Unfortu-
nately, we could not compare characteristics between GPs 
included and GPs who did not reply (the URML database 
did not allow this). However, the characteristics of our 
sample of participating GPs were similar to those of the 
whole population of GPs working in the Midi-Pyrénées 
area, particularly where gender, mean age and duration 
of practice were concerned, as can be seen from the re-
gional demographic data made available by the French 
General Medical Council  [12] . By contrast, GPs working 
in rural areas and suburbs were overrepresented in our 
sample, whereas GPs working in town centers were un-
derrepresented. In 2008, in the Midi-Pyrénées area, 
58.3% of GPs worked in town centers, 12.7% in the sub-
urbs and 29.1% in rural areas (data provided by the re-
gional monitoring center for public health, Observatoire 
Régional de la Santé-Midi-Pyrénées). 
 In this study, 24.1% of GPs treated opiate-addicted pa-
tients regularly and 30.1% prescribed OST. These figures 
were probably inflated due to selection bias, as physicians 
involved in addictology were more inclined than the oth-
ers to offer a response. However, other French data iden-
tified that 20% of GPs treated 73% of opiate-addicted pa-
tients and 35% of GPs had prescribed OST at least once 
 [3] . Considering GPs who were used to treat opiate-ad-
dicted patients more than once a month like GPs regu-
larly treating opiate-addicted patients was a choice we 
made to identify GPs involved in treatment of opiate ad-
diction and who could be, thus, concerned by DTs. As 
expected, GPs who regularly treated these patients were 
working mainly in town centres and were more frequent-
ly trained in addictology in the Midi-Pyrénées area. The 
involvement of French GPs in the management of drug 
addicts is lower than that of GPs in other countries: in a 
national survey in England, 51% of GPs had seen opiate 
addicts over the course of the preceding four weeks  [13] . 
Table 5.  Interest in ODUTs in the group of GPs regularly treating opiate-addicted patients (n = 116)
Questions on interest of GPs Yes No No response
Interest in ODUTs?
For initiating OMT 65 (56%) 23 (19.8%) 28 (24.1%)
For follow-up of OMT 73 (62.9%) 16 (13.8%) 27 (23.3%)
Would it be possible to manage more opiate-addicted
patients and prescribe more OMT if ODUTs were
available at the practice?
44 (37.9%) 53 (45.7%) 19 (16.4%)
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This could be partly explained by the differences between 
the health-care systems in the two countries. In England, 
being treated by GPs rather than in drug clinics seems to 
offer the advantage of decreasing consumption practices 
associated with OMT and the occurrence of psychologi-
cal disorders  [14] . By contrast, 24.1% is high compared to 
other countries: in a study carried out in Australia in 
2008, around 1% of all GPs in some jurisdictions pre-
scribed OMT  [15] . In our study, the small number of
GPs regularly treating opiate-addicted patients can be ex-
plained by the generally low level of addictology training 
observed in the GP population and by the GPs’ low rate 
of participation in specialized addiction networks. These 
low levels of training and involvement were also observed 
in a French study in 2005, which reported that 32% of
GPs were trained in addictology and 21% were in touch 
with a specialized addictology network  [16] . One expla-
nation of this low level of involvement should be that GPs 
struggle to assess the extent of patients’ honesty about 
their use of substances (OMT and other illicit drugs)  [17] . 
In reality, one to two thirds of patients on OMT are re-
ported to consume alcohol and benzodiazepines  [18, 19] . 
Furthermore, many French GPs are afraid of bolstering 
drug trafficking  [20] , particularly with the resale of bu-
prenorphine and the increasingly widespread nature of 
OMT. Performing DTs might be an appropriate response 
to these barriers.
 Our results suggest that, in the Midi-Pyrénées area, 
GPs who regularly treat opiate-addicted patients do not 
usually perform screening tests in line with national rec-
ommendations on DTs. Only 23.3% of GPs regularly 
treating opiate-addicted patients reported performing 
DTs for OMT initiation and follow-up. This practice is 
not related to implementation of national guidelines, 
which asked about knowledge of these guidelines. Actu-
ally, GPs who began prescribing OST after implementa-
tion of guidelines (for less than 5 years) were not likely to 
use DTs more than other GPs. For a few GPs using DTs, 
the consequence was mainly increased dialogue with the 
patient. Carrying out ODUTs at the consultation site re-
mained a rarity. This is doubtless unrelated to difficulties 
in accessing a laboratory (none of these GPs reported that 
they could not easily access such a facility). This could 
probably be explained by GPs’ lack of knowledge about 
ODUTs, which was undoubtedly more significant than 
the observations suggested given the nonresponse rate for 
questions on reasons for not using ODUTs and interest
in them. Around half of GPs claimed that they lacked 
knowledge about ODUTs, and the other half did not re-
spond, making it impossible to establish whether they 
lacked knowledge or not. This suggests that the actual 
level of unawareness of ODUTs is higher than that ob-
served. As regards the last question on GPs’ interest about 
ODUTs, a quarter of GPs did not respond; this is unsur-
prising given that they did not know of the existence of 
ODUTs. Indeed, use of DTs is a known practice in the US 
by GPs involved in opiate-addicted patients’ treatment: in 
2008 it was practiced by 82% of practice-based physicians 
authorized to prescribe buprenorphine in Massachusetts 
 [21] . 
 The main finding to have emerged from this study, in 
spite of its limits, is that GPs lacked information con-
cerning the existence and reliability of ODUTs and ways 
to obtain them. This lack of awareness also reflects the 
lack of data in the literature on the topic. A study per-
formed by an addictology network in the capital city of 
the Midi-Pyrénées area (Réseau Passages) reported that 
carrying out ODUTs made it possible to reconsider 17.7% 
of OMT first prescriptions [unpubl. results]. As far as we 
know, few studies have assessed the consequences of per-
forming ODUTs in order to manage addicted patients. 
We have identified systematic reviews in schools  [22] and 
for occupational drivers  [23] : ODUTs seemed to be an 
effective tool on clinical outcomes. ODUTs’ effectiveness 
in limiting abuse in chronic pain patients seems to be 
real  [24, 25] , but needs to be confirmed by further stud-
ies. We also identified studies evaluating ODUTs in an 
emergency context, and these studies did not demon-
strate ODUTs’ effectiveness  [26, 27] . As far as we know, 
no study assessed ODUTs’ effectiveness in ambulatory 
settings or for the management of opiate addicts. Various 
studies looked at the inherent characteristics of ODUTs 
and showed that they are less efficient than liquid chro-
matography-mass spectrometry  [28] . This is due to the 
high number of false-negative results, mainly for cocaine 
and benzodiazepines. By contrast, the performance of 
ODUTs seemed to be more efficient in identifying opiate 
drugs  [29] . A recent Norwegian study  [30] revealed sat-
isfactory levels of sensitivity and specificity on the part 
of ODUTs; these levels were, respectively, 76–97% and 
82–100% compared to liquid chromatography-mass 
spectrometry. This study compared the physician’s as-
sessment of patients’ current intake with the combined 
results of blood and urine laboratory analyses in the psy-
chiatric emergency context; physicians were rather suc-
cessful in assessing alcoholic consumption but less so in 
evaluating illicit drug consumption (76% for amphet-
amines, 57% for opiates and 50% for cocaine). All of 
these results are encouraging and suggest that ODUTs 
could be useful in family practice. However, as far as we 
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know, the usefulness and reliability of ODUTs have not 
been evaluated in ambulatory general practice. Further 
studies are needed for such assessments to be carried out. 
ODUTs should be of significant use for GPs treating opi-
ate-addicted patients by promoting dialogue, further ed-
ucating patients in treatment-related issues and network-
based work.
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STUDY 2: DOES URINE DRUG ABUSE SCREENING HELP FOR MANAGING PATIENTS? A 
SYSTEMATIC REVIEW 
 
PRESENTATION OF THE STUDY  
Dupouy J, Mémier V, Catala H, Lavit M, Oustric S, Lapeyre-Mestre M.  
Does urine drug abuse screening help for managing patients? A systematic review.  
Drug and Alcohol Dependence 2014; 136: 11-20 (Dupouy, Mémier, et al., 2013) 
OBJECTIVE  
In front of the lack of significant evidence of efficacy for managing patients, we conducted a 
systematic review to summarize the evidence pertaining to the efficacy of drug abuse urinary 
screening test for the medical management of patients. 
METHOD  
A systematic review of clinical trials, quasi-randomized and observational studies was 
performed using PubMed, Cochrane database of systematic review, Cochrane central register 
of controlled trials, PsycINFO, National Institute on Drug Abuse, ISI Web of Science. The 
methodological quality was assessed with the score developed by Starrels et al.; the report 
quality using the CONSORT and the STROBE checklists. The main outcome was medical 
management or consequences of management for patients in terms of psychoactive substance 
consumption and its complications, be they medical, social or professional. 
RESULTS 
In this evaluation, a total of 8 studies met the inclusion criteria: one randomized clinical trial 
in psychiatric emergency settings, two quasi-randomized studies in emergency settings and 
pain centre, one cohort in adolescent ambulatory care, and four descriptive transversal studies 
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in cancer centre, emergency settings and family medicine. The quality of the methodology of 
these studies was judged to be poor, with the exception of the randomized clinical trial where 
the quality was judged to be fair. The value of the urine drug screening in managing patients 
was not clearly indicated in these studies. 
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Background:  In the  field  of addiction,  assessment  of psychoactive  substance  use is  a key  element.  Nev-
ertheless,  self-reports  and  clinical  examination  underestimate  the  use  of psychoactive  substances.  The
implementation  of urine drug  screening  tests  (UDS)  should  improve  this  assessment.  While  the  diagnos-
tic  value  of UDS  is  well  demonstrated,  the  consequences  of  carrying  out UDS  on medical  management
have  not  been  established.  Our  aim  was  to summarize  the  evidence  pertaining  to  the efficacy  of  UDS  for
medical  management.
Methods: A systematic  review  of  clinical  trials,  quasi-randomized  and  observational  studies  was  per-
formed  using  PubMed,  Cochrane  database  of systematic  review,  Cochrane  central  register  of controlled
trials,  PsycINFO,  National  Institute  on Drug  Abuse,  ISI  Web  of  Science.  The  methodological  quality  was
assessed  with  the  score  developed  by Starrels  et  al.;  the  report quality  using  the  CONSORT  and  the
STROBE  checklists.  The  main  outcome  was  medical  management  or consequences  of management  for
patients  in  terms  of  psychoactive  substance  consumption  and  its complications,  be  they  medical,  social
or  professional.
Results:  Eight  studies  met  the  inclusion  criteria:  one  randomized  clinical  trial,  two  quasi-randomized
studies,  one  cohort,  and  four cross-sectional  studies.  The  methodological  quality  was  judged  to  be poor,
with  the exception  of  the randomized  clinical  trial (fair quality).  The  value  of  UDS  in  managing  patients
was  not clearly  indicated  in  these  studies.
Conclusions: Few  studies,  with  poor  quality,  have  assessed  the  value  of UDS  in managing  patients  using
psychoactive  substances;  though  with  insufficiency  to demonstrate  the  interest  of carrying  out  UDS.
Therefore,  pragmatic  intervention  studies  are  necessary.
©  2013  Elsevier  Ireland  Ltd.  All  rights  reserved.
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. Background
In the field of addiction, assessment of psychoactive substance
se is a key element for diagnosis and medical management.
evertheless, this assessment is often difficult as self-reports
nderestimate the use of psychoactive substances (Galletly et al.,
993; Kilpatrick et al., 2000; Lundy et al., 1997; Olshaker et al.,
997; Perrone et al., 2001). One Scandinavian study compared
he performance of psychiatrists versus the use of urine drug
creening tests (UDS) in the context of emergency settings for the
ssessment of drug use, using chromatography–tandem mass spec-
rometry as the reference (Mordal et al., 2010). The sensitivity of
he physicians’ assessment was 76% for amphetamines, 61% for
enzodiazepines, 57% for opiates, 55% for cannabis and only 50%
or cocaine. The specificity varied from 94 to 99% for the various
lasses of substances. By contrast, the sensitivity of UDS was 76% for
mphetamines, 83% for benzodiazepines, 80% for opiates and 97%
or cannabis. The specificity ranged from 82 to 100% for the various
lasses of substances. Actually, physicians’ assessment of psychoac-
ive drug use lead to underestimate the true consumptions, and
DS should improve this assessment.
UDS are based on immunoassay techniques and enable a qual-
tative and non-quantitative analysis with detection-based on
esignated thresholds. It is essential to ensure their proposition
f qualitative determination, in order to be able to interpret their
ignificance. In addition, their limits need to be recognized to guar-
ntee pertinent interpretation. Numerous false negatives exist,
otably for cocaine and benzodiazepines (Pesce et al., 2010); the
ests provide better intrinsic qualities for the detection of opiates
1.9% false negatives). UDS can be performed in physicians’ con-
ulting rooms or at the patient’s bedside, thanks to commercial
its as well as by an automaton at the laboratory. In the physician’s
ffice, immunoassays have been shown to be reliable (Manchikanti
t al., 2011a,b). Whatever the method, caution is recommended for
anagers of clinical laboratories and good quality information is,
herefore, required for clinicians in the field (Melanson et al., 2010).
While the diagnostic value of UDS is well demonstrated (Galletly
t al., 1993; Kilpatrick et al., 2000; Lundy et al., 1997; Olshaker
t al., 1997; Perrone et al., 2001), the consequences of carrying
ut these tests on medical management have not been established.
evertheless, UDS are widely used. American general practitioners
uestion the possibility of using these tests in their daily practice
Standridge et al., 2010) at a time when, in some countries, the . . . . . . .  . . . . . .  . . . . . . .  . . .  . . . . .  . . .  . . . . .  . .  . . . . . . .  .  . . . .  . .  .  . . .  .  .  .  . . .  . . . .  . . .  . . .  . .  20
implementation of rapid blood tests as a therapeutic aid is becom-
ing common practice (i.e., glycosylated hemoglobin, cholesterol,
INR, etc.; Blattner et al., 2010; Laurence et al., 2008).
In  the field of pain management, UDS are utilized to reduce the
risk of misuse of opioids, prescribed over the long term for chronic
non cancer pain. The American recommendations advocate, before
initiating treatment, the collection of written consent from the
patient, and UDS to identify any risk of abuse (Chou et al., 2009).
The same recommendations are also given in Canada (Gourlay et al.,
2005). Procedures for urine drug testing are well described in this
field (Christo et al., 2011; Owen et al., 2012). UDS are also used
for adolescents, generally at the request of their parents, however
there is a great lack of training in carrying out and analyzing these
tests correctly (Levy et al., 2006a). For opioid maintenance treat-
ments, these tests should be applied to assess the achievement of
abstinence and the intake of opioid maintenance drugs as well as
for the assessment of other addictions.
On the basis of the current literature, it could be expected that
carrying out UDS would provide an improvement in the manage-
ment of patients with addictive behavior. UDS would be helpful,
particularly in community office-based settings, as office-based
management of opioid dependence grows up (Walley et al., 2008).
Despite the lack of significant evidence of efficacy, UDS are recom-
mended to assess the use of psychoactive substances when abuse
or addiction is suspected. Thus, this systematic review is under-
taken to summarize the evidence pertaining to the efficacy of UDS
for medical management of patients.
The aim was  to assess whether carrying out UDS changes the
management of patients using psychoactive substances and the
consequences of this management for these patients.
2.  Methods
This review was realized according to a systematic review pro-
cess derived from the Preferred Reporting Items for Systematic
reviews and Meta-Analyses (PRISMA) statement (Liberati et al.,
2009; Moher et al., 2009).
2.1.  Inclusion criteria2.1.1.  Types of studies.
Clinical trials: randomized or not, blind or not, controlled or not.
ohol Dependence 136 (2014) 11–20 13
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Table 1
Databases and retrieval formula used.
Databases Retrieval formula
PubMed ((“Substance-Related
Disorders”[Mesh]) OR “Central
Nervous System
Agents”[Mesh]) AND
“Substance  Abuse
Detection”[Mesh]
Cochrane database of systematic
reviews
drug  abuse AND screening test*
Cochrane central register of controlled
trials
drug abuse AND screening test*
Cochrane Drugs and Alcohol group –
PsycINFO drug abuse AND screening test*J. Dupouy et al. / Drug and Alc
Quasi-randomized studies: before/after, here/elsewhere.
Observational studies: prospective or historic cohort, case-control,
nested  case-control.
Series  of cases.
.1.2. Types of participants.
Participants of interest were patients treated as outpatients or
inpatients.
Using psychoactive substances.
Users  or abusers or addicted (or suspected to be).
.1.3. Types of interventions.
Carrying out UDS using the enzyme immunoassay technique.
At  the patient’s bedside, in consulting rooms or in the laboratory.
Possibly  completed by a confirmation technique (chromatogra-
phy).
If  the test technique was not indicated in the article, the authors
of  the article were contacted to collect this information.
Comparison arm had to be the absence of UDS but studies without
comparator  were also included.
.1.4. Types of outcome measures.
Medical management: medical treatment reassessment, request
for  specialist opinion, prescription of additional tests, prescription
of  medicinal products, hospitalization, duration of hospital stay,
orientation  toward a hospital department or another participant
whether  medical or not (i.e., paramedical, psychosocial, etc.).
Or  consequences of management for patients in terms of psy-
choactive  substance consumption and their complications (i.e.,
medical,  social or professional).
The  link between carrying out a urine test and the medical man-
agement  achieved, or its consequences, needed to be clearly
identified as such in the article.
.2. Exclusion criteria
.2.1.  Types of participants. Studies dealing with pregnancy or peri-
atal period, with drug intoxications, voluntary or not (overdoses)
r seen in connection with occupational health or medical jurispru-
ence were excluded.
.2.2.  Types of interventions. If the procedure was a test different
han enzyme immunoassay screening techniques or biological tests
ther than urine or was focusing on the frequency of carrying out
ests (scheduled, at random, close together or not, etc.), or if another
ntervention was following the test results, studies were excluded.
n the latter case, not the test itself was assessed, more precisely
he test was the eligibility criterion for the scheduled procedure
easured (reward, scheduled consultation, etc.).
.2.3. Types of outcome measures. If the assessment criterion was
conomic (if this was the only criterion assessed) or intrinsic
erformance of the tests (if it was the only criterion assessed)
r characteristics of population or prognosis (predictive factor)
epending on the result of the test, studies were also excluded.
n this last case, the test only has a descriptive role by identifying
istinct populations.
.3.  Literature searchThe  search for articles was carried out by two authors (J.D. and
.M.) on several databases: PubMed, Cochrane database of system-
tic review, Cochrane central register of controlled trials, PsycINFO,NIDA drug abuse AND screening test
ISI  Web  of Science drug abuse AND screening test*
National Institute on Drug Abuse (NIDA), ISI Web  of Science on
October 26th 2011. Table 1 indicates the databases and the retrieval
formula used for each one.
Previous  literature reviews on the same topic were examined to
identify manually potential eligible articles.
2.4. Search strategy
The  search strategy included two notions: drug abuse first and,
secondly, screening test. The Medical Subject Heading (MeSH) and
keywords used are listed in Table 1. Keywords on the topic are
not very specific and leading to a too high number of references
to screen. Therefore, MeSH terms were applied for PubMed. In
Cochrane databases, MeSH terms led to few results, we  decided
not to use them. In other databases, searching by MeSH terms was
unavailable; consequently our strategy included pre-listed key-
words. Keywords and MeSH terms were chosen to be sensitive
rather than specific. The choice of keywords was done according
to keywords more often present in papers of the field. Only articles
reporting an original study in English, French, German or Spanish
were included.
2.5.  Data collection and analysis
Two authors (J.D. and V.M.) in a blinded standardized man-
ner collected and analyzed independently the data. Disagreements
were resolved by discussion between the two  authors; if no agree-
ment could be reached, a third author (M.L.-M.) decided.
2.5.1.  Selection of studies. The two authors selected independently
the articles. An initial selection was  completed on the title and/or
the abstract. After, a second reading of the full text was  done for
further selection. The  coefficient of inter-raters concordance was
calculated.
All possibly relevant articles were retrieved in full text. With
regard to conference proceedings, the authors were contacted to
obtain access to the full data (whether in the form of published
article, or not).
2.5.2.  Methodological quality assessment. A methodological quality
assessment of the studies confirming our inclusion criteria was  car-
ried out independently by the two authors with the score applied
by Starrels et al., 2010) in a systematic review similar to our subject
(i.e., treatment agreements and urine drug testing to reduce opioid
misuse in patients with chronic pain).The overall score applied by Starrels et al. is based on a quality
assessment checklist derived from the Emergency Care Research
Institute (ECRI) Institute (Noble et al., 2008), Downs and Black
(1998), and Jadad et al. (1996) and includes a quality assessment
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6479 r ecords  through database searching  
-3270 from Medline  
-291 from Cochrane review   
-77 from Cochrane central  
-87 from Cochrane Drug and alcohol group  
-1510 from Psychinfo  
-59 from NIDA  
-1185 from Web of Science  
1 addi tional r ecord  throu gh manual s earch   
- 1 from Medline  
- 0 from references included in literature reviews  
6046 r ecords  after duplicates removed  
1st selectio n on title  an d/or abstra ct 
2nd  selection on full text  
8 full -text articles selected   
8 studies includ ed in the qualitative analysis 
Ident ification  
5836 records  excl uded  
210 records  selected  
202 full-text articles excluded    
74 on assessment cr iteria                 
44 on the procedure used   
63 on the type of stud y 
21 on the study popula tion  
am of
b
o
-
o
o
-Fig. 1. Flow diagr
y the GRADE (Grading of Recommendations Assessment, Devel-
pment and Evaluation) grid (Atkins et al., 2005).
 The quality checklist consists of 15 criteria spread over 2 domains:
sample  and design.
 The population included in the study is assessed on 3 points; 1
point is given if the sample consisted of persons with diverse
types  of chronic pain conditions, persons with history of sub-
stance  abuse, persons with mental health disorders.
 With regard to the type of study, a total of 12 points is attributed
if  one of the following criteria was found: prospective design,
control  group included, control participants from a similar pop-
ulation,  intervention described clearly, intervention consistent
among  groups, outcome described clearly, objective outcome,
completion or response rate ≥ 85%, distribution of potential con-
founders provided, multivariate analysis conducted, adequate
adjustment for confounding, results clearly presented.
 The GRADE grid (Atkins et al., 2005) enabled a global assess-
ment  of the articles based on the rigor of the chosen design, its
bias,  and its limits. This quality scale comprises 4 levels: 4, high
if  the study was a randomized clinical trial; 3, moderate if the
study  was virtually experimental; 2, low if it was an observational
study;  1, very low if it was another type of study, not previ-
ously  mentioned. After, levels are moderated assessing bias of the
study. literature search.
On  the basis of scores on the quality checklist and the GRADE
grid, one of the following ratings was assigned to each study: excel-
lent (score ≥ 11 and GRADE ≥ 3), good (score ≥ 11 and GRADE ≥ 2),
fair (score = 6–10 and GRADE ≥ 2), or poor (score ≤ 5 or GRADE = 1).
2.5.3. Report quality assessment. We  also assessed the report
quality of the studies using the CONSORT (CONsolidated
Standards of Reporting Trials) checklist for clinical trials and the
STROBE (STrengthening the Reporting of OBservational studies
in Epidemiology) checklist for cross-sectional, observational or
cohort studies, scoring the number of items followed by the articles
selected. The results were expressed in percentages in relation to
the total of possible recommendations.
2.5.4.  Data extraction and management. Data were extracted from
the included studies by two authors independently using a
pre-established standard list. The assessment sheet included:
Author/year, type of study (study design), settings, characteristics
of the sample (population), management strategy (intervention),
reference group (comparator), follow-up, measuring the study
(outcome), results and quality assessed by the GRADE grid (Atkins
et al., 2005), the overall score proposed by Starrels et al. (2010), and
the CONSORT or STROBE checklist.
2.5.5. Qualitative analysis. Qualitative analysis was divided into
two parts: the main analysis concerning the studies where the
J. Dupouy et al. / Drug and Alcohol Dependence 136 (2014) 11–20 15
Table  2
Methodological quality assessment score used by Starrels (Starrels et al., 2010).
Passik et al.
(2000)
Eisen  et al.
(2004)
Schiller et al.
(2000)
Murnion et al.
(2007)
Dupouy et al.
(2012)
Manchikanti
et al. (2006)
Tennant
(1994)
Levy  et al.
(2006b)
Sample domain
Persons with diverse pain
types  included
√
0 0 0 0
√
0 0
Persons  with history of
substance  abuse includeda
0 0 0 0 0
√
0 0
Persons  with mental health
disorders includeda
0 0
√
0 0
√
0 0
Score  (maximum 3 points)
Design  domain
Prospective 0
√ √
0 0
√ √
0
Control  group included 0
√ √
0 0
√
0 0
Control  participants from a
similar population
NA NA
√
NA NA 0 NA NA
Intervention  described clearly
√ √ √ √
NA
√ √
NA
Intervention consistent among
groups
NA NA
√
NA NA 0 NA NA
Outcome  described clearly
√ √ √  √
NA
√ √
NA
Outcome  objective 0 0
√
0 NA
√ √
NA
Completion or response
rate  ≥ 85%
NA  NA NA NA 0
√
NA 0
Distribution  of potential
confounders  provided
0 0 0 0 0 0 NA
√
Multivariate  analysis
conducted
0 0 0 0 0 0 NA
√
Adequate  adjustment for
confounding
0 0 0 0 0 0 NA
√
Results  clearly presented
√ √ √ √ √ √ √ √
Score  (maximum 12 points)
Sample  + design score
(maximum 15 points)
4 5 9 3 1 10 5 4
Global  assessment based on
the GRADE (26) algorithm
Initial  GRADE scoreb 2 3 4 2 2 2 2 2
Adjustmentc −1 −1 - −1 −1 −1 −1 −1
Reason  for adjustment Design and limitsd Designe - Designf Limitsg Selection biash Limitsi Limitsg
Final GRADE score (maximum
4  points)
1 2 4 1 1 1 1 1
Quality  rating Poor Poor Fair Poor Poor Poor Poor Poor
GRADE: Grading of recommendations assessment, development, and evaluation.
a Studies were scored with a check if patients with substance abuse or mental health disorders were not explicitly excluded.
b The initial grade score was based on study design: 4, randomized trial; 3, quasi-randomized trial; 2, observational study; 1, any other evidence.
c GRADE score was  decreased for quality limitations or increased for strong association.
d No control group, Indication bias, Changes in management subjectively assessed.
e Before/after study in the same population, interview of the ordering physician regarding management changes just after the communication of UDS results compared to
planned  management before knowing the results: more an observational study than a real before/after study (i.e.,: after implementation of a urine drug screening program).
f No control group, Changes in management subjectively assessed.
g Changes in management assessed only by declarative data.
fered 
c
a
a
t
s
s
o
3
3
o
t
i
r
th Comparison with a historical control group that was  not well described and dif
o-interventions.
i Changes planned in the method, no control group.
ssessment criterion was medical management and secondary
nalysis regarding the articles where the assessment criteria were
he consequences of management for the patients (psychoactive
ubstances use and its complications; i.e., medical, social or profes-
ional).
Heterogeneity of studies based on methodological design, type
f population, and setting did not allow a quantitative analysis.
.  Results
.1. Study selection
Fig.  1 shows a flow diagram of the study selection as rec-
mmended by the PRISMA statement (Liberati et al., 2009). Six
housand and forty-six titles (± abstracts) were reviewed from the
nitial database search. Two hundred and ten full text articles were
eviewed and screened. After the exclusion of studies not meeting
he inclusion criteria, 8 articles were identified for methodologicalfrom the intervention group in inclusion criteria and in exposure to contaminating
quality  assessment (Dupouy et al., 2012; Eisen et al., 2004; Levy
et al., 2006b; Manchikanti et al., 2006; Murnion et al., 2007; Passik
et al., 2000; Schiller et al., 2000; Tennant, 1994). The observed
agreement between reviewers was 99.9% ( = 0.75).
3.2. Methodological quality assessment
The quality of the 8 included studies (Dupouy et al., 2012; Eisen
et al., 2004; Levy et al., 2006b; Manchikanti et al., 2006; Murnion
et al., 2007; Passik et al., 2000; Schiller et al., 2000; Tennant, 1994)
was assessed through the Starrels’ score (Starrels et al., 2010) as
shown in Table 2.
The  8 selected studies consisted of: 1 double-blind random-
ized clinical trial (Schiller et al., 2000), 2 quasi-randomized studies
(Eisen et al., 2004; Manchikanti et al., 2006), 1 observational cohort
(Tennant, 1994) and 4 cross-sectional studies (Dupouy et al., 2012;
Levy et al., 2006b; Murnion et al., 2007; Passik et al., 2000). The ran-
domized clinical trial (Schiller et al., 2000) was assessed as “fair”
while the other studies were assessed as “poor” (Dupouy et al.,
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Table 3
Qualitative analysis of the studies covering the main assessment criterion (medical management).
Study (year) Study design Setting Sample
characteristicsa
Urine drug
screening
Control
condition
Follow-up Screening effect
measure
Results  Limitations Qualityb
Passik et al. (2000) CSS  Cancer center
USA
111  cancer
patients (82%),
mainly
hospitalized
(91%);  mean
age,  43 y
Urine  drug
screening test
(the  first one for
patients  having
multiple UDS)
None  Chart review
consisting of
only  the
admissions in
which  the UDS
was  obtained for
inpatients  and
including 1
month  before
and  1 month
after  the test for
outpatients
Medical
management
modification
assessed thanks
to  chart review
8  (7.2%) patients
had
documentation
that  the UDS led
to  a change in
clinical
management
Subjective
unexplained
assessment of
outcome criteria
(change:  yes/no)
Poor;
strobe = 13/32
Schiller et al. (2000) RCT Psychiatric
emergency
setting USA
198  inpatients
in  the
mandatory-
drug-screen
group, 67% of
patients  from 25
to  45 y
Standard
immunoassay
and
confirmatory
tests  performed
for  positive
screens
194 inpatients
in  the usual-care
group;
Psychiatrists
ordered urine
drug  screens for
patients  in both
groups  if a
screen  was
needed in their
clinical
judgment
During
hospitalization;
data  collected
from hospital
records and
databases
Dispositions
after  emergency
settings.
Duration of
hospitalization
in  psychiatric
ward
No significant
difference in
dispositions or
duration  of
hospitalization
between  the
two  groups.
Difference in
dispositions of
patients  for
whom  a drug
screen was
ordered by a
physician  with
dispositions of
patients  for
whom  no drug
screen  was
ordered
Test  results
often not always
available  to
psychiatrists
before  patients
were  discharged
from the
emergency
service
Fair; con-
sort  = 17/37
Murnion et al.
(2007)
CSS  Emergency
settings or
medical  wards
Australia
171  patients;
121  presenting
via  the accident
and emergency
center and 50
inpatients in
medical wards;
mean  age, 36 y
Immunoassay
followed  by
confirmatory
test  (thin-layer
chromatogra-
phy)
None During
hospitalization;
review of case
histories by  2
trained
assessors  in a
blinded  manner
Test utility
(categorized in
diagnostic,
prognostic,
“management”
and  scored with
a  visual analog
scale)  by the 2
trained  assessor
86  tests of utility
(50%):  47(38.8%)
requested from
accident  and
emergency
center  and 38
(76%)  from
medical ward;
more  likely that
a  test will be of
utility  if it was
requested from
a  medical ward
than  from the
accident  and
emergency
center
Subjective
assessment of
test  utility
Poor;
strobe = 16/32
Tennant (1994) PCS Outpatient
clinics USA
100  adolescents
whom parents
request  UDS;
mean  age, 16 y
Urine  screening
by  polarized
fluorescent
immunoassay
(confirmatory
method not
used)
None  Weekly
follow-up urine
screening  (up to
8  weeks)
Clinical
purposes
29 patients
entered
outpatient
counseling. 8
were  judged to
be  dependent
and received
outpatient
medical
detoxification or
inpatient
treatment
Clinical
purposes
planned  in the
method, urine
screening
follow-up  at
request of the
parents, no
medical
intervention
Fair;
strobe = 8/32
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Dupouy et al. (2012) CSS Family medicine
(ambulatory
setting) France
482  PCPs of
whom 31
regularly
managing
opioid-addicted
patients and
using drug tests
Urinary  or blood
test,
immunoassay or
chromatography
None  None Changes in
medical
management
following drug
testing  reported
by  PCPs using
drug  test in self-
administrated
questionnaire
(ended-
questions)
Nonprescription
of  opiate
substitutive
treatment:
29.0%.
Increasing
counseling:
71.0%. Referral
to  a consultant:
48.4%
Low response
rate. Changes
reported by GPs
but  not assessed
in  their practice
Poor;
strobe = 24/32
Levy et al. (2006b) CSS Primary care
USA
359  primary
care providers
(122
pediatricians,
126 adolescent
specialists, and
103  family
physicians)
Urine drug
testing (in
general medical
clinics, in school
and  at home)
None None Steps following
a  positive urine
drug  test as
declared by
physicians
48%:  share
results with
parents. 70%:
assess in the
office.  61%:
mental health
referral. 27%:
begin  treatment
in  the office
Outcome
reported by
physicians but
not  assessed in
their  practice
Poor;
strobe = 22/32
Eisen et al. (2004) QRS Emergency
settings Canada
110  inpatients;
mean age 39 y
Immuno  assay
confirmed by
chromatography
Same
population but
before  results of
the  UDS having
been
communicated
to  the ordering
physician
Interview of
physicians
about  medical
management of
the  patient
before test
result and after
Medical
management
assessed by
telephone
interview +
chart  review;
assessment
changes in
medical
management
and  in changes’
reasons by an
independent
expert  reviewer
4  over 110 tests
led  to
management
changes;
changes judged
not  substantive
(3/4) and
unjustified (4/4)
by  the
independent
expert reviewer
Subjective
unexplained
assessment of
management
changes  by the
independent
expert  reviewer
Poor;
strobe = 18/32
CSS, cross-sectional study; PCP, primary care provider; PCS, prospective cohort study; QRS, quasi-randomized study; and RCT, randomized clinical trial.
a Sample characteristics provided, as available.
b Quality rating: excellent (score ≥ 11 and GRADE ≥ 3), good (score ≥ 11 and GRADE ≥ 2), fair (score = 6–10 and GRADE ≥ 2), or poor (score ≤ 5 or GRADE = 1).
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2012; Eisen et al., 2004; Levy et al., 2006b; Manchikanti et al., 2006;
Murnion et al., 2007; Passik et al., 2000; Tennant, 1994).
Three  studies took place in emergency settings (Eisen et al.,
2004; Murnion et al., 2007), whereby one of them was in a psychi-
atric emergency setting (Schiller et al., 2000). Two were conducted
in specialized pain centers (Manchikanti et al., 2006) or cancer cen-
ters (Passik et al., 2000), one in outpatient clinics (Tennant, 1994),
and two  in primary care (Dupouy et al., 2012; Levy et al., 2006b).
3.3.  Report quality assessment
Details  of the CONSORT, STROBE (cohort), and STROBE (cross-
sectional study) checklists are presented in Supplementary
Material.1
3.4. Study Characteristics
Seven studies evaluated the main assessment criterion of the
present review: medical management (Dupouy et al., 2012; Eisen
et al., 2004; Levy et al., 2006b; Murnion et al., 2007; Passik et al.,
2000; Schiller et al., 2000; Tennant, 1994); one evaluated the
secondary assessment criteria (Manchikanti et al., 2006): use of
substances or drugs with abuse or addiction potential and associ-
ated comorbidities.
3.4.1. Analysis on main assessment criterion. The analysis of the 7
studies (Table 3) indicates a modest efficacy of the tests.
In  cancer centers, changes in management were rare: 8 patients
over 111 included (7.2%) provided documentation on changes in
clinical management related to UDS: ordering psychiatric or pain
management consultations, placing restrictions on the patient, dis-
charge of patient or postponement of treatment or procedures,
medication changes, or referral for substance abuse treatment
(Passik et al., 2000). All changes were presented in the group with
positive UDS results, defined as the detection of one or more illicit
drugs, prescription medications not documented as ordered or
given, or alcohol (blood alcohol level was  also taken into account).
In a randomized controlled trial aiming to test whether dispo-
sitions from a psychiatric emergency service would differ between
patients receiving a routine mandatory UDS (n = 198) compared
to those with an administered UDS only if psychiatrists’ clinical
judgment deemed it as useful (usual care, n = 194), no significant
differences in dispositions or duration of hospitalization was found
between these two  groups (Schiller et al., 2000). Nevertheless, there
was a significant difference in the dispositions of patients with an
ordered drug screen by a physician compared to the dispositions
of patients without ordered drug screen (analysis limited to the
mandatory-drug-screen group). This difference was attributable to
the referral of a larger proportion of patients for whom drug screens
were not ordered to an inpatient unit at a county hospital (29.9%
versus 15.3%, p = 0.014).
In  50 patients hospitalized in medical wards, 38 UDS (76.0%)
were judged of utility; it was more likely that a test would be of
utility if it was requested from a medical ward than from the acci-
dent and emergency center (Murnion et al., 2007). In this Australian
study, presentations including psychosis, confusion, and behavioral
disturbances were associated with a likelihood of UDS as important
diagnostically, in management, and for prognosis.
UDS of adolescents on request of parents facilitated the entry
to treatment (Tennant, 1994). In two outpatient clinics, UDS led to
outpatient counseling in 29 adolescents over 100. Eight of them
had repeated positive follow-up tests, confided their unability to
1 Supplementary material can be found by accessing the online version of this
paper  at http://dx.doi.org/10.1016/j.drugalcdep.2013.12.009.
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ease drug use and desired help for their problem. They were judged
o be dependent and received outpatient medical detoxification or
npatient treatment.
Two  cross-sectional studies were in primary care settings
Dupouy et al., 2012; Levy et al., 2006b). The first one in France
escribed that, in consequence of drug testing, changes in manage-
ent reported by 482 primary care practitioners (PCPs), managing
pioid-addicted patients and using drug tests, were mainly an
ncrease of counseling (71.0%), secondly, the referral to a consult-
nt (48.4%), and finally, the non-prescription of opiate substitutive
reatment (29.0%). The second one in the United States presented
hat, follow-up practices with drug test results testified by 359
hysicians (pediatricians, adolescent specialists, and family physi-
ians) were mainly assessment in the office (70%), mental health
eferral (61%), sharing results with parents (48%) and beginning
reatment in the office (27%). After controlling for physician age
nd gender, pediatricians, and family, physicians were more likely
o share results with parents than adolescent providers (OR 2.4
1.4–4.0] and 3.4 [1.9–6.1] respectively). Pediatricians presented
 higher probability to refer to mental health services (OR 2.4
1.4–4.2]); same trend existed, however was not significant for
amily physicians. Pediatricians were less likely to assess in the
ffice and to begin treatment in the office (OR 0.25 [0.14–0.46] and
.29 [0.13–0.54] respectively); same trends existed nevertheless it
evealed insignificant for family physicians.
On the other hand, the efficacy of UDS was not demonstrated in
mergency departments (Eisen et al., 2004; Murnion et al., 2007).
n a Canadian emergency department, in 110 patients tested, 4 UDS
3.6%) led to management changes arranged by the ordering physi-
ian (Eisen et al., 2004). These changes concerned the cancelation
f a planned head CT scan (for presentation of bizarre behavior),
 consult to internal medicine changed to psychiatry (for presen-
ation of “neurologic symptoms” sic), a medicine consult in a case
here the physician was unsure which consultant was required
presentation of new onset psychosis), and a psychiatry referral
ancelation due to the patient’s confrontation with tetra-hydro-
annabinoid (THC) use admitted by the patient and observed in
he emergency department (for presentation of confusion; fell in a
ake). Only one of these changes was viewed as substantive by an
ndependent expert reviewer (the last change cited above) and all
f them were judged unjustified. This study confirmed a diagnostic
alue of UDS as of the 110 UDS ordered, the ordering physician was
ble to completely predict the result in 48 cases (43.6%). The effi-
acy of urine tests was not demonstrated in psychiatric emergency
nits, in terms of duration of hospitalization (Schiller et al., 2000).
.4.2.  Analysis on secondary assessment criteria. An analysis of the
ncluded quasi-randomized study in an interventional pain man-
gement practice (Table 4) indicated a modest efficacy of the tests
or patients with chronic pain (n = 500) for the consequences of
anagement with a decrease of the total prevalence of drug use
rom 22% [18–27] to 16% [13–20], and a decrease of the THC preva-
ence from 18% [8–14] to 11% [14–22]; these differences were
ignificant (Manchikanti et al., 2006).
. Discussion
This systematic review evaluating the value of UDS in managing
atients showed poor evidence. In this review, a total of 8 stud-
es met  the inclusion criteria: one randomized clinical trial, two
uasi-randomized studies, one cohort, and four descriptive cross-
ectional studies. The methodological quality of these studies was
udged to be poor, with the exception of the randomized clinical
rial where the quality was judged to be fair. Nevertheless, thereependence 136 (2014) 11–20 19
is  no evidence of the value for UDS in managing patients through
these studies.
This  review brought to light one of the first American study (pub-
lished in 1981) investigating the impact of monitoring patients on
methadone by urine tests (Havassy and Hall, 1981). However, this
study was  not eligible to be included due to the tests applied, a
chromatographic technique (most certainly related to the time at
which the study was conducted). It showed that subjects having
been monitored by tests were more likely to terminate their treat-
ment than others. Two  hypotheses were raised by the authors: the
tests could help patients trying to stop the habit of using methadone
(recovery?), or the tests represented a supplementary cost for
patients causing them to abandon treatment (probable relapse).
Most  of the included studies took place in emergency settings. A
systematic review of the literature (Tenenbein, 2009) did not show
any interest in carrying out UDS in emergency rooms, whereby
the review included mostly articles studying patients in acute
intoxication. This is a very different clinical situation compared to
patients who  are chronic users, thus we  chose to exclude this type
of population in our review. Only one randomized clinical trial in
a psychiatric emergency setting (Schiller et al., 2000) showed an
impact of UDS on the patients’ management if the physician had
found it suitable to carry them out. However, this was a secondary
analysis, independently from the primary objective of this study
where no impact on the group systematically tested compared to
the untested was found. This result is nevertheless interesting and
supports a reasoned use of UDS depending on the context and the
physician’s opinion. The survey of the French General Practitioners’
reporting seemed also to be in accordance with that (Dupouy et al.,
2012).
Two  studies were in specialized centers: a pain center
(Manchikanti et al., 2006) and a cancer center (Passik et al., 2000).
A review in patients with chronic pain found only a low level of
evidence supporting urine tests in these patients with a view to
decreasing opioid abuse (Starrels et al., 2010).
Some excluded studies often concluded on the interest of the
tests (Bast et al., 2000; Buchfuhrer and Radecki, 1996; Claasen
et al., 1997). However, these studies described two  different
populations according to the result of the screening (tradition-
ally differentiated into two groups: positive or negative) in terms
of socio-demographic characteristics, medical data and treatment
process. It can be concluded that patients having used psychoactive
substances are different but in no way that the results of the tests
affect their treatment process, thus we excluded these studies.
Our  review is limited by the considerable variation of settings
and patients included. We  chose not to limit them, to have the abil-
ity to offer an overview of the value of UDS. Another limitation was
the difficulty to define medical management and to find studies of
which outcome was medical management rather than diagnostic
criteria. Moreover, the implementation of urine drug testing inter-
ventions (e.g., frequency, or type of assays) varied among studies
and was reported inconsistently. All of these reasons contributed
to the heterogeneity of the studies included and the difficulty to
synthesize their results. Again, our objective was to synthesize the
evidence supporting the use of UDS for the management of patients.
This explains that we chose a broad retrieval formula and databases
both general and specific on the topic, increasing the sensitivity of
our search strategy whereby not specificity. Finally, publication bias
and language bias may  have limited the evidence available for this
review.
Our systematic review reveals that weak evidence supports the
use of UDS in settings where abusers or addicted patients are man-
aged (i.e., psychiatric settings, primary care, pain clinics, outpatient
clinics. . .).
In conclusion, few studies have assessed the value of UDS in
managing patients using psychoactive substances; due to their poor
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uality, these studies are not sufficient to demonstrate the inter-
st of carrying out these tests. Pragmatic intervention studies with
bjective assessment criteria are necessary to underpin the imple-
entation of these tests in daily practice to improve the treatment
nd health of these patients.
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PART 2: A PHARMACOEPIDEMIOLOGICAL APPROACH 
 
After informing the poor use of urine drug screening tests in France and the lack of 
evidence of their efficacy, the second part aimed to assess the effectiveness of drug tests in 
managing opioid-addicted patients. For that, we used observational cohorts conducted from 
French health insurance system databases. In front of the difficulty to find financial support 
to conduct a clinical trial, we choose to use one existing tool available for academic 
researchers in France: French health insurance system databases. 
 
Partie 2 : approche pharmacoépidémiologique 
Evaluation  de l’efficacité des tests pour la prise en charge des patients dépendants aux opiacés par des 
études observationnelles de cohorte sur les bases de données de l’Assurance Maladie  
Bases de données de l’Assurance Maladie : 
Toute la population française étant couverte par un système public d’Assurance Maladie, toutes les données 
de remboursement sont collectées dans une énorme base de données appelée Système National d’Information 
Inter-Régime de l’Assurance Maladie SNIIR-AM. Ces données de remboursement sont reliées avec les 
données d’hospitalisation et les données de décès. Afin d’avoir un suivi prolongé, un échantillon randomisé 
au 1/97
ème
 a été construit : l’Echantillon Généraliste des Bénéficiaires EGB. Celui-ci est accessible pour les 
chercheurs affiliés à un organisme de recherche public après une formation spécifique et permet de faire des 
études descriptives sur les patients et les médecins ainsi que des études de cohortes pour étudier des 
associations.  
Troisième publication : 
L’objectif de cette étude était d’évaluer l’impact de la réalisation de tests de recherche de substances psycho 
actives sur le maintien sous Médicament Substitutif aux Opiacés (MSO) en médecine ambulatoire en 
constituant une cohorte de patients ayant débuté un traitement par MSO à partir de juin 2009 et suivis 18 à 
30 mois à partir de la base de données de la Caisse Nationale d’Assurance Maladie des Travailleurs 
Salariés en Midi Pyrénées. Deux groupes de patients ont été définis : le groupe biologie (ayant eu au moins 
un remboursement de test de recherche de substances psycho actives) et le groupe témoin (n’en ayant pas 
eu). Le maintien sous MSO a été analysé dans un modèle de Cox ajusté sur les potentiels facteurs de 
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confusion ; l’exposition au test biologique étant considérée comme une variable dépendante du temps. Cette 
cohorte comprenait 1507 patients dont 39 (2,6%) dans le groupe biologie. La durée moyenne de maintien 
sous MSO était de 207 jours dans le groupe témoin versus 411 jours pour le groupe biologie, p<0,0001. 
Dans le modèle de Cox, la réalisation d’un test de recherche de toxiques favorisait le maintien sous MSO : 
Risque Relatif RR =  0,55 [IC95% : 0,38 – 0,80]. La réalisation de test de recherche, bien que rare, 
améliorait le maintien sous MSO.  
Quatrième travail : 
L’objectif de cette étude était d’évaluer l’impact de la réalisation de tests de recherche de substances 
psychoactives sur la mortalité en constituant une cohorte de patients ayant débuté un traitement par MSO à 
partir de janvier 2007 et suivis jusqu’à décembre 2013 à partir de l’EGB. Deux groupes de patients ont été 
définis : le groupe biologie (ayant eu au moins un remboursement de tests de recherche de substances psycho 
actives) et le groupe témoin (n’en ayant pas eu). Une analyse de survie (modèle de Cox) a permis d’étudier 
les facteurs associés à la mortalité. Dans cette étude, plus de 15% des patients appartenaient au groupe 
biologie. Avoir eu un test n’était pas associé à la mortalité en univarié : RR = 0,60 [IC95% : 0,21 – 1,69]. 
Néanmoins la mortalité était supérieure hors traitement que sous traitement. Les autres facteurs associés à 
la mortalité étaient des facteurs indiquant la sévérité de la pathologie addictive. 
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FRENCH HEALTH INSURANCE SYSTEM DATABASES 
 
All the French population is covered by a publicly funded health system. The French 
health insurance reimbursement databases gather information concerning these individuals. 
For some years, French health insurance system databases have been widely used for 
public health and pharmacoepidemiological purposes (Blin et al., 2012; Bongue et al., 
2011; Fournier & Zureik, 2012; Frauger et al., 2011; Pariente et al., 2010), particularly in 
the field of addiction (Lapeyre-Mestre et al., 2003; Thirion et al., 2002). 
The first used database (Extraction, Recherches, Analyses pour un Suivi Médico-
Economique ERASME) is the database of the main French health insurance system 
(Régime Général des travailleurs salariés RG) for the Midi-Pyrenees area. This health 
insurance system covers 87% of the French general population: salaried workers and their 
families, and patients with universal coverage (attributed to the unemployed and low 
income insurees) (Martin-Latry & Bégaud, 2010).  
This database includes locally and prospectively collected reimbursement data. 
Available data are those from the last 24 months. They comprise demographic data of the 
beneficiaries of the main health insurance system, out-hospital reimbursement data (drug, 
laboratory, radiology, medical acts) and medical data (costly long-term diseases called 
Affections de Longue Durée ALD – all acts concerning the concerned disease are 
reimbursed at 100% -, occupational diseases, and sick leaves). Other kinds of data are 
computerized in this database: characteristics of health professionals, data concerning 
health facilities. Concerning drug dispensing, the database contains information on the date 
of dispensing, quantity dispensed, and prescriber. Drugs are classified according to the 
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Anatomical Therapeutic Chemical system. The access to this database mainly depends on 
the relationship with the local physician of the health insurance system. 
The validity of the ERASME database of the health insurance system has been 
confirmed (Latry, Molimard, Bégaud, & Martin-Latry, 2010). It has been shown in the 
Three-Cities (3C) cohort that the reimbursement data of the health insurance system agreed 
with consumption data with an acceptable concordance between drug consumption 
estimated through health insurance system databases and self-reported drug consumption 
(Noize et al., 2009). Although, as for all prescription or reimbursement databases, we 
cannot exclude that, even if the drug is prescribed and reimbursed, it is not consumed by 
the patient. 
Local databases are united at a national level in a big database comprising also data 
from other health insurance systems; the two other systems are the Régime Social des 
Indépendants RSI (for self-employed) and the Régime Social Agricole RSA (for 
agricultural workers, farmers, and their employees) (other systems cover specific 
populations such as soldiers, railway workers, etc). All these data are organized since 2003 
into a huge digital data warehouse, the Système National d’Information Inter-Régime de 
l’Assurance Maladie SNIIR-AM. It covers the entire French population (65 million 
inhabitants).  
The SNIIR-AM includes demographic, out-hospital reimbursement (including drug 
dispensing), medical (costly long-term diseases, occupational diseases, sick-leaves…), and 
in-hospital data. In-hospital data of the Programme de Médicalisation des Systèmes 
d’Information PMSI are linked with the out-hospital reimbursement database Données de 
Consommation Inter-Régimes DCIR. In-hospital data in the SNIIR-AM include the PMSI 
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Médecine Chirurgie Obstétrique MCO (medicine, surgery and obstetrics), the PMSI of 
psychiatric wards, of hospital-in-the-home care, and of rehabilitation wards. Death data are 
also comprised thank to a linkage with the data of the Institut National de la Statistique et 
des Etudes Economiques INSEE. All these data are prospectively recorded, individualized, 
made anonymous and linkable. All consumers of medical services are recorded. 
The access to the SNIIR-AM is conditioned by a request to the Institut des Données 
de Santé IDS and then to the Commision Nationale Informatique et Libertés CNIL. Mean 
time to have the data is 13 months and can be, in some cases, more than 24 months (IDS, 
2013). Available data are data of the three last years plus the on-going year. 
In order to facilitate studies on more frequent conditions, a random sample of 1/97
th 
of national health system beneficiaries has been built since 2005, called the Echantillon 
Généraliste de Bénéficiaires (EGB) or the permanent beneficiaries sample (Tuppin, de 
Roquefeuil, Weill, Ricordeau, & Merlière, 2010). EGB is a permanent representative 
sample of subjects affiliated with the French health insurance system. It is obtained by 
1/97
th 
national random sampling with control for distribution of age, and gender. The EGB 
database includes approximately 660,000 beneficiaries from the national health insurance 
scheme (Tuppin et al., 2010). The value of EGB is to have a long follow-up (20 years of 
which 8 years available). 
 Available data are almost the same as in the SNIIR-AM with the exception that 
only the PMSI MCO has been included for now. All consumers and non-consumers are 
recorded. 
EGB has been used for 5 years for pharmacoepidemiological purposes (Blin et al., 
2012; Bongue et al., 2011; Dupouy, Fournier, et al., 2013; Fournier & Zureik, 2012; 
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Frauger et al., 2011; Pariente et al., 2010). The access is possible for academic researchers 
affiliated to a partner institution (for example the Institut National de la Santé et de la 
Recherche Médicale INSERM). The access to EGB required a specific training for all 
researchers and professionals of the health insurance: one first one-day training about the 
architecture of SNIIR-AM and one second three-day training about the EGB. The second 
formation is now about the EGBS (EGB simplifié) which is a simplified version of the 
EGB. In this EGBS, data are less raw than in the EGB, that means that data have been a 
little bit worked on to be more easily used. For researchers affiliated to INSERM, the 
access is easy: the synopsis has to be submitted to one person in charge of INSERM; after 
it is approved, the researcher can begin his work on the EGB. The person in charge of 
INSERM is responsible of the communication with the IDS. No other specific 
authorization is needed as data are anonymous (Journal Officiel de la République 
Française, 2012). Nevertheless, one restriction is that the researcher has to choose between 
one of four profiles to be connected to data. These different profiles give access to data 
according to the access to sensitive data that cannot be matched: date of birth (in month, 
year), date of death (in day, month, year), date of the act (in day, month, year) and the 
home town.  
For the academic researcher, data access is simple. After a connection on the server 
of the Caisse Nationale d’Assurance Maladie des Travailleurs Salariés CNAM-TS, data 
are directly available online via the Citrix software
®
. Communication is facilitated between 
researchers thanks to documentation and a forum in the server. 
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The EGB is a new tool for researchers, evolving and progressing. The CNAM-TS is 
attentive to suggestions expressed by researchers using this database and a national club of 
users as well as local clubs enable researchers to progress by helping one another. 
Limits of these databases are the lack of medical data: few medical data are 
available and the use of proxies is common to identify a disease. Proxies are sensitive and 
specific when they use drugs specifically used in one disease but can be less efficient when 
drugs are not specific for one disease. Data from costly long-term diseases are also useful 
but identify severe diseases (as ALD is given for severe chronic disease requiring a 100% 
reimbursement). The validity of these ALD codes is debated. More precisions can be 
obtained using codes of the International Classification of Diseases 10
th
 version ICD10, 
these codes are recorded by physician of the health insurance system when they record 
ALD codes. They are more precise than ALD codes (a restrictive list of 33 codes) but their 
validity is also poorly known. For these reasons, identifying a population by the 
prescription of a drug is much more comfortable than identifying a population by a disease. 
Nevertheless, more and more research teams are working in defining algorithms to identify 
specific diseases. 
 To conclude, these databases are useful for all researchers and, specifically, for 
researchers in primary care, to: 
- Describe  
 characteristics of patients  
 characteristics of prescribers and patterns of prescriptions 
 at a specific time or to describe the evolution on several years 
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- Analyze association and causality using retrospective cohorts and nested 
case-control studies 
- Probabilistically match these data with clinical data of observational studies 
or randomized clinical trials. 
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STUDY 3: EFFECTIVENESS OF DRUG TESTS IN OUTPATIENTS STARTING OPIOID SUBSTITUTION 
THERAPY 
 
PRESENTATION OF THE STUDY  
Dupouy J, Dassieu L, Bourrel R, Poutrain J-C, Bismuth S, Oustric S, et al.  
Effectiveness of drug tests in outpatients starting opioid substitution therapy. 
Journal of Substance Abuse Treatment 2013; 44: 515-21 (Dupouy, Dassieu, et al., 
2013) 
OBJECTIVE  
We aimed to assess the effectiveness of drug tests for treatment retention in outpatients 
starting opioid substitution therapy. 
METHOD  
A retrospective cohort was created from the data of the French health insurance system 
database for the Midi-Pyrenees region. Patients starting OMT were included and followed 
for 18 to 30 months. Two groups of patients were defined: the drug test group (at least one 
drug test reimbursement) and a control group (no drug test reimbursement). Survival 
analyses were performed. 
RESULTS 
The cohort included 1,507 patients. During follow-up, 39 subjects (2.6%) had at least one drug 
test reimbursement. Mean treatment retention was 207 days in the control group and 411 days 
in the drug test group (P < 0.001). Kaplan-Meyer curves showed a higher opiate substitutive 
treatment retention for drug tested patients. With a multivariate Cox model, drug tests were 
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associated with treatment retention: hazard ratio 0.55 [95% CI: 0.38 – 0.80]. Use of a drug test 
in follow-up of opioid substitution treatment, although rarely prescribed, significantly 
improved treatment retention. Nevertheless, persistent confounding related to the use of an 
administrative reimbursement database limited the significance of our results.  
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In 2009, nearly 140,000 patients were treated in France with an
opioid substitute (OS) (Commission Nationale des Stupéfiants et des
Psychotropes, 2010). Methadone and buprenorphine received mar-
keting authorization in 1995 and 1996, respectively, for substitution
treatment for major opiate dependence as part of overall medical,
social and psychological therapeutic management. These two drugs
are prescribed and delivered according to two different, very strict
guidelines. Methadone, a pure μ agonist, is a listed narcotic and can
be prescribed for a maximum of 14 days and delivered for a
maximum of 7 days. Primary prescription of methadone is restricted
to physicians in specialized units and to hospital physicians. When
the patient is stabilized, treatment may be continued in an outpatient
setting and followed up by any physician, whether specialist or
primary care physician (PCP). Buprenorphine, a partial μ agonist, is a
class I psychotropic drug (Schedule III of the 1988 Convention) and
can be prescribed for maximum periods of 28 days and delivered for
periods of 7 days. It is widely used in France as it can be prescribed by
any physician, whether specialist or PCP, and can be delivered in anylocal pharmacy, so in this country more than three-quarters of
patients treated for opioid addiction receive buprenorphine (Aur-
iacombe, Fatséas, Dubernet, Daulouède, & Tignol, 2004; Fatseas &
Auriacombe, 2007). In summary, in France, methadone must be
started in a specialized unit or a hospital and can be continued, after
the patient is stabilized, in an outpatient setting, whereas buprenor-
phine is easily accessible as it can be started in a specialized unit, a
hospital or an outpatient setting. The physician can prescribe
methadone for a maximum of 14 days and buprenorphine for
28 days, but the pharmacist must deliver the medication only for
7-day periods unless otherwise indicated by the prescriber. The
systematic review by Mattick, Kimber, Breen, and Davoli (2008)
demonstrated the efficacy of buprenorphine maintenance treatment,
with a lower retention rate than methadone but giving a similar
decrease in opiate consumption. Maintenance on OS is requisite for
successful treatment.
Methadone prescription guidelines detail the recommended urine
tests: a first, obligatory test before starting methadone treatment and
later control tests. The first urine test confirms current drug
consumption and the absence of methadone intake. Tests are
subsequently done once or twice a week during the first 3 months
of treatment, then twicemonthly. When the patient has transferred to
an outpatient setting, tests can be done if the physician considers it
necessary. Tests are not obligatory for buprenorphine. In 2004,
updated French guidelines on optimal opiate addict care reinforced
these recommendations and advised a standardized screening test
516 J. Dupouy et al. / Journal of Substance Abuse Treatment 44 (2013) 515–521schedule in the initiation and follow-up of methadone and buprenor-
phine treatment (Haute Autorité de Santé, 2004).
The drug tests can be carried out by immunochemical methods,
either by automated analyzers in the biology laboratory or by drug
screening kits. Screening can be done during the patient's visit, in
either a specialized addiction center or the physician's office. These
tests (whether on a laboratory automat or using a commercial kit) are
qualitative and have defined thresholds. False negatives exist for
cocaine and benzodiazepines in particular, but test quality is
intrinsically better for opiate detection (1.9% false negatives) (Pesce
et al., 2010). Results can be confirmed by the reference method, liquid
or gas phase chromatography with mass spectrometry, which gives
quantitative measurements (Bagøien, Morken, Zahlsen, Aamo, &
Spigset, 2009). Laboratory tests, regardless of the method or the
biological medium, are reimbursed by the French health insurance
system with no limit on their number or time period. A recent study
has shown that PCPs rarely used these tests and that most had limited
knowledge of the subject (Dupouy, Bismuth, Oustric, & Lapeyre-
Mestre, 2012).
The value of drug tests for the diagnosis of substance abuse has
been demonstrated: many studies agreed that drug tests were more
sensitive than self-reports (Galletly, Field, & Prior, 1993; Kilpatrick,
Howlett, Sedgwick, & Ghodse, 2000; Lundy et al., 1997; Olshaker,
Browne, Jerrard, Prendergast, & Stair, 1997; Perrone, De Roos,
Jayaraman, & Hollander, 2001) or physician clinical evaluation
(Mordal, Holm, Mørland, & Bramness, 2010). The value of drug
testing for clinical management and patient outcomes has been
further assessed in several settings: in school programmes (Roche,
Bywood, Pidd, Freeman, & Steenson, 2009) and in occupational
drivers (Cashman, Ruotsalainen, Greiner, Beirne, & Verbeek, 2009),
drug tests are known to be effective. In emergency settings, a recent
review found that drug tests had no influence on therapeutic
management (Tenenbein, 2009). In chronic non-cancer pain patients,
the effectiveness of urine testing to reduce opioid misuse is still
debated (Starrels et al., 2010).
As far as we are aware, no study has yet assessed the effectiveness
of these tests in ambulatory care in opioid-dependent patients,
although they are recommended and they could help to improve
therapeutic management when opiate substitutes are used. Our aim
was to assess the effectiveness of drug tests for treatment retention in
outpatients starting opioid substitution therapy.2. Materials and methods
Data were extracted from the database of the main French health
insurance system (Extraction, Recherches, Analyses pour un Suivi
Médico-Economique, ERASME) for the Midi-Pyrenees region from
January 1, 2009 to December 31, 2011 in order to build a cohort of
patients whowere starting opioid substitution therapy (Appendix Fig.
1). This health insurance system covers 87% of the French general
population (other systems cover specific populations such as farmers,
soldiers and railway workers) (Martin-Latry & Bégaud, 2010).
Patients with universal coverage (coverage for the unemployed and
low income insurees) are automatically registered in this system.
Inclusion criteria for the study were absence of reimbursement for OS
between January 1, 2009 and June 30, 2009 and at least one recorded
reimbursement for OS between July 1, 2009 and June 30, 2010. These
patients had therefore started an OS between July 1, 2009 and June 30,
2010 and were followed for 18 to 30 months. The reference date was
defined as the first OS delivery. The period of 30 days before the first
delivery of the first OS prescribed to the end of opioid substitution
treatment (OST) was considered as the addiction treatment period.
The study was approved by the French Data Protection Authority
(Commission Nationale Informatique et Libertés, CNIL), authorization
for evaluation of health care practices n°1516745.2.1. Definition of exposure
The exposure studied was prescription of a drug test during the
addiction treatment period. Exposure was considered as a time-
dependent variable with a single change, and the period of exposure to
a drug test was defined as the period extending 30 days before the first
testwas carried out until occurrence of the event or censoring (Appendix
Fig. 1). Laboratory tests were identified and described by the laboratory
classification codes used for reimbursement by the health insurance
system (Appendix Table 1). Tests for analgesics, narcotics and psycho-
tropic drugs were taken into account, whatever the biological medium.
2.2. Definition of the event
The primary outcome measure was OST retention, defined as
regular delivery of an OS (delivery every 35 days maximum for
buprenorphine and 18 days for methadone). A period of more than
35 days between two deliveries of buprenorphine (or more than
18 days for methadone) was considered as treatment interruption
and has been validated as such in other studies (Pradel et al., 2004,
2009). This definition of OST retention takes into account the
particular conditions of prescription and delivery of these drugs. A
patient who interrupted treatment was considered as having
discontinued treatment (any later reinitiation was considered a new
treatment cycle and was not analyzed here). Data were right-
censored at the end of the study period (administrative censoring at
December 31, 2011), at the patient's death or loss to follow-up. For
patients who presented the event “treatment discontinuation” before
death, the event was taken into account if it occurred more than
30 days before death. If the date of the last reimbursed act or the last
reimbursed drugwas prior to the date of treatment discontinuation by
the patient, he/she was considered as lost to follow-up.
2.3. Definition of co-variables
The doctor-shopping indicator, proposed by Pradel et al. (2004,
2009), was used to take into account simultaneous use of several
physicians by a patient in order to obtain prescriptions. To determine
the doses of methadone and buprenorphine delivered, we used
defined daily doses according to the World Health Organization
guidelines (WHO Collaborating Centre for Drug Statistics Methodol-
ogy). The dose delivered corresponded to the daily dose delivered to
the patient. The dose prescribed corresponded to the daily dose that
would have been delivered to the patient if he/she had only one
physician. The doctor-shopping dose corresponded to the daily dose
obtained by the prescriptions of several physicians in a same period of
time. The doctor-shopping indicator was obtained by dividing the
doctor-shopping dose by the dose delivered. If the doctor-shopping
indicator was greater than zero, we considered that the patient
exhibited doctor-shopping behavior (binary variable).
We used other reimbursed drugs as indicators of associated
comorbidities. These drugs were identified by their anatomical
therapeutic chemical classification code (ATC code) throughout the
study period (Appendix Table 2). The variables taken into account
during the addiction treatment period were hospital admission, status
of the beneficiary (insured person or their dependent), health insurance
coverage for a chronic disease (100% reimbursement of health care for
the disease in question), complementary private insurance, universal
coverage (coverage for theunemployed and low income insurees), state
medical aid (coverage for foreigners not legally resident in France), and
pregnancy (identified through maternity benefit).
2.4. Statistical analysis
Qualitative variables were expressed in numbers and percentages
and compared between the drug test group (patients prescribed at
Fig. 1. Flow diagram of patient inclusion.
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prescription) using the chi-square test or Fisher test. Quantitative
variables were expressed as means and standard deviations, and were
compared between the two groups using the Wilcoxon rank test. The
primary outcome measure in both groups was survival analysis by
Kaplan-Meier curves. A Cox proportional hazards model was
constructed to assess treatment retention in the two groups. The
Cox model tested the different variables and adjusted for potential
confounding factors. The alpha risk threshold was set at 0.20 for
selection of variables entered in the multivariate model. The
definition of time-dependent exposure was tested using the Cox
model in univariate and multivariate analysis (backward procedure,
α=5%). Data analysis was carried out using SAS 9.2 software (SAS
Inst., Cary, North Carolina, USA).3. Results
The data collected concerned 1554 patients. Thirty patients were
excluded because of missing demographic data (Fig. 1). Following a
check by the medical officer of the health insurance system, 14
patients aged less than 16 years were excluded due to mistaken
attribution as their parents were the consumers. Lastly, three patients
did not meet the inclusion criteria as they had been reimbursed for an
OS before July 1, 2009. Finally, 1507 patients were analyzed.
In the cohort of 1507 patients, 39 (2.6%) had at least one
reimbursement for a drug test during the addiction treatment
period (mean 1.2, SD 0.4). These tests (68 tests) consisted of
measurement of analgesics or narcotics in a biological fluid other
than blood (38 tests, 55.9%), testing for benzodiazepines in a
biological fluid other than blood (12 tests, 17.6%), testing and
measurement in a biological fluid other than blood of a psychotro-Table 1
Demographic characteristics and type of health insurance cover in the whole cohort, the dr
All patients
(N=1507)
Gender n (%)
Male 1123 (74.5)
Female 384 (25.5)
Mean age (SD) in years 33.2 (9.3)
Status of beneficiary (dependent versus insured) n (%) 73 (4.8)
Health insurance coverage for a chronic disease n (%) 282 (18.7)
Complementary insurance n (%)
No 43 (2.9)
Yes 364 (24.2)
Universal coverage 605 (40.1)
Not specified 495 (32.8)
State medical aid n (%)
No 1460 (96.9)
Yes 18 (1.2)
Not specified 29 (1.9)pic agent not otherwise categorized (8 tests, 11.8%), measurement
of analgesics or narcotics in blood (7 tests, 10.3%), testing and
measurement of a psychotropic drug in blood (2 tests, 2.9%) and
testing for benzodiazepines in blood (1 test, 1.5%).
Regarding the physicians of the patients in the drug test group, 137
had prescribed an OS and 41 of these physicians had started OST in
these patients. Thirty physicians (25 PCPs, 5 psychiatrists) had
prescribed drug tests.
Regarding PCPs of the Midi-Pyrenees region, 841 had prescribed
OS. A total of 2620 PCPs were shown in our database to have
prescribed a drug or carried out a medical act.
The social and demographic characteristics of the patients of the
whole cohort, the drug test group and the control group are given in
Table 1. Of the 384women of the cohort, 14 (3.7%)were pregnant during
follow-up (all in the control group, p=1.00). During follow-up, 37 (2.5%)
subjects died (none in the drug test group, p=0.62). Two hundred forty
five subjects were considered as lost to follow-up: 234 (15.9%) in the
control group and 11 (28.2%) in the drug test group (p=0.041).
Type of OS, durations of treatment retention, retention rates,
characteristics of primary prescriber of an OS and doctor-shopping
indicators are given in Table 2. Three hundred twenty-four patients
(21.5%) exhibited doctor-shopping behavior: 19 (48.7%) in the drug
test group and 305 (20.8%) in the control group (pb0.001).
Reimbursements of medications according to class are given in
Table 3. Few hospital admissions were observed during the addiction
treatment period (mean 2.1, SD 9.3) with no difference between the
two groups (p=0.25).
Overall, 1252 (83.1%) patients discontinued OST: 1224 (83.4%) in
the control group and 28 (71.8%) in the drug test group. Kaplan–Meier
curves revealed differences in OST retention between the two groups
(Fig. 2). This difference was significant in the log rank test (pb0.001).
In univariate analysis, the variables associated with treatment
retention included age, doctor-shopping behavior, drug tests, one or
more hospital admissions, zolpidem reimbursements, morphine
sulfate reimbursements, antidepressants reimbursements, alcohol
abstinence drugs reimbursements, the type of OS prescribed (bupre-
norphine or methadone), the primary prescriber speciality and
primary prescriber previously known to patient. Table 4 shows the
results of multivariate analysis in a Cox model. In the multivariate Cox
model, a drug test was independently associated with OST retention
with an HR of 0.55 (95% CI, 0.38–0.80) (p=0.002).4. Discussion
Of the 1507 patients who had started OST, only 39 had been
reimbursed for a drug screening test during the medical managementug test group and the control group.
Drug test group
(n=39)
Control group
(n=1468)
p value
29 (74.4) 1094 (74.5) 0.98
10 (25.6) 374 (25.5)
31.5 (8.9) 33.3 (9.3) 0.182
0 (0.0) 73 (5.0) 0.26
5 (12.8) 277 (18.9) 0.34
0 (0.0) 43 (2.9) 0.68
9 (23.1) 355 (24.2)
14 (35.9) 591 (40.3)
16 (41.0) 479 (32.6)
39 (100.0) 1421 (96.8) 1.00
0 (0.0) 18 (1.2)
0 (0.0) 29 (2.0)
Table 2
Characteristics of opioid substitution treatment (OST) in the whole cohort, the drug test group and the control group.
All patients
(N=1507)
Drug test group
(n=39)
Control group
(n=1468)
p value
OST n (%)
Buprenorphine 1053 (69.9) 23 (59.0) 1030 (70.2) 0.089
Methadone 344 (22.8) 10 (25.6) 334 (22.8)
Buprenorphine and/or methadone 110 (7.3) 6 (15.4) 104 (7.1)
Mean duration of treatment retention (SD) 212 (241) 411 (267) 207 (238) b0.001
Retention rate at 6 months n (%) 547 (36.3) 27 (69.2) 520 (35.4) b0.001
Retention rate at 12 months n (%) 321 (21.3) 21 (53.9) 300 (20.4) b0.001
Retention rate at 18 months n (%) 224 (14.9) 16 (41.0) 208 (14.2) b0.001
Primary prescriber of an OS
Specialty n (%)
Primary care physician 1422 (94.3) 38 (97.4) 1384 (94.3) 0.78
Specialist 75 (5.0) 1 (2.6) 74 (5.0)
Not known 10 (0.7) 0 (0.0) 10 (0.7)
Hospital physician n (%) 285 (18.9) 7 (18.0) 278 (18.9) 0.88
Physician previously known to patient n (%)
No 1190 (79.0) 30 (76.9) 1160 (79.0) 0.75
Yes 317 (21.0) 9 (23.1) 308 (21.0)
Doctor-shopping indicators
Mean dose delivered (SD)a 1.6 (1.8) 2.0 (1.0) 1.5 (1.9) b0.001
Mean dose prescribed (SD)a 1.5 (1.8) 1.8 (0.9) 1.5 (1.8) b0.001
Mean doctor-shopping dose (SD)a 0.1 (0.3) 0.1 (0.3) 0.1 (0.3) b0.001
Mean doctor-shopping indicator (SD) 0.04 (0.09) 0.05 (0.12) 0.03 (0.09) b0.001
a In defined daily dose (DDD), dose delivered=daily dose delivered to the patient, dose prescribed=daily dose that would have been delivered to the patient if he/she had only
one physician; doctor-shopping dose=daily dose obtained by the prescriptions of several physicians in a same period of time, doctor-shopping indicator=doctor-shopping dose/
dose delivered.
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The association between drug tests and OST retention was confirmed
by multivariate analysis.
This observational study is based on the data of the French health
insurance system. Use of such databases has become generalized in
France for more than 10 years, particularly in the field of addiction
(Lapeyre-Mestre et al., 2003; Thirion et al., 2002), and the validity of the
ERASME database of the health insurance system has been confirmed
(Latry, Molimard, Bégaud, & Martin-Latry, 2010). It has been shown in
the Three-Cities (3C) cohort that the reimbursement data of the health
insurance system agreed with consumption data (Noize et al., 2009).
Incident status was defined as non-reimbursement for an OS
during the first 6 months of the study period. It can be assumed that
the absence of a prescription for an OS over a 6-month period
indicates that there was no previous treatment, or at least a prolongedTable 3
Drugs reimbursed for patients in the whole cohort, the drug test group and the control gro
All patients
(N=1507)
Dr
(n
Class of drugs reimbursed
Cardiovascular system n (%) 232 (15.4) 8
Platelet antiaggregants n (%) 37 (2.5) 1
Lipid-lowering agents n (%) 45 (3.0) 1
Statins n (%) 36 (2.4) 1
Hepatitis C treatment n (%) 30 (2.0) 0
HIV treatment n (%) 23 (1.5) 0
Alcohol abstinence drugs n (%) 112 (7.4) 5
Psychotropic agents n (%) 1058 (70.2) 29
Antipsychotics n (%) 391 (26.0) 18
Benzodiazepines n (%) 1031 (68.4) 29
Antidepressants n (%) 536 (35.6) 23
Potential drugs of abuse
Flunitrazepam n (%) 23 (1.5) 1
Clonazepam n (%) 145 (9.6) 8
Diazepam n (%) 236 (15.7) 9
Bromazepam n (%) 305 (20.2) 6
Oxazepam n (%) 319 (21.2) 15
Alprazolam n (%) 215 (14.3) 5
Zolpidem n (%) 362 (24.0) 13
Methylphenidate n (%) 1 (0.1) 0
Morphine sulphate n (%) 80 (5.3) 2interruption of treatment so that the patient can again be considered
as starting treatment. Nevertheless, this raises the problem of the first
delivery of methadone, which must be prescribed in a specialized
center or in a hospital setting. Data concerning drugs delivered in
hospital settings are not available in the database. For some subjects
receiving methadone, the duration of treatment retention has in fact
probably been underestimated.
We studied the influence on therapeutic management of the use of
drug tests, whether in blood or urine, in the physician's office or in the
laboratory. These tests can be used in various clinical situations, but in
our selected population of patients starting OST and during the
defined period of medical addiction treatment, we may assume that
they were prescribed in connection with the management of opiate
addiction. As PCPs seldom carry out such tests (Dupouy et al., 2012),
we may consider that differences in practice do not limit the validityup.
ug test group
=39)
Control group
(n=1468)
p value
(20.5) 224 (15.3) 0.37
(2.6) 36 (2.5) 1.00
(2.6) 44 (3.0) 1.00
(2.6) 35 (2.6) 0.62
(0.0) 30 (2.0) 1.00
(0.0) 23 (1.6) 1.00
(12.8) 107 (7.3) 0.21
(74.4) 1029 (70.1) 0.57
(46.2) 373 (25.4) 0.004
(74.4) 1002 (68.3) 0.42
(59.0) 513 (35.0) 0.002
(2.6) 22 (1.5) 0.46
(20.5) 137 (9.3) 0.047
(23.1) 227 (15.5) 0.20
(15.4) 299 (20.4) 0.45
(38.5) 304 (20.7) 0.007
(12.8) 210 (14.3) 0.79
(33.3) 349 (23.8) 0.17
(0.0) 1 (0.1) 1.00
(5.1) 78 (5.1) 1.00
Patients at risk, n
Drug test group 
Control group
39
1,468 738 520 390 301 242 209 142 97 38 3
36 28 25 22 18 17 12 6 3 1
Fig. 2. Kaplan–Meier curves comparing opioid substitution treatment (OST) retention
in the two groups (drug test group and control group), log rank test pb0.001.
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since only six laboratory test codes were in fact recorded out of the
eight codes initially selected. Also, the majority of codes corresponded
to tests in a biological fluid other than blood, probably urine tests.
Adding 30 days before the first delivery of the first OS to define the
addiction treatment period was justified because a drug test could be
prescribed earlier and could, therefore, influence patient behavior.
This study is subject to several sources of bias. Affiliation to the
main French health insurance system is dependent on occupation;
part of the population, with a different social and economic profile, is
not included in our analysis. This leads to a selection bias. This bias
was limited by the fact that we were able to access the data of student
health insurance organizations and by the fact that persons in
difficulty were included.
Some patients possibly had drug tests in a specialized center or a
hospital. Nevertheless, data concerning tests performed in hospital
settings are not available in the database. Furthermore, some patients
possibly had urine tests with commercial strips or kits. As these tests
are not covered by the health insurance system, we had no trace of
them and some patients were probably wrongly included in the
control group, leading to underestimation of the hazard risk of drug
screening. Use of a time-dependent variable to study exposure to a
drug screening test avoided immortal time bias.
Only a small number of subjects were tested by physicians. This
highlights that physicians seldom carry out such tests, which is inTable 4
Analysis of opioid substitution treatment retention using the multivariate Cox model.a
Adjusted hazard ratio (95% CI) p value
Drug test 0.55 (0.38–0.80) 0.002
Doctor-shopping behavior 0.36 (0.31–0.41) b0.001
Primary prescriber specialist versus PCP 0.69 (0.53–0.90) 0.007
Age (years)
25–30 (versus b25) 0.88 (0.75–1.05) 0.153
30–40 (versus b25) 0.78 (0.67–0.91) 0.002
N40 (versus b25) 0.75 (0.63–0.89) b0.001
1 or more hospital admission 1.14 (1.01–1.28) 0.036
Morphine sulfate 1.35 (1.06–1.71) 0.014
Alcohol abstinence drugs 1.38 (1.11–1.70) 0.004
PCP=primary care physician.
a Variables initially included in the model were age, gender, status of beneficiary,
health insurance coverage for a chronic disease, universal coverage, complementary
insurance, state medical aid, pregnancy, being hospitalized at least once, OST, specialty
of primary prescriber, primary prescriber being an hospital physician, primary
prescriber previously known to patient, dose delivered, doctor-shopping behavior,
other drugs reimbursed and potential drugs of abuse reimbursed.agreement with declarative data (Dupouy et al., 2012) but raises
concerns about selection of patients tested. Two different hypotheses
with opposite effects can be imagined. First, patients tested may be
more compliant patients andmay be self-selected on theirmotivation.
However, this hypothesis is not in agreement with exposure of tested
patients to certain drugs of abuse (benzodiazepines in particular) and
doctor-shopping behavior which was more frequent in tested
patients. The second hypothesis is that tested patients may be more
heavily addicted patients, as physicians need to test them to assess
their consumption.
Lastly, residual confounding factors are another bias in this work.
Personal history, addiction severity, parallel drug consumption
(Duburcq, Charpak, Blin, & Madec, 2000), injection profile, family
support and the occupational (Stein, Cioe, & Friedmann, 2005), and
social context (Batel et al., 2004) are variables that have a strong
impact on OST retention in these patients, but these factors are not
available in the database. The population that underwent drug tests
was possibly more severely addicted, as suggested by exposure to
certain drugs of abuse.
Demographic data of included patients were similar to demo-
graphic data of a French cohort in the same area (Lapeyre-Mestre
et al., 2003). The primary care physicians who had issued a
prescription or performed any medical act in this patient population
represented 68.7% of PCPs in regular practice in the Midi-Pyrenees
region on January 1, 2010 according to the data of the national order of
physicians, the Ordre National des Médecins (Conseil National de
l'Ordre des Médecins, 2010). This high proportion suggests that our
data are exhaustive. Of these PCPs, 32.1% prescribed OST. This is in
agreement with the declarative data we collected during a previous
survey in the same area (Dupouy et al., 2012). Of the physicians
treating patients in the drug test group, 30 had prescribed a test. This
indicates that the differences between the two groups were not due
only to differences in practice or training of some physicians.
Drug tests appeared to be associated with better OST retention.
This can be explained by better assessment of drug consumption and
easier dialogue between patient and practitioner. Drug tests are
known to be effective in school programmes (Roche et al., 2009) and
in screening of occupational drivers (Cashman et al., 2009). In an
emergency setting, a recent review found no influence of drug tests on
therapeutic management (Tenenbein, 2009). The effectiveness of
urine testing to reduce opioid misuse in chronic non-cancer pain
patients is still debated (Starrels et al., 2010).
Doctor-shopping appeared to be independently associated with
better OST retention. This may simply be explained by the fact that
doctor-shopping results in bias in the measurement of treatment
retention time. Patients who see several prescribers are more likely to
have a shorter timebetween twoprescriptiondeliveries and so to remain
in treatment longer, leading to a non-differential information bias.
In conclusion, our study increased our knowledge of the value of
drug tests in treatment of opioid addiction in an outpatient setting. In
a cohort of 1507 patients starting OS treatment and followed for 18 to
30 months, only 39 (2.6%) had at least one reimbursement for a drug
test. Treatment retention was longer in these patients, after taking the
available confounding factors into account. These findings deserve to
be confirmed by more detailed study.Acknowledgments
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Medical laboratory classification codes used to identify drug screening tests in the
French health insurance system database.Medical
laboratory code
Label of corresponding analysis
1659 Measurement in blood of analgesics or narcotics not otherwise
categorized
0659 Measurement in a biological fluid other than blood of
analgesics or narcotics not otherwise categorized
1662 Testing andmeasurement in blood for a psychotropic agent not
otherwise categorized
0662 Testing and measurement in a biological fluid other than blood
of a psychotropic agent not otherwise categorized
1667 Testing inblood for benzodiazepines (not for treatment follow-up)
0667 Testing for benzodiazepines in a biological fluid other than
blood (not for treatment follow-up)
1668 Diazepam and its metabolite (measurement)
1669 Clonazepam (measurement)Appendix Table 2
Anatomical Therapeutic Chemical (ATC) codes used to identify drugs in the French
health insurance system database.
Class of drugs reimbursed ATC code Label of corresponding drugs
Cardiovascular system drugs C Cardiovascular system
Platelet antiaggregants B01AC Platelet aggregation inhibitors
excluding heparin
Statins C10AA HMG-CoA reductase inhibitors
C10B Lipid modifying agents,
combinations
Hepatitis C drugs J05AB04 Ribavirin
L03AB01 Natural interferon α
L03AB04 Interferon α-2A
L03AB05 Interferon α-2B
L03AB06 Interferon α-N1
L03AB09 Interferon alfacon-1
L03AB10 Peginterferon α-2B
L03AB11 Peginterferon α-2A
L03AB12 Albinterferon α-2B
L03AB60 Peginterferon α-2B,
combinations
L03AB61 Peginterferon α-2A,
combinations
Antiretroviral drugs (HIV) J05AE Protease inhibitors
J05AF Nucleoside and nucleotide
reverse transcriptase inhibitors
J05AG Non-nucleoside reverse
transcriptase inhibitors
J05AR Antivirals for treatment of HIV
infections, combinations
Alcohol abstinence drugs N07BB Drugs used in alcohol
dependence
Psychotropic drugs N05 Psycholeptics
Antipsychotics N05A Antipsychotics
Benzodiazepines N05B Anxiolytics
N05C Hypnotics or sedatives
N03E Benzodiazepine derivatives
(clonazepam)
Antidepressants N06A Antidepressants
Drugs with known abuse potentiala
(monitored by the French
addictovigilance system)
N05CD03 Flunitrazepam
N03AE01 Clonazepam
N05BA08 Bromazepam
N05BA12 Alprazolam
N05BA01 Diazepam
N05BA04 Oxazepam
N05CF02 Zolpidem
N06BA04 Methyphenidate
N02AA01 Morphine sulphate
a These drugs were taken from the last report of the OSIAP survey (Agence française de
sécurité sanitaire desproduits de santé, 2011).We selected thefirst 5 drugs cited (excluding
buprenorphine): zolpidem, bromazepam, clonazepam, alprazolam, morphine. Methylphe-
nidate abuse has recently been reported in France (Frauger et al., 2011). Diazepam is also
known for its high potential for abuse (Pradel, Delga, Rouby, Micallef, & Lapeyre-Mestre,
2010). Oxazepamwas selected as it is widely prescribed (Rosman, Marc, & Nathalie, 2011).References
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A recent study has shown that UDT was a protective factor for mortality (McCowan, Kidd, 
& Fahey, 2009). This retrospective cohort study performed through data obtained from a 
primary care prescription registry in Tayside, Scotland aimed to assess predictors of 
mortality in a population of 2378 people prescribed methadone. A history of involvement 
in urine testing programmes (irrespective of the result) was associated with a reduced risk 
of all-cause mortality with a reduction of 70% of risk of death (adjusted hazard ratio of 
0.33 [0.22 to 0.49]). The magnitude of the estimated risk ratio was similar to the hazard 
ratio observed in our previous presented study. Thanks to the previous conducted study and 
to this Scottish cohort, we could hypothesize that the benefit to perform UDT was found in 
several studies and is stable.   
OBJECTIVE  
This study aimed to assess the effectiveness of UDT on all-cause mortality in patients 
treated by OMT. 
METHOD  
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We performed a pharmacoepidemiological retrospective cohort study on patients newly 
treated with OMT, using the database EGB. We used data from 01/01/2006 to 31/12/2013. 
As data for agricultural workers, farmers and self-employed were added in EGB in 2011, 
we decided to include only the population of the main French health insurance system (ie. 
salaried workers, retirees and patients with the universal coverage representing 86% of the 
French population)  in order to work on the same population throughout the follow-up. We 
included patients who had a first dispensation of OMT between 01/01/2007 and 
31/12/2011 and who were never exposed during the previous twelve months. Patients were 
followed-up at least one year until the end of the study period or censoring (death or drop 
out). Reimbursements of drug tests were identified and patients classified in two groups 
according to it. Survival analyses on all-cause mortality were conducted. 
 
RESULTS 
In this study, among patients starting OMT, more than 15% had a reimbursement for a 
drug test. Having been drug tested was not associated with mortality, HR 0.60 [95%CI 
0.21 – 1.69]. Nevertheless, mortality risk was higher off treatment than on treatment. 
Factors associated with mortality were covariates representing the severity of the disease. 
In front of this non-significant result concerning drug tests, we did not perform a 
multivariate analysis. The first analysis of these data showed that around 15% of patients 
had been drug tested and that this practice was quite heterogeneous with a first test 
happening 680 +/- 603 days after the first reimbursement of OMT (median: 583 [144 – 
1063]; minimum -30, maximum 2263 days). These data will be more precisely analyzed 
distinguishing drug tests occurring in the initiation of opioid addiction management and 
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drug tests occurring in the follow-up. We will then valorize this work not only on drug 
tests but more globally on factors associated with mortality.  
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Abstract 
We aimed to assess the effectiveness of drug tests for all-cause mortality in outpatients 
starting opioid substitution therapy. A retrospective cohort was created from the data of a 
French health insurance system database called EGB. Patients starting opioid maintenance 
treatment were included and followed up for 2 to 7 years. Two groups of patients were 
defined: the drug test group (at least one drug test reimbursement) and a control group (no 
drug test reimbursement). The cohort included 1,076 patients. During follow-up, 177 subjects 
(16.4%) had at least one drug test reimbursement. Crude mortality rate was 0.53/100 person-
year [95%CI 0.36 – 0.70]. Thirty-seven patients (3.4%) deceased during the follow-up: 4 
(2.3%) in the drug test group and 33 (3.7%) in the control group (P = 0.346). Drug tests were 
not associated with all-cause mortality: hazard ratio 0.60 [95%CI 0.21 – 1.69]. Use of a drug 
test in follow-up of opioid substitution treatment, did not significantly improved all-cause 
mortality. 
  
Keywords: 
Opioid-related disorders 
Substance abuse detection 
Opiate substitution treatment 
Mortality 
Ambulatory care 
Cohort studies 
 
  
1. Introduction 
Opioid addiction is currently defined as a “chronic, relapsing disorder” (1,2). Mortality of 
untreated heroin dependence is consistently estimated at 1–3% per year, at least half of which 
because of heroin overdose (3). Data from systematic reviews show that methadone 
maintenance is the most effective treatment in retaining patients in treatment and suppressing 
heroin use (4,5).  
More recent data estimates that near 150 000 patients are treated, in France, by an opioid 
substitute (OS) (6). In France, methadone must be started in a specialized unit or a hospital 
and can be continued, after the patient is stabilized, in an outpatient setting, whereas 
buprenorphine can be started in a specialized unit, a hospital or an outpatient setting. The 
physician can prescribe methadone for a maximum of 14 days and buprenorphine for 28 days. 
Because buprenorphine is easily obtainable (7), more than three-quarters of patients treated 
for opioid addiction receive buprenorphine
 
(7–9) and most of them are treated in general 
practice using this drug (7,10). The number of people receiving opiate maintenance treatment 
(OMT) was estimated at around 100,000 for buprenorphine and around 35,000 for methadone 
in 2009 (6). 
One difficulty of physicians involved in treating opioid-addicted patients is to evaluate the 
concordance between the patient's word and his drug use (OMT and other illicit drugs) (11) as 
self-reports and clinical examination use to under estimate psychoactive substances’ 
consumption (12–17). By contrary, in certain context, patients can overestimate their use of 
psychoactive substances notably when entering a detoxification program (18).  
Urine drug testing (UDT) can improve this assessment (17). Drug tests can be carried out by 
immunochemical methods, either by automated analyzers in the biology laboratory or by drug 
screening kits in the surgery of the physician. These tests are qualitative and have defined 
thresholds. Results can be confirmed by the reference method, liquid or gas phase 
chromatography with mass spectrometry, which gives quantitative measurements (19). 
Laboratory tests, regardless of the method or the biological medium, are reimbursed by the 
French health insurance system with no limit on their number or time period. On-site urine 
drug screening by commercial kits is not reimbursed by the French health insurance system 
but some specialized addiction networks in France provide them to their members. 
Methadone prescription guidelines detail the recommended urine tests: a first, obligatory test 
before starting methadone treatment and later control tests. When the patient has been 
transferred to an outpatient setting, tests can be done if the physician considers it necessary. 
Tests are not obligatory for buprenorphine but advised in the initiation of buprenorphine 
treatment and for the follow-up with the patient’s consent (20).  
The value of these tests could be to complete the initial assessment before prescribing OMT; 
and for the follow-up, to monitor the consumptions and the craving, to evidence with the 
patient the achievement of abstinence, to have a positive reinforcement when results are 
negative and to deter as soon as possible the use of the substance to reinforce the therapeutic 
management. 
But, while diagnostic value of these tests is well demonstrated (12–17), the consequences of 
carrying out these tests on management of treatment have not been established. A recent 
systematic review reveals that weak evidence supports the use of UDS in settings where 
abusers or addicted patients are managed (i.e., psychiatric settings, primary care, pain clinics, 
outpatient clinics…). Few studies, with poor quality, have assessed the value of UDS in 
managing patients using psychoactive substances; though with insufficiency to demonstrate 
the interest of carrying out UDS (21). 
Nevertheless, in a cohort of 1,507 patients starting OS treatment and followed for 18 to 30 
months, of whom 39 (2.6%) had at least one reimbursement for a drug test, treatment 
retention was longer in these patients, after taking the available confounding factors into 
account (22). 
Furthermore, a recent study has shown that UDT was a protective factor for mortality (23). 
This retrospective cohort study performed through data obtained from a primary care 
prescription registry in Tayside, Scotland aimed to assess predictors of mortality in a 
population of 2378 people prescribed methadone. A history of involvement in urine testing 
programmes (irrespective of the result) was associated with a reduced risk of all-cause 
mortality with a reduction of 70% of risk of death (adjusted hazard ratio of 0.33 [0.22 to 
0.49]).  
Thus, we could hypothesize that the benefit to perform UDT was found in several studies and 
is stable. This study aimed to assess the effectiveness of UDT on all-cause mortality in patient 
treated by OMT.  
2. Material and methods 
We performed a pharmacoepidemiological retrospective cohort study on patients newly 
treated with OMT, using the database EGB (24). EGB is a permanent representative sample 
of subjects affiliated with the French Health Insurance System. It is obtained by 1/97
th 
national random sampling with control for distribution of age and gender. The EGB database 
includes approximately 660,000 beneficiaries (24). For some years, French Health Insurance 
System databases have been widely used for public health and pharmacoepidemiological 
purposes (25–30). 
We used data from 01/01/2006 to 31/12/2013. As data for agricultural workers, farmers and 
self-employed were added in EGB in 2011, we decided to include only the population of the 
main French health insurance system (ie. salaried workers, retirees and patients with the 
universal coverage representing 86% of the French population)  in order to work on the same 
population throughout the follow-up.  
We included patients who had a first dispensation of OMT between 01/01/2007 and 
31/12/2011 and who were never exposed during the previous twelve months. OMT were 
identifies by the ATC codes: N07BC (including N07BC01: buprenorphine, N07BC02: 
methadone, N07BC52: buprenorphine-naloxone). Patients were followed-up at least two years 
until the end of the study period or censoring (death or drop out). Patients were defined 
incidents if they had a first reimbursement between the age of 16 and 60 when starting OMT. 
The exposure to drug tests was prescription of a drug test during the OMT period. Laboratory 
tests were identified and described by the laboratory classification codes used for 
reimbursement by the health insurance system (Appendix Table 1). Tests for analgesics, 
narcotics and psychotropic drugs were taken into account, whatever the biological medium. 
The outcome was all-cause death. The date of death without the reason is encoded in the EGB 
from the national death register of the Institut National de la Statistique et des Etudes 
Economiques INSEE. Data were right-censored at the end of the study period (administrative 
censoring at December 31, 2013).  
The exposure to OMT (buprenorphine, methadone, or buprenorphine-naloxone) was 
considered as a time-dependent covariate. To define different OMT exposure periods, OMT 
retention was defined as regular reimbursements of an OS with two definitions of treatment 
interruption: 1) reimbursement every 35 days maximum for buprenorphine and 18 days for 
methadone; 2) reimbursement every 70 days maximum for buprenorphine and 35 days for 
methadone. A period of more than 35 or 70 days between two reimbursements of 
buprenorphine (or more than 35 or 18 days for methadone) was considered as treatment 
interruption (any later reinitiation was considered a new OMT period). The first definition of 
OST retention takes into account the particular conditions of prescription and dispensing of 
these drugs. The period of more than 35 days between two reimbursements of buprenorphine 
(or more than 18 days for methadone) has been validated as such in other studies to identify 
doctor-shopping (31,32). As we disposed of a long follow-up (until seven years), we chose in 
a second definition to double this delay to increase specificity and sensitivity of the detection 
of OMT interruption, as we had already experienced in another study (33). 
To determine the doses of methadone and buprenorphine dispensed, we used defined daily 
doses according to the World Health Organization guidelines (34). OMT period duration was 
the duration between the first and the last reimbursement of the period plus the number of 
reimbursed DDD of the last reimbursement. We defined patients as being “on treatment” on 
all the OMT period duration and “off treatment” the remaining time. 
The doctor-shopping indicator, proposed by Pradel et al., was used to take into account 
simultaneous use of several physicians by a patient in order to obtain prescriptions (31,32). 
The dose prescribed corresponded to the daily dose that would have been dispensed to the 
patient if he/she had only one physician. The doctor-shopping dose corresponded to the daily 
dose obtained by the prescriptions of several physicians in a same period of time. The doctor-
shopping indicator was obtained by dividing the doctor-shopping dose by the dose dispensed. 
If the doctor-shopping indicator was greater than zero, we considered that the patient 
exhibited doctor-shopping behavior (binary variable).  
We used other reimbursed drugs as indicators of associated comorbidities. These drugs were 
identified by their anatomical therapeutic chemical classification code (ATC code) throughout 
the study period (ATC codes N05A for antipsychotics, N06A for antidepressants, N03A for 
antiepileptics, N07BB for alcohol maintenance drugs). The co morbidity score of Charlson 
was calculated using codes defined by Quan (35). The variables taken into account during the 
addiction treatment period were complementary private insurance, universal coverage 
(coverage for the unemployed and low income insurees); status of the beneficiary (insured 
person or their dependent), psychiatric diseases identified by health insurance coverage for a 
chronic psychiatric disease (ALD code 23) and associated ICD10 codes (Appendix Table 2), 
hospital admission for a psychoactive substance use or for a psychiatric disease (GHS and 
ICD10 codes in Appendix Table 3).  
Qualitative variables were expressed in numbers and percentages and compared between the 
drug test group (patients prescribed at least one drug test) and the control group (patients with 
no drug test prescription) using the chi-square
 
test or Fisher test. Quantitative variables were 
expressed as means and standard deviations, and were compared between the two groups 
using the Wilcoxon rank test. The primary outcome measure in both groups was survival 
analysis by Kaplan-Meier curves. A Cox proportional hazards model was constructed to 
assess mortality in the two groups. The Cox model tested the different variables (and will 
adjust for potential confounding factors). The alpha risk threshold was set at 0.20 for selection 
of variables entered in the multivariate model. The definition of time-dependent OMT 
exposure was tested using the Cox model in univariate (and multivariate) analysis (backward 
procedure, α = 5%). Data analysis was carried out using SAS Guide43 ® software (SAS Inst., 
Cary, North Carolina, USA).  
We performed an observational study on anonymous data. Thus, considering the French 
legislation, it did not need to be approved by a regulatory structure or an ethic committee (36). 
The use of EGB for research teams is, thus, authorized by law and does not require the 
submission of a request to the National data protection commissions (CNIL and CCTIRS), but 
the study synopsis including source of funding was submitted to INSERM which approved 
the project. 
  
3. Results 
Between 2007 and 2013, 654 816 were in the EGB database. Among them, 543 576 (83.0%) 
were affiliated to the main French health insurance system. Among the beneficiaries of this 
scheme, 1076 (0.2%) began an OMT between the age of 16 and 60.  
During the follow-up of these 1076 patients, 177 (16.4%) had at least one reimbursement for a 
drug test with a mean number of drug tests of 3.6 (+/- 6.7) per patient, median of 2 [1 – 3], 
maximum: 57 tests. The first test happened 680.0 +/- 603.0 days after the first reimbursement 
of OMT (median: 583 [144 – 1063]; minimum -30, maximum 2263 days). Table 1 described 
reimbursed drug tests. Most of them were the measurement in a biological fluid other than 
blood of analgesics or narcotics not otherwise categorized. 
 
Table 1. Nature of the first urine test performed  
 
Nature of the first urine test performed  
 
n = 177 
 
Measurement in a biological fluid other than blood of analgesics or narcotics not otherwise categorized 
 
143 (80.8) 
Testing and measurement in a biological fluid other than blood of a psychotropic agent not otherwise 
categorized 
9 (5,2) 
Testing for benzodiazepines in a biological fluid other than blood (not for treatment follow-up) 2 (1,1) 
Measurement in blood of analgesics or narcotics not otherwise categorized 20 (11,3) 
Testing and measurement in blood for a psychotropic agent not otherwise categorized  3 (1,7) 
 
Included patients were mostly young men (75.3% of men, 32.4 years +/- 8.8 at the first OMT 
reimbursement). Table 2 described the characteristics of included patients.   
 
Table 2. Sociodemographic characteristics of patients according to their group. 
 
Overall 
(n = 1076) 
Drug test group 
(n = 177) 
Control group 
(n = 899) 
 
P-value 
Gender    0.885 
Male 810 (75.3) 134 (75.7) 676 (75.2)  
Female 266 (24.7) 43 (24.3) 223 (24.8)  
 
Overall 
(n = 1076) 
Drug test group 
(n = 177) 
Control group 
(n = 899) 
 
P-value 
Age at the first OS reimbursement    <0.001 
Mean +/- SD 32.4 +/- 8.80 29.1 +/- 7.16 33.0 +/- 8.96  
Median [Q1 – Q3] 31 [26 - 38.5] 28 [24 - 33] 32 [26 - 39]  
Status of beneficiary    0.660 
Insured 1028 (95.5) 168 (94.9) 860 (95.7)  
Dependent 48 (4.5) 9 (5.1) 39 (4.3)  
Universal coverage 400 (37.2) 56 (31.6) 344 (38.3) 0.095 
First OS ATC class    0.094 
buprenorphine N07BC01 875 (81.3) 136 (76.8) 739 (82.2)  
methadone N07BC02 201 (18.7) 41 (23.2) 160 (17.8)  
Specialty of the first OS prescriber *    0.876 
General Practice 1021 (94.9) 173 (97.7) 848 (94.3)  
Unknown 23 (2.1) 3 (1.7) 20 (2.2)  
Psychiatry 16 (1.5)  16 (1.8)  
Gastroenterology 3 (0.3) 1 (0.6) 2 (0.2)  
Activity of first OS prescriber    0.040 
Private practice 828 (77.0) 148 (83.6) 680 (75.6)  
Salaried in a private establishment 212 (19.7) 27 (15.3) 185 (20.6)  
Unknown 36 (3.3) 2 (1.1) 34 (3.8)  
Deprivation index (Fdep09)    <.001 
Mean +/- SD 0.4 +/- 1.50 1.0 +/- 1.32 0.3 +/- 1.52  
Median [Q1 – Q3] 0.5 [-0.5 ; 1.4] 0.9 [0.1 ; 1.7] 0.4 [-0.6 ; 1.3]   
Charlson score    0.053 
Mean +/- SD 0.2 +/- 0.82 0.0 +/- 0.21 0.2 +/- 0.89  
Median [Q1 – Q3] 0 [0 ; 0] 0 [0 ; 0] 0 [0 ; 0]  
Maximum 9 1 9  
Health insurance coverage for a psychiatric disorder 85 (7.9) 10 (5.6) 75 (8.3) 0.225 
Addictive disorders 25 (2.3) 6 (3.4) 19 (2.1) 0.303 
Depressive or recurrent depressive disorder 10 (0.9) 3 (1.7) 7 (0.8) 0.246 
Anxiety disorders 0 (0.0) 0 (0.0) 0 (0.0)  
Schizophrenia, schizotypal and delusional disorders 20 (1.9) 3 (1.7) 17 (1.9) 0.860 
Manic episode and bipolar affective disorders 7 (0.7) 1 (0.6) 6 (0.7) 0.877 
Specific personality disorder 29 (2.7) 2 (1.1) 27 (3.0) 0.159 
Epilepsy 2 (0.2) 1 (0.6) 1 (0.1) 0.194 
Number of consultations and visits    0.761 
Mean +/- SD 7.3 +/- 12.12 7.0 +/- 11.74 7.3 +/- 12.20  
Median [Q1 – Q3] 4 [1 ; 8] 3 [2 ; 7]                         4 [1 ; 9]  
Maximum 157 80 157  
Hospitalization for a psychiatric disorder 38 (3.5) 11 (6.2) 27 (3.0) 0.034 
Hospitalization for an addictive disorder 2 (0.2) 2 (1.1) 0 (0.0) 0.001 
Hospitalization for another disorder 156 (14.5) 29 (16.4) 127 (14.1) 0.436 
Number of nervous system drugs (ATC class N)    0.903 
 
Overall 
(n = 1076) 
Drug test group 
(n = 177) 
Control group 
(n = 899) 
 
P-value 
Mean +/- SD 2.5 +/- 3.31 2.4 +/- 3.31 2.5 +/- 3.31  
Median [Q1 – Q3] 1 [0 ; 4] 1 [0 ; 3] 1 [0 ; 4]  
Maximum 25.0 18.0 25.0  
Antipsychotics 352 (32.7) 61 (34.5) 291 (32.4) 0.587 
Antidepressants 487 (45.3) 85 (48.0) 402 (44.7) 0.419 
Antiepileptics 234 (21.7) 28 (15.8) 206 (22.9) 0.046 
Alcohol abstinence drugs 101 (9.4) 15 (8.5) 86 (9.6) 0.649 
 
* Specialties for which n ≥ 3 are represented (overall patients) 
 
 
Table 3 describes characteristics of OMT periods with the second definition of OMT periods 
(long definition). Patients were treated 1190.2 +/- 798.28 days by OMT and had 2.4 +/- 1.95 
periods of OMT. Total duration under OMT was longer for patient of drug test group than for 
those of the control group (P <0.001). Characteristics of OMT periods with the first definition 
of OMT periods (short definition) are in Appendix Table 4. Seventy-seven patients (43.5%) of 
the drug test group experienced doctor-shopping versus 288 patients (32.0%) of the control 
group (P = 0.003). 
 
Table 3. Characteristics of OMT periods (long definition).  
 
 
Overall 
(n = 1076) 
Drug test group 
(n = 177) 
Control group 
(n = 899) 
 
P-
value 
     
Total duration under OMT     <0.001 
Mean +/- SD 1190.2 +/- 798.28 1438.9 +/- 684.19 1141.2 +/- 810.26  
Median [Q1 – Q3] 1235 [454. 8 ; 1851.1] 1506 [1069.5 ; 1984.8] 1171.8 [336; 1814]  
Number of OMT periods    0.198 
Mean +/- SD 2.4 +/- 1.95 2.6 +/- 1.93 2.4+/- 1.93  
Median [Q1 – Q3] 2 [1 ; 3] 2 [1 ; 3] 2 [1 ; 3]  
Maximum 26 13 26  
Mean duration of OMT periods    0.001 
Mean +/- SD 610.9 +/- 552.28 747.6 +/- 558.49 584.0 +/- 547.35  
Median [Q1 – Q3] 466.5 [221.1; 818.8] 600.8 [346.6 ; 1056.8] 438.9 [201.8 ; 777.5]  
Mean daily dose of OMT periods 
(DDD) 
   0.845 
Mean +/- SD 1.1 +/- 1.47 1.1 +/- 1.04 1.1 +/- 1.55  
Median [Q1 – Q3] 0.7 [0.4 ; 1.4] 0.8 [0.5 ; 1.6] 0.7 [0.4 ; 1.3]  
Maximum 28.0 8.3 28.0  
Duration of the first OMT period    0.091 
Mean +/- SD 459.9 +/- 612.84 531.0 +/- 643.69 445.9 +/- 605.97  
Median [Q1 – Q3] 157.1 [28.0 ; 695.2] 234.8 [39.5 ; 846.0] 151.0 [28.0 ; 621.0]  
Daily dose of the first OMT period 
(DDD)  
   0.700 
Mean +/- SD 1.5 +/- 1.93 1.4 +/- 1.54 1.5 +/- 2.01  
Median [Q1 – Q3] 1 [0.5; 1.8] 0.9 [0.5 ; 1.9] 1 [0.5 ; 1.8]  
Maximum 28.0 10.5 28.0  
Doctor-shopping indicator in the first 
OMT period 
   0.332 
N 836 143 693  
Mean +/- SD 0.0 +/- 0.09  0.0 +/- 0.07 0.0 +/- 0.10  
Median [Q1 – Q3] 0 [0 ; 0] 0 [0 ; 0] 0 [0 ; 0]  
Maximum 0.7 0.6 0.7  
Having doctor-shopping behavior 365 (33.9) 77 (43.5) 288 (32.0) 0.003 
Reimbursed OMT in the first OMT 
period 
   0.039 
buprenorphine 835 (77.6) 127 (71.8) 708 (78.8)  
methadone 195 (18.1) 37 (20.9) 158 (17.6)  
buprenorphine et méthadone 46 (4.3) 13 (7.3) 33 (3.7)  
Summary of OS of OMT periods*    0.062 
bup1 359 (33.4) 45 (25.4) 314 (34.9)  
bup1/met1 23 (2.1) 5 (2.8) 18 (2.0)  
bup1/met9 138 (12.8) 22 (12,6) 116 (12.9)  
bup1/mix1/bup1 20 (1,9) 4 (2,3) 16 (1,8)  
bup13 99 (9.2) 13 (7.3) 86 (9.6)  
bup17 54 (5.0) 8 (4.5) 46 (5.1)  
bup2/met17 76 (7.1) 6 (3,4) 20 (2.2)  
bup2/met5 75 (7,0) 10 (5.6) 66 (7.3)  
bup22 46 (4.3) 15 (8.5) 31 (3.4)  
bup3/b+n1 27 (2.5) 5 (2.8) 22 (2.4)  
bup4 27 (2.5) 8 (4.5) 19 (2.1)  
 
* OMT periods for which n ≥ 20 (overall patients are represented); bup1 = 1 period with only 
buprenorphine reimbursed; bup1/met9 = 1 period with only buprénorphine reimbursed then 9 periods 
with only methadone reimbursed; mix = 1 period with reimbursements of buprenorphine and 
methadone together ; b+n = buprenorphine + naloxone 
 
Thirty-seven patients (3.4%) died during the follow-up: 4 (2.3%) in the drug test group and 33 
(3.7%) in the control group (P = 0.346). Death occurred 879.2 +/- 585.4 days after the first 
reimbursement of OMT (833 [392 – 1361]); this delay was 1014.5 +/- 586.7 in the drug test 
group (1186 [633 – 1396]) and 862.8 +/- 592.2 in the control group (775 (392 – 1361]).  
Among those who died, 13 died while “on treatment”: 1 in the drug test group and 12 in the 
control group (P = 1.0). Six died in the 2 weeks after interrupting their treatment (1 in the 
drug test group and 5 in the control group, P = 0.524); 3 died in the week 3 and 4 after 
interrupting their treatment (1 in the drug test group and 2 in the control group (P = 0.298); 
and 16 died while off treatment (in the remaining time): 1 in the drug test group and 14 in the 
control group (P = 0.618). Crude mortality rate was 0.53/100 person-year [95%CI 0.36 – 
0.70]. In the general population of EGB (subjects with same inclusion criteria: age from 16 to 
60 from 2007 to 2011), crude mortality rate was 0.24/100 person-year [0.24 – 0.25].  
Survival analysis did not show difference between the drug test and the control group on all-
cause mortality (P = 0.327). Figure 1 represents Kaplan-Meyer curves.  
 
 
Figure 1. Descriptive survival analysis of all-cause mortality according to the group (drug test 
or control group) using Kaplan Meyer curves. 
 
 
In an univariate Cox model, drug tests were not associated with all-cause mortality: hazard 
ratio HR 0.60 [95%CI 0.21 – 1.69]. By contrast, being “off treatment” versus “on treatment” 
was associated with an HR of 3.33 [1.75 – 6.35] using the first definition of OMT periods 
(short definition) and with an HR of 11.51 [5.85 – 22.64] using the second definition (long 
definition). Total duration of OMT and number of OMT periods were also associated with 
mortality. Table 4 describes covariates associated in univariate with mortality. 
 
Table 4. Covariates associated with mortality in an univariate Cox model.  
 
 Crude hazard ratio [95%CI] P 
 
Off treatment (versus on treatment) 
 
11.51 [5.85 – 22.64] 
 
<0.001 
Total duration under OMT (long definition) 0.999 [0.998 - 0.999] <0.001 
Age  1.10 [1.06 - 1.14] <0.001 
Number of OMT periods (long definition) 0.68 [0.50 - 0.90] 0.010 
Antiepileptics 2.33 [1.21 - 4.49] 0.012 
Heath insurance coverage for a psychiatric disorder 2.86 [1.26 - 6.52] 0.012 
Charslon score 1.37 [1.06 – 1.76] 0.016 
Number of consultations 1.02 [1.00 - 1.03] 0.031 
Hospitalization for another disorder than a psychiatric one 2.20 [1.07 – 4.55] 0.033 
Number of nervous system drugs (ATC class N) 
 
1.08 [1.00 - 1.16] 
 
0.037 
 
 
  
4. Discussion 
Among patients starting OMT, more than 15% had a reimbursement for a drug test. While 
drug tests were not associated with mortality, mortality risk was higher off treatment than on 
treatment. Factors associated with mortality were covariates representing the severity of the 
disease. 
This observational study is based on the data of the French health insurance system. Use of 
such databases has become generalized in France for more than 10 years and, specifically, 
EGB has been used for 5 years for pharmacoepidemiological purposes (25–30). Some studies 
have shown an acceptable concordance between drug consumption estimated through Health 
Insurance System databases and self-reported drug consumption (37). Although, we cannot 
exclude that, even if the drug is prescribed and reimbursed, it is not consumed by the patient. 
Incident status was defined as non-reimbursement for an OS during the first 12 months of the 
study period. Nevertheless, the first delivery of methadone must be prescribed in a specialized 
center or in a hospital setting. Data concerning drugs delivered in hospital settings are not 
available in the database. For some subjects receiving methadone, the duration of treatment 
retention has in fact probably been underestimated. 
We studied drug tests, whether in blood or urine, in the physician’s office or in the laboratory. 
These tests can be used in various clinical situations, but in our selected population of patients 
starting OMT, we may assume that they were prescribed in connection with the management 
of opiate addiction. This was confirmed by our findings, since the majority of codes 
corresponded to tests in a biological fluid other than blood, probably urine tests. Some 
patients possibly had drug tests in a specialized center or a hospital and some patients possibly 
had urine tests with commercial kits. As data concerning tests performed in hospital settings 
are not available in the database and as on-site drug tests are not covered by the health 
insurance system, we had no trace of them and some patients were probably wrongly included 
in the control group.  
The proportion of patients having drug tests was more important than in another French 
regional study (22) which might highlight heterogeneous practices even if this result is 
influenced by the longer time of follow-up in our present study. Whatever it is, drug tests are 
rarely done and when they are, they are performed occasionally for each patient. We can 
imagine that drug tests are not seen like a repeated evaluation of consumptions and thus 
craving but as “safeguard” for patients younger and with a more severe disease as our results 
suggest (more hospitalizations, more nervous system drugs, and more doctor-shopping in drug 
tested patients). This, and the low number of events, could explain that we did not find an 
association between drug tests and mortality as shown in another study (23). Drug tests were 
associated with longer OMT retention as we had already found in a south-western France area 
(22). 
The protective role of OMT for mortality has been confirmed with an off treatment HR 
between 3 and 11 according to the chosen definition of OMT retention. As far as we know, it 
is the first French study showing this protective effect, while French context is quite particular 
with the widespread of buprenorphine. Another finding was that longer was OMT, less 
patients died. Patients had around two periods of OMT representing a little bit than three 
years of OMT. Over seven years, it represents limited therapeutic managements in time while 
the protective effect of OMT for mortality has been demonstrated in larger studies in Scotland 
(23) and in the United Kingdom (38).  
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Appendix. Table 1.  
 
Medical laboratory classification codes used to identify drug screening tests in the EGB 
database. 
Medical laboratory code Label of corresponding analysis 
 
1659 
 
 
measurement in blood of analgesics or narcotics not otherwise categorized 
0659 measurement in a biological fluid other than blood of analgesics or narcotics not 
otherwise categorized  
1662 testing and measurement in blood for a psychotropic agent not otherwise categorized  
0662 testing and measurement in a biological fluid other than blood of a psychotropic agent 
not otherwise categorized 
1667 testing in blood for benzodiazepines (not for treatment follow-up)  
0667 testing for benzodiazepines in a biological fluid other than blood (not for treatment 
follow-up) 
1668 diazepam and its metabolite (measurement)  
1669 clonazepam (measurement)  
 
 
Appendix. Table 2.  
 
 
ICD10 codes associated to costly long–term diseases (Affections de longue durée ALD) used 
to identify for diseases in the EGB database. 
Identified disease ICD10 codes 
dementia F01, F02, F03 
addictive disorder F10, F11, F12, F13, F14, F15, F16, F17, F18, F19 
schizophrenia, schizotypal and delusional disorders F20, F21, F22, F23, F24, F25, F28, F29 
manic episode and bipolar affective disorders F30, F31 
depressive or recurrent depressive disorder F32, F33 
anxiety disorders F40, F41, F42, F43, F44, F45, F48 
specific personality disorder F60 
mixed disorder of conducts and emotions F92 
epilepsy G40, G41 
 
 
  
Appendix. Table 3.  
 
GHS and ICD10 codes used to identify hospitalization for psychiatric disorders in the EGB 
database. 
 
Hospital admission 
 
 
GHS codes 
 
PMSI 
 
For a psychoactive substance 
use 
 
7250, 7251, 7252, 7253, 7254, 7255, 7256, 7257, 7258, 
7259, 7260, 7261, 7262, 7263, 7264, 7265, 7266, 7267, 
7268, 7269, 7270, 7271, 7272, 7273, 7274, 7275, 7276, 
7277, 7278, 7279, 7280, 7281, 7282, 7283, 7284, 7285, 
7286, 7287, 7288, 8315, 8316 
 
none 
 
For a psychiatric disease 
 
7000, 7001, 7002, 7003, 7004, 7050, 7051, 7052, 7053, 
7054, 7055, 7056, 7057,  7058, 7059, 7060, 7061, 7062, 
7063, 7064, 7065, 7066, 7067, 7068, 7069, 7070, 7071, 
7072, 7073, 7074, 7075, 7076, 7077, 7078, 7079, 7080, 
7081, 7082, 7083, 7084, 7085, 7086, 7087, 7088, 7089, 
7090, 7091, 7092, 7093, 7094, 7095, 7096, 7097, 7098, 
7099, 7100, 7101, 7102, 7103, 7104, 7105, 7106, 7107, 
7108, 7109, 7110, 7111, 7113, 7114, 7115, 7116, 7117, 
7118, 7119, 7120, 7121, 7122, 7123, 7124, 7125, 7126, 
7127, 7128, 7129, 7130, 7131, 7132, 7133, 7134, 7135, 
8034, 8291, 8292 
 
principal or associated 
diagnoses of the 
ICD10 class F 
  
Appendix. Table 4. 
 
 
Characteristics of OMT periods (short definition) 
 
 
Overall 
(n = 1073) 
Drug test group 
(n = 174) 
Control group 
(n = 899) 
 
P-
value 
     
Total duration under OMT     <.001 
Mean +/- SD 1261.0 +/- 860.63 1506.1 +/- 724.88 1212.7 +/- 877.23  
Median [Q1 – Q3] 1296.9 [473.1 ; 1963.0] 1576.0 [1091.0 ; 2068.8] 1235.0 [357.0 ; 1911.2]  
Number of OMT periods    0.656 
Mean +/- SD 5.5 +/- 5.67 5.6 +/- 4.90 5.4 +/- 5.82  
Median [Q1 – Q3] 2 [4 ; 7] 2 [4 ; 8] 3 [2 ; 7]  
Maximum 56 28 56  
Mean duration of OMT periods    0.006 
Mean +/- SD 330.8 +/- 359.09 398.0 +/- 357.66 317.6 +/- 358.09  
Median [Q1 – Q3] 221.1 [108.4 ; 420.8] 309.5 [174.3 ; 535.0] 206.8 [99.5 ; 401.7]  
Mean daily dose of OMT periods 
(DDD) 
   0.823 
Mean +/- SD 1.0 +/- 1.72 1.0 +/- 0.98 1.1 +/- 1.84  
Median [Q1 – Q3] 0.7 [0.3 ; 1.2] 0.7 [0.4 ; 1.3] 0.6 [0.3 ; 1.2]  
Maximum 28.0 8.3 28.0  
Duration of the first OMT period    0.298 
Mean +/- SD 222.3 +/- 389.33 250.1 +/- 397.10 216.8 +/- 387.78  
Median [Q1 – Q3] 59.6 [21.0 ; 232.0] 76.0 [21.0 ; 290.5] 57.0 [21.0 ; 216.0]  
Daily dose of the first OMT period 
(DDD)  
   0.453 
Mean +/- SD 2.0 +/- 6.34 1.6 +/- 1.65 2.1 +/- 6.94  
Median [Q1 – Q3] 1.1 [0.6 ; 2.0] 1.0 [0.7 ; 2.1] 1.1 [0.6 ; 2.0]  
Maximum 151.2 10.5 151.2  
Doctor-shopping indicator in the 
first OMT period 
   0.195 
N 762 133 629  
Mean +/- SD 0.0 +/- 0.09  0.0 +/- 0.07 0.0 +/- 0.10  
Median [Q1 – Q3] 0 [0 ; 0] 0 [0 ; 0] 0 [0 ; 0]  
Maximum 0.7 0.7 0.7  
Having doctor-shopping behavior 365 (33.9) 77 (43.5) 288 (32.0) 0.003 
Reimbursed OMT in the first OMT 
period 
   0.039 
buprenorphine 859 (79.8) 131 (74.0) 708 (78.8)  
methadone 200 (18.6) 40 (22.6) 158 (17.6)  
buprenorphine et méthadone 17 (1.6) 6 (3.4) 33 (3.7)  
Summary of OS of OMT periods*    0.004 
bup1 208 (19.3) 16 (9.0) 192 (21.4)  
bup2 127 (11.8) 20 (11.3) 107 (11.9)  
bup3 73 (6.8) 9 (5.1) 64 (7.1)  
bup4 48 (4.5) 14 (7.9) 34 (3.8)  
bup5 58 (5.4) 9 (5.1) 49 (5.5)  
bup6 33 (3.1) 6 (3.4) 27 (3.0)  
bup7 36 (3.3) 5 (2.8) 31 (3.4)  
bup8 26 (2.4) 3 (1.7) 23 (2.6)  
bup9 20 (1.9) 4 (2.3) 16 (1.8)  
met1 31 (2.9) 4 (2.3) 27 (3.0)  
met2 25 (2.3) 7 (4.0) 18 (2.0)  
met3 20 (1.9) 7 (4.0) 13 (1.4)  
 
* OMT periods for which n ≥ 20 (overall patients are represented); bup1 = 1 period with only 
buprenorphine reimbursed; bup1/met9 = 1 period with only buprénorphine reimbursed then 9 periods 
with only methadone reimbursed; mix = 1 period with reimbursements of buprenorphine and 
methadone together ; b+n = buprenorphine + naloxone 
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PART 3: PROTOCOL OF AN INTERVENTION STUDY (STUDY 5)  
 
Finally, the last part aimed to confirm the value of urine drug screening test in real life and 
thus, to assess their efficacy planning a pragmatic cluster randomized controlled trial in 
general practice. 
 
Partie 3 : Protocole d’une étude d’intervention 
La dernière partie a pour objectif la confirmation de l’intérêt des tests urinaires de dépistage en médecine 
générale en planifiant la mise en place d’un essai pragmatique contrôlé randomisé. 
L’objectif principal de cet essai clinique randomisé ouvert en cluster est d’évaluer l’impact des tests 
urinaires de dépistage des toxiques en médecine générale chez des patients initiant un traitement par 
buprénorphine ou buprénorphine/naloxone sur le maintien sous MSO à 6 mois. 
L’intervention consistera en : 1) Une formation spécifique des MG (sur comment réaliser les tests urinaires 
et comment les interpréter) 2) La mise à disposition des tests urinaires dans les cabinets médicaux des MG, 
les MG seront libres de réaliser les tests urinaires pour le suivi s’ils le jugent nécessaire 3) La réalisation 
d’un test urinaire avant la première prescription de buprénorphine ou buprénorphine/naloxone. Le bras 
témoin correspondra à la stratégie médicale standard pour évaluer les consommations de substances 
psychoactives.  
Le critère de jugement principal est le maintien sous MSO à 6 mois. 
Six centres, représentés par un binôme département de médecine générale – centre d’évaluation et 
d’information sur la pharmacodépendance-addictovigilance (Clermont-Ferrand, Grenoble, Marseille, 
Nancy, Poitiers, Toulouse), seront responsables d’inclure 200 médecins généralistes (exerçant dans un 
cabinet médical de ville en secteur 1 et prenant en charge régulièrement des patients traités par 
buprénorphine ou buprénorphine/naloxone) pour un total 400 patients (âgés d’au moins 18 ans et consultant 
pour une initiation de buprénorphine ou buprénorphine/naloxone) à inclure. 
Cet essai devrait avoir un niveau de preuve suffisant pour évaluer l’efficacité des tests en médecine générale 
pour les patients traités par buprénorphine. 
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PRESENTATION OF THE STUDY  
Dupouy J.  
Impact of urine drug screening on opiate maintenance in general practice in France: 
the ESUB-MG pragmatic cluster randomized trial.  
Manuscript ready for submission. 
OBJECTIVE  
The main objective will be to assess the impact of on-site urine drug screening tests in 
general practice compared to routine medical care on OMT retention at six months in 
opioid-dependent patients initiating buprenorphine. 
METHOD  
The ESUB-MG study uses a pragmatic, cluster randomized controlled trial design. GPs 
regularly managing patients treated with buprenorphine and consenting for participating to 
the trial will be invited to participate. GPs will be randomly assigned to one of two groups 
for 6 to 24 months: (a) control group (usual care: standard medical strategy for assessing 
drug use); (b) intervention (including 1/ a training session on practice and interpretation of 
OS-UDS; 2/ the supply of OS-UDS at GPs’ medical offices; 3/ performing an OS-UDS 
before the first prescription of buprénorphine). GPs will have to include 1 to 10 patients 
aged 18 years-old or more, consulting for starting treatment by buprenorphine, not opposed 
to participate. The primary outcome will be OMT retention at 6 months. 
RESULTS 
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This randomized intervention trial should bring sufficient level of evidence to assess 
effectiveness of performing OS-UDS in general practice for patients treated by 
buprenorphine.  
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ABSTRACT 
Background and aims In addiction care, urine drug screening tests are recommended to be 
used to assess psychoactive substances use as self-reports underestimate their use. While 
intrinsic diagnostic value of these tests is already demonstrated, the consequences of carrying 
out these tests on opiate maintenance treatment (OMT) have not been clearly established. The 
main objective will be to assess the impact of on-site urine drug screening tests in general 
practice compared to routine medical care on OMT retention at six months in opioid-
dependent patients initiating buprenorphine. Methods The ESUB-MG study uses a pragmatic, 
cluster randomized controlled trial design. GPs regularly managing patients treated with 
buprenorphine and consenting for participating to the trial will be invited to participate. GPs 
will be randomly assigned to one of two groups for 6 to 24 months: (a) control group (usual 
care: standard medical strategy for assessing drug use); (b) intervention (including 1/ a 
training session on practice and interpretation of OS-UDS; 2/ the supply of OS-UDS at GPs’ 
medical offices; 3/ performing an OS-UDS before the first prescription of buprénorphine). 
GPs will have to include 1 to 10 patients aged 18 years-old or more, consulting for starting 
treatment by buprenorphine, not opposed to participate. The primary outcome will be OMT 
retention at 6 months. Discussion This randomized intervention trial should bring sufficient 
level of evidence to assess effectiveness of performing OS-UDS in general practice for 
patients treated by buprenorphine. Training GPs to drug tests and supplying them in their 
office should lead to an improvement of opioid-addicted patients' care through helping 
decision. 
 
Trial registration: Clinical Trials (n°) 
Keywords: opioid related disorder, opiate substitutive treatment, buprenorphine, substance 
abuse detection, urine drug screening test, outpatient, general practitioner, maintenance 
  
BACKGROUND 
Opioid addiction is currently defined as a “chronic, relapsing disorder” (1,2). Mortality of 
untreated heroin dependence is consistently estimated at 1–3% per year, at least half of which 
is because of heroin overdose (3). Beyond mortality and morbidity, heroin dependence inflicts 
enormous social and economic costs due to crime, unemployment, relationship breakdown, 
and the cost of law enforcement. Data from systematic reviews show that methadone 
maintenance is the most effective treatment in retaining patients in treatment and suppressing 
heroin use when compared with buprenorphine (4,5).  
The management of opiate-dependent patients in France is shared among specialized 
centres and general practitioners (GPs). Three drugs are available for the maintenance 
treatment methadone, buprenorphine (approved since 1995) and buprenorphine-naloxone 
(approved since 2006). Methadone must be initially prescribed by practitioners in specialized 
centers, whereas buprenorphine and buprenorphine-naloxone should be prescribed by any 
general practitioner and available through community pharmacies. The number of people 
receiving maintenance treatment was estimated around 100,000 for high-dose buprenorphine 
and around 40,000 for methadone in 2010 (6). Because the availability and the easy access to 
buprenorphine (7) most of opiate-dependent patients are managed in general practice (8). 
Actually, few GPs take care of these patients: they were only 24% in 2009 to regularly take 
care of patients under opiate maintenance treatment (OMT) (9). One of their difficulties is to 
evaluate the concordance between the patient's word and his drug use (OMT and other illicit 
drugs) (10). Indeed, one or two thirds of patients under OMT would also consume alcohol and 
benzodiazepines (11). Several GPs are afraid of drug trafficking which keeps growing (12), 
particularly with the reported frequent resale of buprenorphine (13,14).  
The assessment of psychoactive substance use is often difficult as patients’ self-reports 
under estimate the use of psychoactive substances (15–19). One Scandinavian study 
  
compared the performance of the psychiatrist versus the use of urine drug screening test 
(UDS) in the context of emergency setting for the assessment of drug use, using 
chromatography-tandem mass spectrometry as the reference (20). The sensitivity of the 
physician assessment was 57% for opiates, when it was 80% for opiates: this study clearly 
showed that physicians’ assessment of psychoactive drug use lead to underestimate the true 
consumptions, and UDS should improve this assessment. 
French guidelines highlight the need to assess opiate dependence for the management 
of patients taking OMT: screening tests have to be performed before introducing methadone; 
they are recommended before starting treatment with buprenorphine and during the follow up 
of both treatments. Methadone prescription guidelines detail the recommended urine tests: a 
first, mandatory test before starting methadone treatment and later control tests. The first urine 
test confirms current drug consumption and the absence of methadone intake. Tests are 
subsequently done once or twice a week during the first 3 months of treatment, then twice 
monthly. When the patient has transferred to an outpatient setting, tests can be done if the 
physician considers it necessary. Tests are not obligatory for buprenorphine, but highly 
recommended. In 2004, updated French guidelines on optimal opiate addict care advised a 
standardized screening test schedule in the initiation and follow-up of methadone and 
buprenorphine treatment (22).  
The drug tests can be carried out by immunochemical methods, either by automated 
analyzers in the biology laboratory or by drug screening kits. These tests (whether on a 
laboratory automat or using a commercial kit) are qualitative and have defined thresholds. 
False negatives exist for cocaine and benzodiazepines in particular, but test quality is 
intrinsically better for opiate detection (1.9% false negatives) (23). Results can be confirmed 
by the reference method, liquid or gas phase chromatography with mass spectrometry, which 
gives quantitative measurements (24). Screening can be done during the patient's visit, in 
  
either a specialized addiction centre or the physician's office. Laboratory tests, regardless of 
the method or the biological medium, are reimbursed by the French health insurance system 
with no limit on their number or time period. In medical offices, immunoassays have been 
shown to be reliable (25,26); nevertheless, on-site urine drug screening (OS-UDS) by 
commercial kits are not reimbursed by the French health insurance system but some 
specialized addiction networks in France provide them to their members. 
In a recent study performed among a sample of French GPs, only 12.2% of GPs 
reported to perform urinary screening tests and in this proportion were counted GPs who 
reported to use them for other reasons than initiation and follow up of OMT (9). The main 
reason for not performing UDS was a lack of knowledge about screening test (9). Among the 
few GPs using tests, the consequence they reported was mainly reinforcing dialogue with the 
patient. In another study performed in the same area among 1,507 patients initiating an OMT 
with buprenorphine or methadone, only 2.6% had at least a drug test reimbursed by the Health 
Insurance System during their addiction treatment period (27).  
Few studies explored the consequences of carrying out these tests on medical 
management. In the previous cited study, having been drug tested was associated with a better 
opiate substitution maintenance, with 45% decrease of drop-outs (95% CI: 0.38–0.80) (27). In 
a retrospective cohort study of methadone users performed through data obtained from a 
primary care prescription registry in Tayside, Scotland, a history of having urine tested was a 
protective factor in relation to all-cause mortality with a reduction of 70% of risk of death 
(HR 0.33, 0.22 to 0.49) (28). On the basis of the literature, one would suppose that carrying 
out UDS would provide an improvement in the management of patients with opioid addiction 
and positive outcomes for patients such as longer opiate substitution maintenance and its 
clinical consequences in which a decrease in mortality. However, this hypothesis relies only 
on observational data, and we cannot rule out confusion bias. 
  
In order to provide more consolidated data on the interest of using UDT in the context 
of general practice, we propose an interventional trial, which the main objective is to assess 
the impact of on-site urine drug screening tests in general practice compared to routine 
medical care on OMT retention at six months in opioid-dependent patients initiating 
buprenorphine. Second objectives are to assess the acceptability of OS-UDS by patients and 
GPs, to assess patient adherence to buprenorphine and to assess associated consumptions 
(decrease in using psychoactive substances). 
 
  
METHODS 
Study design 
The ESUB-MG study is a pragmatic, cluster randomized controlled trial design. Clustering is 
at the level of the GP. A cluster design is needed as the intervention concerns the GP and as 
the evaluation concerns the patient. Furthermore, patients of a same GP are more correlated 
than patients of different GPs. 
 
Research objectives 
This study is designed to assess the impact of on-site urine drug screening tests in general 
practice compared to routine medical care on OMT retention at six months in opioid-
dependent patients initiating buprenorphine. 
 
Study population 
GP inclusion criteria 
Professional criteria: to practice as a GP, to be in activity, to practice in general ambulatory 
practice (in a medical office) 
patients’ characteristics: to regularly manage patients treated with buprenorphine  
legal characteristic: to be registered in sector 1 
consent for participating to the trial 
GPs exclusion criteria 
to practice in a group medical office in which another GP has been included in the trial 
Patients inclusion criteria 
Aged 18 years-old or more 
to consult for starting buprenorphine or OMT 
  
affiliated to a health insurance scheme 
not opposed to participate 
Exclusion criteria 
Patients exclusion criteria 
to consult for continuing buprenorphine or for another complain related to opiate substitution 
treatment 
to be known and yet managed by the GP for an opiate substitutive treatment 
to have started buprenorphine in a specialized centre or in a hospital 
to be treated with methadone 
to be treated with methadone and asking a switch toward buprenorphine 
not consenting to participate to the study 
 
Recruitment 
GPs recruitment  
Six academic general medicine department and six centers for evaluation and information on 
pharmacodependence-addictovigilance (CEIP-A) will work in pairs to recruit voluntary GPs 
within their network of working GPs and through regional addiction networks.  
 Recently, in France, general medicine was recognised as a specialty with a specific 
training. Consecutively, academic general medicine departments were developed in each 
faculty. In 2008, an academic pathway of general medicine was created. 
In order to assist the French Committee for Narcotics and Psychotropic Drugs, in 
charge  of the monitoring and the scheduling of psychoactive substances with abuse potential, 
a monitoring system for psychoactive medications abuse consisting of a network of 13 centers 
for evaluation and information on pharmacodependence-addictovigilance (CEIP-A) was 
created in 1999. 
  
In both sources for selection, GP will be contacted by postal mail comprising a 
questionnaire for validating inclusion criteria for the GP, and an agreement form for 
participating to the ESUB-MG study. A pre-stamped return envelope will be included. 
Monetary compensation is planned for participating GPs as compensation for the time and 
contribution to the study.  
GPs in both groups will receive both oral and written information about study design 
and conduct (patients’ recruitment, inclusion criteria). Material for data collection will 
comprise a GP questionnaire on basic demographic information and location, GP information 
notice (detail on recruitment and study conduct), questionnaire for the inclusion and follow up 
visit. 
GPs agreeing to participate to the study will be randomly assigned to one of two 
groups: one group with intervention, one control group.  
 
Patients’ recruitment 
GPs will be requested to include all consecutive patients that would be eligible. Each GP have 
to include at least 2 patients within 18 months.  
Participant recruitment will commence in March 2015, and patient participation will 
be completed by August 2017. The planned end date for the trial is December 2018. 
 
Consent 
GPs will inform eligible patients of their involvement in the study and that their medical data 
will be used for the purpose of the research. As a research on standard care GPs will have to 
ensure that patient are not opposed to take part to the research.  
  
Patients that would explicitly express their opposition will not be included. Patients 
who are not opposed to participate but refusing to submit to one or several OS-UDS will be 
maintained in their group defined by their cluster. 
 
Randomization 
Randomization will be undertaken at the cluster (GP) level. Based on the procedure allocated 
to GP, all patients within a cluster will be assigned to either intervention or control group.  
Randomization of participating GP will be performed after obtaining consent of GP and 
collecting complete questionnaire including basic demographic information and their location. 
The randomization list will be generated by an independent biostatistician in the clinical 
research methodological support unit (Unité de Soutien Méthodologique à la Recherche 
Clinique USMR) of the University hospital (Centre Hospitalier Universitaire CHU) of 
Toulouse, France. Clusters will not be randomized all at once (first patients inclusion need to 
begin whereas GPs’ recruitment will be on-going), thus the allocation for each consecutive 
participating GP will be obtained from the USMR through a specific website. To avoid 
contamination bias, no more than one GP could be included in a given medical practice.    
 
Intervention  
Intervention will consist in: 1) a training session for GPs on use and interpretation of OS-
UDS; 2) the supply of OS-UDS at GPs’ medical offices; 3) performing an OS-UDS before the 
first prescription of buprenorphine. GPs will be let free to perform OS-UDS for the follow-up 
if they judge it necessary.  
GP assigned to the intervention group will be visited by a clinical research assistant 
(CRA) to be trained on the methods for performing test (urinary sample collection and 
reading of the test results). The training session is expected to last about 1 hour, and a written 
  
guidance will be provided. Material for testing (OS-UDS) will also be supplied during this 
session. OS-UDSs will be centrally bought by the CHU de Toulouse and will be provided by 
the CRA in charge of the training session. 
During the consult, GPs of the intervention group will dedicate an average 5 minutes 
to perform OS-UDS. Patients will be asked to collect a urine sample at the GP’s medical 
office. GP will read and communicate the results immediately to the patients. GPs will keep 
free of their management according to OS-UDS results. 
OS-UDS characteristics 
OS-UDS will be in accordance with positivity threshold recommended by the National 
Institute on Drug Abuse (NIDA) (29) and the Substance Abuse and Mental Health 
Administration (SAMSHA) (30). The SAMSHA increase the threshold for screening opiates 
in 2008 (2000ng/mL instead of 300ng/mL) to avoid false positive to ingestion of poppy-seeds. 
Nevertheless, many laboratories maintained the threshold of 300 ng/mL to preserve the 
opiates screening sensibility (31). Thus, we will use the threshold of 300 ng/mL.  
Several substances will be screened through the OS-UDS in our study: buprenorphine, 
methadone (or its metabolite, 2-ethylidine-1,5-dimethyl-3,3 diphenylpyrrolidine (EDDP)), 
opiates, and cocaine. Opiate substitutes should be systematically screened before starting 
buprenorphine, according to guidelines. Buprenorphine screening is intended to assess 
adherence to OMT after initiation, whereas opiates are screened to monitor concomitant 
consumptions over the course of OMT, or to confirm an opiate addiction before the first 
prescription (which confirms the indication of OMT). Methadone screening is intended to rule 
out an ongoing treatment by methadone. Cocaine is often consumed with opiates. In France, 
at least 10% of patients would be concerned by cocaine consumption while they are treated 
with an opioid substitute (32,33), and it is associated with negative outcome. Some patients 
  
could request for an OMT being unaware of the indication of these drugs and believing they 
could be offered such treatment.  
Positivity thresholds currently used (29,30) and that we will use are: buprenorphine: 
10 ng/mL ; EDDP (the metabolite of methadone): 100ng/mL ; opiates: 300ng/mL ; cocaine: 
300 ng/mL. 
At these thresholds, sensibility was 80% (IC95%: 55 - 100) and specificity 99% [96 – 
100] for opiates, sensibility not calculable and specificity 100% [100 -100] for cocaine (20). 
In another study, sensibility for buprenorphine with 3 different OS-UDS varied from 88 to 
100% and specificity from 91 to 100 % (34).  
Controlled group 
Controlled arm will correspond to standard medical strategy for assessing consumptions while 
prescribing OMT. Excluding OS-UDS, there will be no prohibited procedure. In particular, 
GPs of the controlled harm are authorized to implement any biological test to ascertain 
associated substances use, including for instance laboratory testing. However, according to 
previous data, we can expected that few drug tests should be performed in this control group: 
1 to 3% (9,27). 
 
Outcome measures 
The primary outcome will be OMT retention at 6 months. Secondary outcomes will be patient 
adherence to buprenorphine, associated psychoactive substances use, acceptability of OS-
UDS reported by the patient, acceptability of OS-UDS reported by the GP. 
Primary outcome 
Retention in treatment at 6 months will be the main judgment criterion. Actually, a 
review on all Cochrane systematic reviews performed by the Cochrane Review Group on 
Drugs and Alcohol highlighted that the main outcomes used in studies assessing effectiveness 
  
of opiate maintenance treatment were retention in treatment and illicit use of heroin (4). 
Whatever the treatments compared, the retention in treatment was the most constant and the 
most reproducible outcome used over the different clinical trials because heroin use (assessed 
through different ways, self-reported or through urinary analysis) is rarely reported in a 
standardized way.  This outcome could be considered as intermediate steps of treatment for 
heroin-addicted patients. Because observational studies showed high rates of mortality in 
heroin-addicted patients (35), especially early after discharge from treatment, the ability of a 
treatment in retaining people in treatment should be reported as a proxy of effectiveness (36).  
Retention in treatment will be defined as patients remaining under opiate maintenance 
treatment at 6 months in a context of medical care (i.e. drug prescribed by a physician, not 
diverted or obtained through an illegal way, whatever the drug considered, buprenorphine; 
buprenorphine/naloxone, methadone) and assessed by the general practitioner at the end of the 
follow-up. Patients switching from buprenorphine to methadone or to 
buprenorphine/naloxone during study follow-up will be considered as remaining under opiate 
maintenance treatment. 
The patient will be defined as retained in treatment if he will be prescribed by the 
same GP a legal opiate maintenance drug, or if the drug will be prescribed by another 
practitioner in connection with the treating physician. In case of loss of follow-up or diverted 
use of drug (intravenous or nasal route or illegal acquisition of the OMT drug), the patient 
will be considered as not retained. In case of death, the patient will be considered as 
maintained until the date of death, and censored after this date. Buprenorphine must be 
prescribed under strict conditions for a maximum of 28 days (methadone for a maximum of 
14 days). Consequently, a patient not attending a medical visit for more than 56 days (2 
months) should be considered as not remaining under opiate maintenance treatment. 
  
Retention in treatment has to be recorded at 6 months (time window tolerated of +/- 14 
days) as there is no scheduled or mandatory visit for the patient.  
 
Secondary outcomes 
The secondary judgment criteria will allow answering secondary objectives of the study: 
adherence to buprenorphine associated psychoactive substances use, acceptability of OS-UDS 
reported by the patient, the GP. 
We will specifically collect for both groups: characteristics of buprenorphine 
utilization (dose, duration), exposure to opiate or other illegal substances (heroin, morphine, 
cannabis, cocaine, benzodiazepines, amphetamines, other…) during the follow-up (self-
reported during medical examination and/or biologically assessed) ; for the intervention 
group: number of OS-UDS performed by GP and by patient acceptability reported by the 
patient and by the GP (self-reported questionnaires). 
Cross-link data 
To ensure completeness in prescription drug record, significant medical event and death 
occurring during follow up, additional information on medical care will also be obtained 
through the database of the health insurance scheme. A query into the information system 
from the national health insurance scheme (SNIIRAM) and national mortality registry will be 
done to complete follow-up. Data collected will not be included in the main analysis.  
 
Sample size calculation 
Comparisons between groups will be performed taking into account clustering which the 
unity will be the GP. Thus the sample size must be corrected by an inflation factor according 
to guidelines on clustered analyses (37–40). According to the results of a previous study 
performed by our group on patients initiating buprenorphine in ambulatory care in the Midi-
  
Pyrénées area (27), we were able to identify clusters of GPs and calculated the intra-cluster 
correlation coefficient (CCI = 2.79%) and the mean cluster size (m=2), giving an inflation 
factor (IF = 1.03). 
According to the literature, the retention rate with buprenorphine at 6 months is 
generally around 40%, with 60% in specialized centers with urinary testing and supervision 
(4,5). In studies performed in our area, observed retention rates were similar (11). Using 
reimbursement data from the French Health Insurance system at the regional level, we 
compared retention rate of patients newly treated by buprenorphine according to performing 
or not urinary testing (27). In this study including 1,507subjects  followed-up over 30 months, 
the retention rate in patients with urinary testing was significantly better than the reference 
group, with an adjusted Hazard Ratio of 0.55 (95% CI: 0.38–0.80). 
Thus, considering a retention rate in the reference group of 36%, and an expected 
retention rate of 50% in the intervention group, if mean cluster size (m) = 2, α risk = 0.05 and 
β risk = 0.20, the theoretical formula of Hayes and Moulton gives 100 clusters by group, i.e. 
100 GPs in each group, corresponding to 200 patients in each group, i.e. 400 patients in all 
(Hayes and Moulton 2009). 
Recruiting 2 patients by GPs over a period of 18 months seems realistic, even if these 
GPs are not working in an addiction specialized network. Hypothesizing that the expected 
retention rate will be 50% in the intervention group is very conservative. Actually, with an 
expected retention rate of 60% (as observed in our previous study) or with an expected 
relative risk of 0.3-0.4 in favour of the intervention group (as observed in the McCowan study 
(28), with a benefit of performing urinary testing -whatever the results- on mortality in 
patients treated by methadone in UK). With this retention rate, only 34 clusters should be 
needed, corresponding to 34 GPs in each group, 68 in the all sample, and consecutively 136 
patients. This hypothesis should be probably optimistic but not completely unrealistic. 
  
This strategy will allow to overcome the proper effect of each GP, to get enough 
clusters for the analysis and to regroup clusters (on the basis of the same geographic area (in 
French “Bassins de santé”) giving a sufficient number of individuals in each cluster (5 
subjects).  
 
Statistical analysis 
Patients, will be analyzed according to the intervention assigned to their GP, whether being 
exposed to OS-UDS during their participation or not, in accordance with the intention-to-treat 
principle.   
For patients followed up until the end of the study, the retention rate will be the 
percentage of patients still under OMT (complete data). For loss of follow up patients, an 
intention to treat approach will be used and loss of follow will be analyzed as failure.  
 
A description of the baseline characteristics of the group will be performed, 
comprising mean ± SD for continuous variables and frequency and percentages for qualitative 
variables. Baseline characteristics and secondary outcomes will be compared among groups 
using the Chi2 test of independency or Fisher test for categorical variables and the Student t 
test or the Wilcoxon test for continuous variables. A significance threshold of 5 % will be 
applied for all the statistical analyses. 
Retention at 6 months will be computed as an individual binary variable, and will be 
analyzed using mixed effect logistic regression, including General practitioners as a random 
effect parameter. Potential confounders or explanatory variables at individual and cluster level 
will be included. An alternative way for analysis would consist in applying generalized 
estimating equation (GEE). These models are appropriate in the study design as the number of 
cluster will be higher than 15 (38).  
  
Univariate analyses on baseline variables as potential predictors for success or failure 
of OMT maintenance will be performed using Chi-square statistics for categorical and 
Student t-test for continuous data. Variables with a P-value of <0.2 after univariate analysis 
will be entered into a multivariate logistic regression model. Crude and adjusted Odds Ratio 
(OR) and their confidence intervals will be estimated. The main analysis will be completed by 
univariate and multivariate clustered survival analyses.  
Analyses will be performed using the SAS ® 9.3 software (SAS Institute Inc., Cary, 
NC, USA).  
  
DISCUSSION 
This randomized intervention trial in primary care context should bring sufficient level of 
evidence to assess effectiveness of performing OS-UDS in general practice for patients 
treated by buprenorphine. The aim is to assess the impact of a global intervention, including a 
better knowledge of UDS (through a specific GP’s training to perform UDS and interpret their 
results), and giving the opportunity to perform OS-UDS for any patient consulting for an 
OMT initiation in the medical office by the GP. The better way to assess this impact with a 
sufficient level of evidence is to perform a randomized intervention trial in primary care 
context, comparing OMT retention at 6 months in patients cared by GPs randomly assigned to 
having on-site UDS, compared to patients cared by GPs randomly assigned to performing 
standard care. 
Most of OMT patients in France are managed in the context of primary care, whereas 
most of OMT clinical assessments have been done in the context of specialized centers. UDS 
should be used in this context of primary care, but are rarely done. Commercial kits are giving 
the possibility to perform UDS extemporarily in the medical office. The limits of these tests in 
terms of sensitivity and specificity are well-known, and this project does not aim to assess the 
intrinsic validity of these tests, assuming that they present a sufficient quality to be licensed in 
France, but to assess effectiveness of performing OS-UDS in general practice for patients 
treated by buprenorphine. 
The widespread use of UDS is already a reality for some (few) GPs working in 
specialized addiction networks and in centers without laboratories inside. However, outside 
this context, urine testing is rare and knowledge of GPs remains scarce. Demonstrating the 
positive impact of OS-UDS on GPs’ practice (in managing patients) and behaviors of patients 
treated with buprenorphine in general practice (adherence) would be an important issue in the 
field of opioid addiction care. 
  
Training GPs to drug tests and supplying OS-UDS in their office should lead to an 
improvement of opioid-addicted patients' care through helping decision making in the GP 
medical office, improving GPs' practices, improving adherence of treated patients, and 
consequently, improving short and long term outcomes of OMT. 
  
Governance and ethical considerations 
The study will be done in the French regulatory context of standard care (in French “Soins 
Courants”), all the procedures used in the study being in the standard care of opiate addicts. 
Thus, the study will not modify the standard follow-up of patients newly treated by an OMT 
and all the medical visits and/or other interventions will be done as needed. 
This study has been approved by Persons’ Protection Committee (CPP) of Bordeaux, France 
(n°2014-A00393-44) and the Consultative Committee on Data Processing in Research in the 
Area of Health (CCTIRS) (n°14.356bis). The protocol is submitted to the National 
Commission for Computing and Civil Liberties (CNIL). 
 
Clinical trial registration  
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GENERAL CONCLUSION 
 
This thesis presented an overview of opioid maintenance treatment in France and 
investigated the potential value of urine drug screening in primary care. The first survey 
has demonstrated that few French GPs prescribed drug tests, the mean reason being that 
they did not know their existence. Then, the systematic review found that weak evidence 
supported the impact of drug tests in managing patients. Specifically, few studies have 
been performed about it in ambulatory care.  
The pharmacoepidemiological approach assessed the effectiveness of drug tests in France 
for opioid substitution retention and all-cause mortality. Drug tests were associated with 
opioid substitution retention but not with mortality. However, in this last study about 
mortality, few events were counted, limiting its power. Furthermore, these cohort studies 
using real life data demonstrated that drug tests are rarely done. When they are, they are 
occasional and for a specific, more severe, population. This can also explain this last non-
significant result on mortality. 
The pharmacoepidemiological approach illustrated the value of French health system 
insurance reimbursement databases for the researcher in primary care. The regional 
ERASME database and the EGB have been interesting tools for exploring the value of 
drug tests in patients treated by OMT and provided first useful results to plan the 
intervention study. 
Finally, the pragmatic randomized controlled trial that we will soon conduct, will 
investigate with better evidence the impact of urine drug screening in general practice for 
patients starting buprenorphine. 
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Conclusion générale : 
Cette thèse a présenté un état des lieux des traitements de maintenance aux opiacés en France et a évalué 
l’intérêt des tests urinaires de dépistage en ambulatoire.  
La première étude a montré que les médecins généralistes étaient peu nombreux à utiliser ces tests ; la 
principale raison étant une méconnaissance de leur existence. La revue systématique a ensuite montré que 
peu d’études soutenaient l’efficacité des tests pour la prise en charge des patients dépendants aux opiacés, 
notamment en ambulatoire, et que ces études avaient une qualité méthodologique faible.  
L’approche pharmacoépidémiologique a montré que la réalisation des tests de recherche de substances 
psychoactives, quoique rare, était associée avec un maintien sous médicament de substitution aux opiacés 
plus long mais pas à une baisse de la mortalité. Néanmoins, un manque de puissance peut avoir affecté les 
résultats de cette dernière étude. Cette approche a illustré l’intérêt de l’utilisation des bases de données de 
l’Assurance Maladie (et particulièrement de l’EGB) pour les chercheurs en soins primaires. 
Pour finir, un essai pragmatique randomisé a été mis en place et évaluera avec un meilleur niveau de preuve 
l’intérêt des tests urinaires de dépistage pour les patients débutant un traitement par buprénorphine.  
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study results 
N Y 
Other information   
Funding 22 Give the source of funding and the role of the 
funders for the present study and, if applicable, for 
the original study on which the present article is 
based 
N N 
NA: Non applicable 
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abstract 
1 (a) Indicate the study’s design with 
a commonly used term in the title 
or the abstract 
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(b) Provide in the abstract an 
informative and balanced summary 
of what was done and what was 
found 
Y Y Y Y Y 
Introduction      
Background
/rationale 
2 Explain the scientific background 
and rationale for the investigation 
being reported 
Y N Y Y Y 
Objectives 3 State specific objectives, including 
any prespecified hypotheses 
Y Y Y Y Y 
Methods      
Study 
design 
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design early in the paper 
Y Y N Y N 
Setting 5 Describe the setting, locations, and 
relevant dates, including periods of 
recruitment, exposure, follow-up, 
and data collection 
Y Y Y Y Y 
Participants 6 (a) Give the eligibility criteria, and 
the sources and methods of 
selection of participants 
Y Y Y Y Y 
Variables 7 Clearly define all outcomes, 
exposures, predictors, potential 
confounders, and effect modifiers. 
Give diagnostic criteria, if 
applicable 
N Y Y Y Y 
Data 
sources/ 
measuremen
t 
8*  For each variable of interest, give 
sources of data and details of 
methods of assessment 
(measurement). Describe 
comparability of assessment 
methods if there is more than one 
group 
N Y Y Y N 
Bias 9 Describe any efforts to address 
potential sources of bias 
N N N N N 
Study size 10 Explain how the study size was 
arrived at 
N N N Y Y 
Quantitative 
variables 
11 Explain how quantitative variables 
were handled in the analyses. If 
applicable, describe which 
groupings were chosen and why 
Y Y NA Y NA 
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Statistical 
methods 
12 (a) Describe all statistical methods, 
including those used to control for 
confounding 
Y Y Y Y Y 
(b) Describe any methods used to 
examine subgroups and interactions 
N N Y Y NA 
(c) Explain how missing data were 
addressed 
N N Y N N 
(d) If applicable, describe analytical 
methods taking account of sampling 
strategy 
NA NA N N N 
(e) Describe any sensitivity 
analyses 
N N N N N 
Results      
Participants 13* (a) Report numbers of individuals 
at each stage of study—eg numbers 
potentially eligible, examined for 
eligibility, confirmed eligible, 
included in the study, completing 
follow-up, and analysed 
Y N Y Y Y 
(b) Give reasons for non-
participation at each stage 
NA N Y Y Y 
(c) Consider use of a flow diagram N N Y N N 
Descriptive 
data 
14* (a) Give characteristics of study 
participants (eg demographic, 
clinical, social) and information on 
exposures and potential 
confounders 
Y N Y Y Y 
(b) Indicate number of participants 
with missing data for each variable 
of interest 
N N Y N Y 
Outcome 
data 
15* Report numbers of outcome events 
or summary measures 
Y Y Y Y Y 
Main results 16 (a) Give unadjusted estimates and, 
if applicable, confounder-adjusted 
estimates and their precision (eg, 
95% confidence interval). Make 
clear which confounders were 
adjusted for and why they were 
included 
N Y N Y Y 
(b) Report category boundaries 
when continuous variables were 
categorized 
N NA Y NA NA 
(c) If relevant, consider translating 
estimates of relative risk into 
absolute risk for a meaningful time 
period 
NA NA NA NA NA 
Other 
analyses 
17 Report other analyses done—eg 
analyses of subgroups and 
interactions, and sensitivity 
N Y Y N NA 
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Discussion      
Key results 18 Summarise key results with 
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N Y Y Y Y 
Limitations 19 Discuss limitations of the study, 
taking into account sources of 
potential bias or imprecision. 
Discuss both direction and 
magnitude of any potential bias 
Y Y Y Y N 
Interpretatio
n 
20 Give a cautious overall 
interpretation of results considering 
objectives, limitations, multiplicity 
of analyses, results from similar 
studies, and other relevant evidence 
Y Y Y Y Y 
Generalisabi
lity 
21 Discuss the generalisability 
(external validity) of the study 
results 
N Y Y N N 
Other information      
Funding 22 Give the source of funding and the 
role of the funders for the present 
study and, if applicable, for the 
original study on which the present 
article is based 
N N Y Y Y 
NA: Non applicable 
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Depuis la reconnaissance de l’addiction comme maladie mentale, des médicaments spécifiques ont été 
développés. Les médicaments de substitution de la dépendance aux opiacés (méthadone, buprénorphine et 
buprénorphine/naloxone) ont montré leur efficacité en diminuant les consommations de drogues, les risques 
infectieux (VIH, hépatite C), en améliorant l’insertion sociale, et en diminuant la morbidité. En France, les 
conditions de prescription et de délivrance de la buprénorphine ont permis de prendre en charge une grande 
partie de ces patients en médecine générale. Néanmoins, l’évaluation des consommations par l’interrogatoire et 
l’examen clinique est connue pour sous-estimer l’usage de substances psychoactives. Proposer un outil 
d’évaluation tel que les tests urinaires de dépistage des substances psychoactives (proposant une évaluation 
qualitative des substances détectées dans les urines du patient) pourrait aider les médecins à identifier les 
consommations et avoir un impact sur la prise en charge.  
L’objectif de cette thèse est d’évaluer l’intérêt des tests urinaires de dépistage pour la prise en charge 
des patients dépendants aux opiacés en médecine ambulatoire. Cette évaluation a été conduite en trois parties. 
Dans la première, les connaissances des tests à partir de la littérature et à partir des déclarations des médecins 
généralistes (MG) français a été décrite. Dans la seconde, l’efficacité des tests sur la prise en charge des patients 
dépendants aux opiacés a été étudiée par des études de cohortes observationnelles à partir des bases de données 
de l’Assurance Maladie. Pour finir, la dernière partie propose de confirmer l’impact des tests urinaires dans la 
vraie vie, en évaluant leur efficacité dans un essai pragmatique randomisé en cluster en médecine générale. 
Dans la première partie, nous avons évalué les connaissances et pratiques des tests par les Médecins 
Généralistes de Midi Pyrénées par une étude transversale descriptive. La plupart des MG prenant en charge 
régulièrement des patients dépendants aux opiacés ne réalisaient pas de tests et ne les connaissaient pas. Dans un 
second temps, pour évaluer l’efficacité des tests urinaires de dépistage pour la prise en charge des patients, nous 
avons conduit une revue systématique de la littérature des essais cliniques, études pragmatiques et études 
observationnelles. L’intérêt des tests urinaires n’était pas clairement démontré dans les études incluses. 
Le premier travail de la seconde partie a évalué l’impact des tests urinaires tests sur le maintien sous 
traitement substitutif aux opiacés. Une cohorte rétrospective a été créée à partir de la base Extraction, 
Recherches, Analyses pour un Suivi Médico-Economique ERASME pour la région Midi Pyrénées. L’utilisation 
des tests urinaires, quoique rare, augmentait significativement le maintien sous traitement. Le deuxième travail a 
évalué l’intérêt des tests sur la mortalité des patients sur une base nationale : l’échantillon des généralistes 
bénéficiaires (EGB). Ce travail a confirmé l’association entre les tests et le maintien sous traitement mais n’a pas 
retrouvé d’association avec la mortalité. 
Les résultats obtenus ont été utilisés pour planifier la troisième partie : la mise en place d’un essai 
pragmatique randomisé en cluster en médecine générale. Nous présentons le protocole de cette étude qui a pour 
objectif d’évaluer l’efficacité d’une intervention (tests urinaires de dépistage au cabinet du médecin généraliste) 
sur le maintien sous traitement de patients débutant la buprénorphine. 
Pour conclure, cette thèse a montré que les tests urinaires étaient peu réalisés en France chez les patients 
dépendants aux opiacés et que peu d’études ont évalué leur intérêt. Néanmoins, les tests semblent avoir un effet 
protecteur sur le maintien sous traitement substitutif aux opiacés. L'essai pragmatique randomisé en cours que 
nous proposons devrait permettre d’apporter des preuves suffisantes de leur intérêt en médecine générale. 
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